Table 1.
Global prevalence, incidence, and YLDs for 2017; percentage change of YLD counts; and percentage change of age-standardised YLD rates for 1990–2007 and 2007–17 for both sexes combined for all Level 5 causes, nature of injury aggregates, and nine impairments
| Prevalence (thousands) 2017 counts | Incidence (thousands) 2017 counts |
YLDs (thousands) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2017 counts | Percentage change in counts, 1990–2007 | Percentage change in counts, 2007–17 | Percentage change in age-standardised rates, 1990–2007 | Percentage change in age-standardised rates, 2007–17 | ||||||
| All causes | 7 369 526·2 (7 344 769·0 to 7 392 430·8) | 38 480 253·2 (36 469 390·1 to 40 567 963·0) | 853 042·6 (642 084·6 to 1 097 347·2) | 29·8% (28·8 to 30·8)* | 17·0% (16·4 to 17·6)* | −3·0% (−3·5 to −2·5)* | −0·9% (−1·4 to −0·4)* | |||
| Communicable, maternal, neonatal, and nutritional diseases | 4 767 056·2 (4 646 620·9 to 4 904 464·9) | 27 145 980·3 (25 247 991·1 to 29 151 315·9) | 117 573·7 (86 670·4 to 154 424·2) | 10·6% (7·4 to 14·8)* | 2·6% (0·5 to 5·5)* | −7·8% (−10·4 to −4·5)* | −7·6% (−9·6 to −5·0)* | |||
| HIV/AIDS and sexually transmitted infections | 1 238 129·2 (1 129 539·6 to 1 359 466·0) | 769 111·2 (694 471·1 to 850 896·0) | 5369·7 (3783·6 to 7272·2) | 204·0% (136·7 to 302·7)* | −6·0% (−20·6 to 8·3) | 130·4% (79·8 to 202·8)* | −17·6% (−30·5 to −4·7)* | |||
| HIV/AIDS | 36 822·2 (34 794·9 to 39 199·8) | 1942·1 (1632·1 to 2287·5)† | 3949·0 (2746·5 to 5419·1) | 372·9% (299·6 to 489·2)* | −11·5% (−26·2 to 5·4) | 257·8% (204·6 to 343·0)* | −22·6% (−35·7 to −7·8)* | |||
| HIV/AIDS and drug-susceptible tuberculosis co-infection | 1049·5 (956·6 to 1149·6) | 1321·6 (1203·1 to 1454·8) | 404·7 (272·3 to 546·5) | 329·9% (316·0 to 345·1)* | −19·6% (−21·8 to −17·3)* | 229·1% (219·0 to 240·1)* | −29·2% (−31·1 to −27·2)* | |||
| HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co-infection | 37·6 (25·2 to 54·5) | 52·0 (37·5 to 71·2) | 15·3 (9·0 to 24·4) | 3509·4% (1734·6 to 6384·8)* | −23·4% (−47·9 to 12·8) | 2591·5% (1256·0 to 4788·1)* | −32·9% (−54·5 to −1·1)* | |||
| HIV/AIDS and extensively drug-resistant tuberculosis co-infection | 1·4 (0·9 to 2·3) | 1·7 (1·2 to 2·3) | 0·6 (0·3 to 1·0) | .. | 37·1% (−12·3 to 116·5) | .. | 19·5% (−23·8 to 88·6) | |||
| HIV/AIDS resulting in other diseases | 35 733·7 (33 669·3 to 38 076·0) | 1942·1 (1632·1 to 2287·5) | 3528·5 (2439·7 to 4941·4) | 376·9% (292·0 to 510·8)* | −10·4% (−26·9 to 9·3) | 260·2% (199·6 to 357·9)* | −21·7% (−36·3 to −4·5)* | |||
| HIV/AIDS not on antiretroviral treatment without tuberculosis | 14 763·0 (13 278·6 to 16 643·9) | 1942·1 (1632·1 to 2287·5) | 1911·1 (1240·9 to 2928·7) | 343·8% (257·7 to 481·8)* | −47·8% (−52·9 to −42·9)* | 235·0% (172·5 to 332·7)* | −53·9% (−58·4 to −49·5)* | |||
| HIV/AIDS on antiretroviral treatment without tuberculosis | 20 970·7 (19 876·1 to 22 058·6) | .. | 1617·4 (1079·5 to 2267·1) | 2 265 649·4% (1 200 289·1 to 5 966 377·3)* | 491·3% (420·4 to 581·8)* | 1 847 617·4% (1 009 483·5 to 4 566 992·3)* | 404·7% (343·7 to 482·1)* | |||
| Sexually transmitted infections excluding HIV | 1 216 425·2 (1 107 618·8 to 1 337 882·9) | 767 169·1 (692 748·8 to 849 178·3) | 1420·7 (764·5 to 2552·2) | 33·8% (32·1 to 35·3)* | 13·4% (12·1 to 14·8)* | 0·8% (−0·2 to 1·5) | 0·8% (−0·3 to 1·8) | |||
| Syphilis | 36 388·6 (31 030·7 to 42 960·2) | 10 263·8 (8574·2 to 11 991·1) | 72·9 (50·9 to 98·3) | 28·7% (25·1 to 33·0)* | 18·5% (15·7 to 21·5)* | −10·8% (−13·8 to −7·4)* | −3·5% (−5·8 to −1·2)* | |||
| Early syphilis | 36 018·0 (30 662·1 to 42 602·0) | 10 263·8 (8574·2 to 11 991·1) | 8·6 (2·6 to 21·9) | 36·6% (32·5 to 40·8)* | 13·7% (10·1 to 17·1)* | 5·0% (2·2 to 7·8)* | 2·2% (−1·0 to 5·3) | |||
| Tertiary syphilis | 370·6 (319·8 to 420·3) | .. | 64·3 (43·9 to 88·2) | 27·7% (23·9 to 32·2)* | 19·2% (16·1 to 22·5)* | −12·5% (−15·3 to −9·4)* | −4·2% (−6·5 to −1·8)* | |||
| Chlamydial infection | 109 822·0 (93 827·4 to 128 829·4) | 297 131·3 (247 050·0 to 358 150·1) | 314·6 (179·4 to 565·4) | 30·9% (28·5 to 33·7)* | 10·1% (7·7 to 12·7)* | 0·3% (−1·0 to 2·0) | −0·7% (−2·7 to 1·6) | |||
| Chlamydia episode | 104 561·0 (88 447·0 to 123 536·5) | 297 131·3 (247 050·0 to 358 150·1) | 175·0 (68·4 to 379·5) | 29·0% (26·4 to 31·4)* | 9·0% (7·7 to 10·3)* | −1·0% (−1·7 to −0·3)* | −1·7% (−2·4 to −1·0)* | |||
| Chlamydial infection complications | 5261·1 (4960·3 to 5607·8) | .. | 139·6 (92·2 to 195·6) | 33·5% (28·8 to 38·4)* | 11·6% (6·5 to 16·6)* | 2·1% (−1·0 to 5·2) | 0·7% (−3·8 to 5·2) | |||
| Gonococcal infection | 47 269·2 (36 099·9 to 61 106·1) | 137 221·5 (105 854·1 to 173 538·4) | 190·3 (102·2 to 356·6) | 27·0% (24·1 to 30·5)* | 10·2% (6·8 to 14·4)* | 1·3% (−0·5 to 3·3) | 1·9% (−1·3 to 5·6) | |||
| Gonococcal infection complications | 1705·4 (1596·2 to 1824·5) | .. | 68·9 (45·3 to 97·9) | 31·9% (26·9 to 36·9)* | 16·9% (9·7 to 24·5)* | 2·6% (−1·1 to 6·4) | 6·6% (0·1 to 13·5)* | |||
| Gonorrhoea episode | 45 563·8 (34 373·4 to 59 361·5) | 137 221·5 (105 854·1 to 173 538·4) | 121·3 (46·5 to 271·5) | 24·7% (22·1 to 28·0)* | 6·7% (2·9 to 9·9)* | 0·7% (−0·9 to 2·6) | −0·5% (−4·2 to 2·7) | |||
| Trichomoniasis | 142 114·5 (118 989·2 to 170 489·8) | 244 855·9 (208 226·8 to 289 024·3) | 242·8 (97·6 to 523·8) | 37·7% (35·4 to 40·1)* | 16·0% (14·2 to 17·7)* | 2·9% (1·9 to 3·8)* | 2·2% (1·1 to 3·2)* | |||
| Genital herpes | 955 894·8 (847 327·5 to 1 087 446·6) | 77 696·7 (68 687·0 to 87 707·7) | 247·4 (79·8 to 593·7) | 41·7% (39·0 to 43·3)* | 19·8% (18·1 to 21·0)* | 1·9% (1·1 to 2·8)* | 1·5% (0·9 to 2·3)* | |||
| Other sexually transmitted infections | 11 860·5 (11 121·7 to 12 735·7) | .. | 352·7 (214·9 to 598·5) | 33·9% (31·9 to 36·2)* | 11·2% (9·6 to 13·1)* | 1·8% (0·7 to 3·1)* | 0·8% (−0·6 to 2·3) | |||
| Other sexually transmitted diseases residual | .. | .. | 193·3 (105·6 to 361·3) | 27·2% (25·3 to 29·5)* | 7·8% (5·7 to 10·4)* | −0·0% (−1·2 to 1·4) | −0·6% (−2·6 to 1·7) | |||
| Other sexually transmitted diseases | 11 860·5 (11 121·7 to 12 735·7) | .. | 352·7 (214·9 to 598·5) | 33·9% (31·9 to 36·2)* | 11·2% (9·6 to 13·1)* | 1·8% (0·7 to 3·1)* | 0·8% (−0·6 to 2·3) | |||
| Respiratory infections and tuberculosis | 2 187 290·0 (1 979 143·1 to 2 449 760·7) | 17 942 622·2 (16 102 037·4 to 20 038 445·4) | 11 670·3 (7845·9 to 16 749·7) | 16·2% (14·9 to 17·6)* | 9·8% (8·9 to 10·7)* | −6·9% (−8·3 to −5·7)* | −2·6% (−3·6 to −1·7)* | |||
| Tuberculosis | 1 929 208·6 (1 710 952·7 to 2 199 199·9) | 8965·8 (8191·8 to 9820·8) | 3120·4 (2133·6 to 4230·6) | 16·3% (14·6 to 18·0)* | 9·4% (7·8 to 11·2)* | −13·9% (−15·1 to −12·7)* | −7·6% (−8·8 to −6·5)* | |||
| Latent tuberculosis infection | 1 918 892·1 (1 701 127·1 to 2 187 433·5) | .. | .. | .. | .. | .. | .. | |||
| Drug-susceptible tuberculosis | 9828·6 (8860·7 to 10 773·9) | 8508·6 (7808·6 to 9371·0) | 2969·7 (2011·4 to 4077·3) | 11·4% (9·4 to 13·5)* | 9·6% (5·2 to 12·7)* | −17·5% (−18·9 to −16·1)* | −7·5% (−11·1 to −5·1)* | |||
| Multidrug-resistant tuberculosis without extensive drug resistance | 464·1 (229·1 to 863·3) | 432·8 (254·6 to 726·9) | 142·8 (66·6 to 281·1) | 589·4% (189·9 to 1708·7)* | 4·8% (−45·2 to 76·4) | 399·5% (110·5 to 1218·1)* | −11·8% (−53·5 to 48·1) | |||
| Extensively drug-resistant tuberculosis | 23·7 (13·9 to 44·1) | 24·5 (17·7 to 35·0) | 7·9 (4·1 to 15·1) | .. | 44·8% (−11·7 to 157·8) | .. | 20·9% (−26·3 to 115·5) | |||
| Lower respiratory infections | 10 638·1 (9729·1 to 11 559·4) | 471 825·5 (429 571·3 to 516 976·9) | 648·9 (432·6 to 927·7) | 3·2% (0·3 to 6·3)* | 15·8% (11·8 to 20·1)* | −11·1% (−13·0 to −9·3)* | 4·4% (0·5 to 8·4)* | |||
| Guillain-Barré syndrome due to lower respiratory infections | 12·3 (6·9 to 19·9) | .. | 3·6 (1·7 to 6·6) | 29·2% (25·3 to 33·5)* | 17·9% (15·5 to 20·6)* | 2·7% (1·1 to 4·3)* | 3·1% (1·9 to 4·2)* | |||
| Lower respiratory infection episode | 10 625·8 (9719·1 to 11 547·2) | 471 825·5 (429 571·3 to 516 976·9) | 645·3 (429·9 to 925·0) | 3·1% (0·1 to 6·1)* | 15·8% (11·8 to 20·1)* | −11·2% (−13·1 to −9·3)* | 4·5% (0·5 to 8·4)* | |||
| Upper respiratory infections | 236 084·8 (211 064·1 to 264 360·3) | 17 144 182·9 (15 334 493·4 to 19 211 715·4) | 5866·0 (3422·5 to 9336·4) | 19·6% (17·3 to 21·9)* | 11·5% (10·3 to 12·8)* | −2·5% (−3·3 to −1·8)* | 0·2% (−0·6 to 1·1) | |||
| Guillain-Barré syndrome due to upper respiratory infections | 33·4 (24·4 to 44·7) | .. | 9·9 (5·8 to 15·5) | 29·2% (25·3 to 33·4)* | 17·9% (15·5 to 20·6)* | 2·7% (1·1 to 4·3)* | 3·1% (1·9 to 4·2)* | |||
| Upper respiratory infection episode | 236 051·4 (211 015·2 to 264 325·0) | 17 144 182·9 (15 334 493·4 to 19 211 715·4) | 5856·2 (3414·4 to 9325·9) | 19·6% (17·3 to 21·8)* | 11·4% (10·3 to 12·8)* | −2·5% (−3·3 to −1·8)* | 0·2% (−0·6 to 1·1) | |||
| Otitis media | 101 690·4 (92 570·7 to 111 633·5) | 317 648·0 (254 458·5 to 397 736·6) | 2034·8 (1230·7 to 3227·8) | 11·6% (8·9 to 14·5)* | 4·3% (1·8 to 7·0)* | −5·8% (−8·0 to −3·7)* | −4·6% (−6·9 to −2·2)* | |||
| Acute otitis media | 18 153·8 (14 592·6 to 22 589·9) | 317 625·1 (254 441·2 to 397 715·6) | 238·4 (117·1 to 437·1) | 10·7% (8·2 to 13·6)* | 7·5% (5·2 to 9·7)* | 4·6% (2·5 to 7·1)* | 0·2% (−2·1 to 2·2) | |||
| Chronic otitis media | 83 536·6 (75 211·7 to 92 279·1) | 22·8 (0·8 to 81·8) | 1796·4 (1107·7 to 2821·4) | 11·7% (8·7 to 14·9)* | 3·9% (1·0 to 7·0)* | −7·1% (−9·4 to −4·6)* | −5·2% (−7·8 to −2·5)* | |||
| Enteric infections | 93 304·4 (86 780·5 to 99 732·5) | 6 307 792·4 (5 822 111·3 to 6 830 241·4) | 10 583·7 (7283·3 to 14 516·1) | 16·4% (13·6 to 19·4)* | 23·6% (20·6 to 26·9)* | −2·5% (−4·2 to −0·7)* | 9·7% (6·8 to 12·7)* | |||
| Diarrhoeal diseases | 93 472·8 (86 857·2 to 99 961·1) | 6 292 936·7 (5 808 374·7 to 6 816 675·4) | 10 465·1 (7203·1 to 14 386·3) | 17·6% (14·8 to 20·7)* | 24·5% (21·5 to 27·9)* | −1·6% (−3·4 to 0·3) | 10·4% (7·6 to 13·4)* | |||
| Guillain-Barré syndrome due to diarrhoeal diseases | 11·4 (7·8 to 15·7) | .. | 3·4 (2·0 to 5·4) | 29·2% (25·3 to 33·5)* | 17·9% (15·5 to 20·6)* | 2·7% (1·1 to 4·3)* | 3·1% (2·0 to 4·2)* | |||
| Diarrhoeal disease episode | 93 461·4 (86 846·3 to 99 951·5) | 6 292 936·7 (5 808 374·7 to 6 816 675·4) | 10 461·7 (7201·2 to 14 382·7) | 17·6% (14·7 to 20·7)* | 24·5% (21·5 to 27·9)* | −1·6% (−3·4 to 0·3) | 10·4% (7·6 to 13·4)* | |||
| Typhoid and paratyphoid | 387·5 (312·6 to 467·9) | 14 321·1 (12 540·3 to 16 337·4) | 114·9 (77·7 to 164·2) | −26·3% (−32·0 to −20·7)* | −24·9% (−30·9 to −18·4)* | −35·2% (−39·8 to −30·4)* | −30·4% (−36·1 to −24·2)* | |||
| Typhoid fever | 691·5 (582·2 to 808·9) | 10 924·3 (9343·0 to 12 597·1) | 105·5 (70·3 to 151·0) | −26·4% (−32·5 to −20·4)* | −25·6% (−32·0 to −18·5)* | −35·2% (−40·2 to −29·8)* | −31·1% (−37·2 to −24·4)* | |||
| Typhoid fever complications | 144·0 (120·1 to 173·7) | 1880·1 (1605·0 to 2191·0) | 45·9 (29·9 to 66·3) | −26·0% (−35·3 to −15·4)* | −25·7% (−35·6 to −14·3)* | −34·9% (−43·0 to −25·5)* | −31·1% (−40·6 to −20·4)* | |||
| Typhoid fever episode | 547·5 (457·7 to 640·9) | 9044·1 (7759·9 to 10 439·8) | 59·6 (39·3 to 87·0) | −26·7% (−33·8 to −18·5)* | −25·6% (−33·2 to −16·9)* | −35·4% (−41·6 to −28·5)* | −31·0% (−38·4 to −22·7)* | |||
| Paratyphoid fever | 149·0 (117·0 to 185·1) | 3396·9 (2666·5 to 4184·1) | 9·4 (5·9 to 13·9) | −25·8% (−32·5 to −18·1)* | −15·8% (−23·8 to −7·1)* | −35·6% (−41·2 to −29·2)* | −22·0% (−29·5 to −13·6)* | |||
| Intestinal perforation due to paratyphoid | 6·7 (5·2 to 8·4) | 173·9 (135·4 to 215·9) | 0·8 (0·5 to 1·1) | −26·4% (−34·5 to −17·6)* | −16·0% (−23·8 to −6·2)* | −36·0% (−42·9 to −28·8)* | −22·1% (−29·7 to −12·6)* | |||
| Paratyphoid fever episode | 142·3 (111·5 to 176·8) | 3222·9 (2537·7 to 3976·5) | 8·6 (5·4 to 12·8) | −25·8% (−32·7 to −17·7)* | −15·8% (−24·2 to −6·5)* | −35·6% (−41·4 to −28·7)* | −21·9% (−29·8 to −13·2)* | |||
| Invasive non-typhoidal salmonella | 20·5 (14·5 to 28·6) | 534·6 (409·0 to 705·0) | 2·7 (1·6 to 4·3) | 97·4% (71·1 to 127·3)* | −20·9% (−30·1 to −9·7)* | 75·1% (52·6 to 101·3)* | −26·9% (−36·1 to −16·0)* | |||
| Other intestinal infectious diseases | .. | .. | 1·0 (0·6 to 1·4) | −40·9% (−47·2 to −33·9)* | −41·4% (−47·4 to −34·8)* | −45·3% (−50·8 to −39·2)* | −47·0% (−52·6 to −40·9)* | |||
| Neglected tropical diseases and malaria | 1 278 896·5 (1 223 506·1 to 1 343 059·2) | 357 652·1 (301 519·2 to 431 965·1) | 13 622·9 (9498·3 to 18 673·3) | 2·4% (−1·9 to 7·7) | −10·3% (−15·0 to −5·6)* | −19·2% (−22·5 to −15·4)* | −20·6% (−24·6 to −16·5)* | |||
| Malaria | 136 085·1 (126 471·7 to 145 009·3) | 208 768·2 (170 214·0 to 257 506·0) | 1468·0 (1034·0 to 2020·6) | 14·1% (4·7 to 24·4)* | −22·6% (−28·0 to −15·7)* | 0·3% (−8·0 to 9·1) | −28·4% (−33·4 to −22·0)* | |||
| Malaria complications | 794·8 (723·8 to 875·7) | .. | 328·3 (255·8 to 405·9) | 43·2% (38·1 to 49·0)* | 26·8% (22·2 to 31·8)* | 17·3% (13·1 to 21·9)* | 17·4% (13·1 to 22·1)* | |||
| Malaria episode | 12 152·1 (7883·1 to 17 229·6) | 208 768·2 (170 214·0 to 257 506·0) | 423·2 (217·3 to 710·8) | 10·0% (−2·3 to 20·4) | −22·1% (−29·0 to −13·9)* | −0·4% (−11·4 to 9·4) | −27·5% (−34·2 to −19·6)* | |||
| Malaria parasitaemia | 123 138·2 (112 779·9 to 133 815·6) | .. | 716·6 (471·7 to 1056·9) | 10·9% (0·3 to 23·5)* | −34·5% (−40·4 to −27·0)* | −2·5% (−11·9 to 8·4) | −39·3% (−44·8 to −32·4)* | |||
| Chagas disease | 6197·0 (5248·5 to 7243·9) | 162·5 (139·0 to 189·0) | 57·3 (38·3 to 82·5) | 10·1% (6·9 to 13·2)* | 2·0% (−1·4 to 5·7) | −24·0% (−26·1 to −21·8)* | −17·8% (−20·6 to −15·0)* | |||
| Acute Chagas disease | 0·9 (0·4 to 1·5) | 162·5 (139·0 to 189·0) | 0·0 (0·0 to 0·1) | −16·2% (−22·1 to −12·7)* | −11·8% (−14·4 to −8·9)* | −32·1% (−36·3 to −29·6)* | −20·8% (−23·1 to −18·5)* | |||
| Asymptomatic Chagas disease | 5274·6 (4437·8 to 6166·6) | .. | .. | .. | .. | .. | .. | |||
| Symptomatic chronic Chagas infection | 921·4 (731·1 to 1128·3) | .. | 57·2 (38·3 to 82·4) | 10·1% (7·0 to 13·3)* | 2·0% (−1·4 to 5·7) | −24·0% (−26·1 to −21·8)* | −17·8% (−20·6 to −15·0)* | |||
| Leishmaniasis | 4130·2 (3515·7 to 4966·8) | 669·1 (506·6 to 874·3) | 264·4 (172·4 to 389·6) | 7·6% (−8·7 to 29·4) | 30·1% (20·2 to 42·3)* | −16·2% (−28·2 to 1·1) | 14·1% (4·6 to 25·9)* | |||
| Visceral leishmaniasis | 10·6 (8·2 to 16·5) | 42·4 (32·9 to 66·1) | 0·8 (0·5 to 1·3) | −96·0% (−97·1 to −94·0)* | −72·4% (−79·4 to −58·3)* | −96·4% (−97·4 to −94·7)* | −74·5% (−81·0 to −61·3)* | |||
| Cutaneous and mucocutaneous leishmaniasis | 4166·6 (3560·7 to 4992·8) | 626·6 (460·0 to 834·2) | 263·6 (171·9 to 388·8) | 65·8% (35·6 to 126·1)* | 31·5% (21·2 to 44·2)* | 21·9% (0·0 to 66·3)* | 15·3% (5·2 to 27·4)* | |||
| African trypanosomiasis | 4·9 (1·3 to 19·8) | 3·3 (2·0 to 8·1) | 1·3 (0·3 to 5·3) | −60·9% (−69·0 to −47·0)* | −79·1% (−94·4 to −11·2)* | −68·9% (−75·4 to −58·4)* | −81·2% (−94·9 to −20·5)* | |||
| Trypanosomiasis Gambiense | 4·8 (1·3 to 19·6) | 3·1 (1·8 to 8·0) | 1·3 (0·3 to 5·3) | −60·3% (−69·1 to −44·4)* | −78·4% (−94·6 to −7·0)* | −68·5% (−75·6 to −56·3)* | −80·5% (−95·1 to −16·4)* | |||
| Trypanosomiasis Rhodesiense | 0·1 (0·0 to 0·3) | 0·2 (0·1 to 0·6) | 0·0 (0·0 to 0·1) | −67·7% (−81·9 to −46·6)* | −91·7% (−97·3 to −73·1)* | −74·2% (−85·6 to −57·6)* | −92·5% (−97·6 to −75·4)* | |||
| Schistosomiasis | 142 788·5 (131 656·9 to 155 480·2) | .. | 1089·1 (535·8 to 2082·0) | 48·4% (44·0 to 51·5)* | −20·7% (−22·2 to −19·2)* | 10·6% (7·3 to 13·0)* | −30·0% (−31·5 to −28·6)* | |||
| Mild schistosomiasis | 114 409·2 (106 010·4 to 124 045·9) | .. | 642·0 (259·2 to 1341·1) | 53·2% (51·5 to 54·7)* | −21·8% (−23·3 to −20·4)* | 13·1% (11·5 to 14·6)* | −31·5% (−32·9 to −30·1)* | |||
| Anaemia due to schistosomiasis | 7618·2 (6901·9 to 8321·6) | .. | 180·6 (119·1 to 268·6) | 33·0% (24·1 to 42·6)* | −30·4% (−35·1 to −25·9)* | −1·3% (−7·6 to 5·6) | −38·6% (−42·8 to −34·6)* | |||
| Schistosomiasis complications | 20 785·2 (18 564·0 to 23 286·9) | .. | 266·5 (146·7 to 472·7) | 50·9% (47·6 to 54·5)* | −9·0% (−11·9 to −4·3)* | 15·7% (12·7 to 18·5)* | −17·9% (−20·4 to −14·4)* | |||
| Cysticercosis | 5417·9 (4662·0 to 6190·3) | .. | 1568·5 (1015·3 to 2181·0) | 13·5% (8·2 to 18·7)* | 8·5% (3·7 to 12·8)* | −17·7% (−21·3 to −14·2)* | −9·1% (−13·1 to −5·6)* | |||
| Cystic echinococcosis | 589·5 (373·9 to 926·5) | 139·6 (90·2 to 213·9) | 48·3 (25·4 to 85·0) | 33·5% (26·3 to 41·9)* | 18·9% (12·4 to 25·5)* | −1·0% (−7·6 to 4·8) | 3·4% (−1·1 to 6·9) | |||
| Lymphatic filariasis | 64 623·4 (59 178·2 to 70 866·1) | .. | 1364·0 (752·0 to 2157·6) | 25·5% (4·6 to 37·4)* | −37·0% (−48·7 to −26·4)* | −6·4% (−22·0 to 2·3) | −44·8% (−54·7 to −35·5)* | |||
| Prevalence of detectable microfilaria due to lymphatic filariasis | 52 285·4 (48 689·8 to 55 843·9) | .. | .. | .. | .. | .. | .. | |||
| Lymphatic filariasis complications | 12 338·1 (8403·3 to 17 434·1) | .. | 1364·0 (752·0 to 2157·6) | 25·5% (4·6 to 37·4)* | −37·0% (−48·7 to −26·4)* | −6·4% (−22·0 to 2·3) | −44·8% (−54·7 to −35·5)* | |||
| Onchocerciasis | 20 938·1 (12 882·3 to 37 227·7) | .. | 1342·9 (639·1 to 2371·9) | −10·6% (−15·5 to −4·3)* | 3·9% (−15·1 to 19·9) | −32·4% (−36·4 to −27·3)* | −8·0% (−25·8 to 6·7) | |||
| Asymptomatic onchocerciasis | 5131·9 (35·8 to 18 859·4) | .. | .. | .. | .. | .. | .. | |||
| Skin disease due to onchocerciasis | 14 654·2 (10 690·5 to 19 713·6) | .. | 1246·9 (552·7 to 2254·6) | −8·6% (−14·3 to −0·6)* | 3·7% (−18·4 to 20·3) | −30·0% (−34·7 to −23·6)* | −7·5% (−27·7 to 7·9) | |||
| Vision loss due to onchocerciasis | 1152·1 (829·0 to 1703·6) | .. | 96·1 (60·6 to 141·5) | −31·6% (−36·5 to −26·5)* | 7·0% (−4·8 to 21·4) | −52·9% (−56·4 to −49·3)* | −15·0% (−24·3 to −3·8)* | |||
| Trachoma | 3818·9 (2842·6 to 5135·2) | .. | 302·9 (201·7 to 425·1) | −12·8% (−18·2 to −6·4)* | −5·5% (−13·1 to 2·0) | −41·8% (−45·6 to −37·6)* | −28·2% (−33·8 to −22·5)* | |||
| Dengue | 6267·4 (3416·1 to 10 611·9) | 104 771·9 (63 759·0 to 158 870·0) | 1019·8 (447·3 to 1909·6) | 178·9% (68·9 to 8404·5)* | 61·1% (41·3 to 148·0)* | 128·0% (38·1 to 6804·6)* | 45·2% (27·4 to 123·4)* | |||
| Post-dengue chronic fatigue syndrome | 4418·2 (2064·8 to 8078·2) | .. | 911·1 (380·7 to 1726·5) | 179·0% (69·0 to 8459·3)* | 61·1% (41·1 to 149·3)* | 128·2% (38·2 to 6850·0)* | 45·2% (27·3 to 124·6)* | |||
| Dengue episode | 1849·2 (1117·6 to 2774·7) | 104 771·9 (63 759·0 to 158 870·0) | 108·7 (56·0 to 189·7) | 177·7% (68·1 to 8513·3)* | 61·1% (42·2 to 140·9)* | 126·7% (37·4 to 6942·1)* | 45·0% (28·0 to 116·7)* | |||
| Yellow fever | 2·6 (0·8 to 7·1) | 97·4 (28·0 to 251·7) | 0·1 (0·0 to 0·2) | −53·3% (−57·7 to −47·9)* | −15·8% (−25·4 to −4·4)* | −61·1% (−64·7 to −56·7)* | −22·4% (−31·4 to −11·4)* | |||
| Asymptomatic yellow fever | 1·5 (0·4 to 4·2) | 54·4 (14·0 to 152·9) | .. | .. | .. | .. | .. | |||
| Yellow fever episode | 1·2 (0·3 to 3·0) | 43·0 (12·5 to 115·1) | 0·1 (0·0 to 0·2) | −53·3% (−57·7 to −47·9)* | −15·8% (−25·4 to −4·4)* | −61·1% (−64·7 to −56·7)* | −22·4% (−31·4 to −11·4)* | |||
| Rabies | 0·5 (0·4 to 0·6) | 13·4 (10·9 to 16·2) | 0·1 (0·0 to 0·1) | −46·8% (−57·6 to −36·0)* | −35·4% (−45·7 to −23·8)* | −56·9% (−66·1 to −48·1)* | −43·3% (−52·3 to −32·9)* | |||
| Intestinal nematode infections | 894 917·5 (836 669·5 to 961 911·6) | .. | 1661·4 (960·3 to 2708·6) | −35·8% (−41·3 to −30·1)* | −30·1% (−33·9 to −26·1)* | −47·3% (−51·8 to −42·6)* | −36·3% (−39·8 to −32·7)* | |||
| Ascariasis | 447 009·0 (394 765·2 to 508 585·1) | .. | 603·8 (325·2 to 1037·6) | −38·3% (−47·2 to −28·7)* | −34·2% (−41·2 to −26·8)* | −48·3% (−55·9 to −40·2)* | −39·9% (−46·2 to −33·1)* | |||
| Asymptomatic ascariasis | 414 347·5 (365 611·9 to 472 277·1) | .. | .. | .. | .. | .. | .. | |||
| Ascariasis complications | 32 661·5 (28 939·0 to 36 737·1) | .. | 603·8 (325·2 to 1037·6) | −38·3% (−47·2 to −28·7)* | −34·2% (−41·2 to −26·8)* | −48·3% (−55·9 to −40·2)* | −39·9% (−46·2 to −33·1)* | |||
| Trichuriasis | 289 617·7 (254 640·5 to 330 724·5) | .. | 212·7 (120·0 to 353·7) | −43·0% (−50·2 to −35·7)* | −23·1% (−29·3 to −15·8)* | −53·4% (−59·4 to −47·5)* | −29·3% (−35·0 to −22·5)* | |||
| Asymptomatic trichuriasis | 278 887·2 (244 650·6 to 318 878·2) | .. | .. | .. | .. | .. | .. | |||
| Trichuriasis complications | 10 730·6 (9782·7 to 11 693·0) | .. | 212·7 (120·0 to 353·7) | −43·0% (−50·2 to −35·7)* | −23·1% (−29·3 to −15·8)* | −53·4% (−59·4 to −47·5)* | −29·3% (−35·0 to −22·5)* | |||
| Hookworm disease | 229 217·1 (212 538·1 to 246 731·6) | .. | 845·0 (510·0 to 1340·3) | −31·6% (−39·5 to −23·8)* | −28·5% (−34·0 to −22·7)* | −44·8% (−51·3 to −38·5)* | −35·2% (−40·2 to −30·0)* | |||
| Asymptomatic hookworm disease | 190 730·4 (176 950·0 to 205 624·5) | .. | .. | .. | .. | .. | .. | |||
| Anaemia due to hookworm disease | 9536·1 (8764·4 to 10 362·8) | .. | 245·9 (164·0 to 360·4) | −41·2% (−49·1 to −32·8)* | −35·4% (−41·8 to −28·5)* | −51·7% (−58·1 to −44·7)* | −41·3% (−47·1 to −34·9)* | |||
| Hookworm disease complications | 28 950·6 (26 952·9 to 31 087·4) | .. | 599·1 (334·2 to 993·7) | −25·8% (−33·7 to −17·7)* | −25·2% (−30·2 to −19·5)* | −40·8% (−47·2 to −34·4)* | −32·2% (−36·8 to −27·1)* | |||
| Food-borne trematodiases | 82 532·4 (74 596·1 to 91 774·9) | 40 746·0 (35 650·0 to 46 019·1) | 1870·7 (1070·9 to 3149·7) | 9·4% (−9·4 to 31·8) | 8·5% (4·8 to 12·0)* | −16·6% (−30·0 to −0·8)* | −6·2% (−9·1 to −3·5)* | |||
| Asymptomatic food-borne trematodiases | 65 832·6 (56 442·3 to 75 378·7) | 30 998·0 (23 711·7 to 37 759·6) | .. | .. | .. | .. | .. | |||
| Food-borne trematodiases complications | 16 699·7 (11 172·6 to 25 636·1) | 9748·1 (5025·4 to 16 377·4) | 1870·7 (1070·9 to 3149·7) | 9·4% (−9·4 to 31·8) | 8·5% (4·8 to 12·0)* | −16·6% (−30·0 to −0·8)* | −6·2% (−9·1 to −3·5)* | |||
| Leprosy | 518·5 (487·7 to 552·5) | 48·5 (45·8 to 51·4) | 31·5 (21·5 to 44·6) | 35·0% (31·7 to 38·2)* | −1·3% (−3·7 to 1·1) | −5·5% (−7·8 to −3·4)* | −20·4% (−22·4 to −18·5)* | |||
| Ebola virus disease | .. | .. | .. | .. | −96·8% (−97·5 to −94·7)* | .. | −97·1% (−97·8 to −95·3)* | |||
| Ebola cases | .. | .. | .. | .. | −97·8% (−97·9 to −97·7)* | .. | −98·1% (−98·1 to −98·0)* | |||
| Post-Ebola chronic fatigue syndrome | .. | .. | .. | .. | −96·7% (−97·5 to −94·6)* | .. | −97·1% (−97·7 to −95·2)* | |||
| Zika virus disease | 37·6 (28·2 to 52·0) | 2232·2 (1659·6 to 3097·6) | 1·2 (0·8 to 1·8) | .. | .. | .. | .. | |||
| Zika virus complications | 0·9 (0·7 to 1·5) | 0·6 (0·4 to 1·2) | 0·5 (0·3 to 0·8) | .. | .. | .. | .. | |||
| Zika virus episode | 36·7 (27·3 to 50·9) | 2231·6 (1659·1 to 3097·0) | 0·7 (0·4 to 1·1) | .. | .. | .. | .. | |||
| Guinea worm disease | .. | .. | .. | −99·6% (−99·6 to −99·6)* | −99·5% (−99·6 to −99·3)* | −99·7% (−99·7 to −99·7)* | −99·5% (−99·7 to −99·3)* | |||
| Moderate pain and limited mobility due to guinea worm | .. | .. | .. | −99·6% (−99·6 to −99·6)* | −99·5% (−99·6 to −99·3)* | −99·7% (−99·7 to −99·7)* | −99·5% (−99·7 to −99·4)* | |||
| Guinea worm disease complications | .. | .. | .. | −99·6% (−99·7 to −99·6)* | −99·5% (−99·6 to −99·2)* | −99·7% (−99·7 to −99·7)* | −99·5% (−99·7 to −99·3)* | |||
| Other neglected tropical diseases | 52 797·1 (51 667·9 to 54 034·5) | .. | 1531·2 (1027·0 to 2201·6) | 2·2% (−1·2 to 5·5) | −5·7% (−9·7 to −1·5)* | −10·9% (−13·7 to −8·0)* | −13·3% (−17·1 to −9·4)* | |||
| Acute infection due to other neglected tropical diseases | .. | .. | 13·3 (6·9 to 23·0) | 164·3% (61·7 to 303·2)* | 107·6% (83·3 to 199·8)* | 135·1% (44·5 to 257·7)* | 86·9% (64·7 to 169·5)* | |||
| Anaemia due to other neglected tropical diseases | 52 797·1 (51 667·9 to 54 034·5) | .. | 1517·9 (1018·7 to 2185·7) | 1·9% (−1·4 to 5·3) | −6·2% (−10·2 to −2·0)* | −11·1% (−14·0 to −8·3)* | −13·7% (−17·6 to −9·8)* | |||
| Other infectious diseases | 101 451·5 (97 425·1 to 105 559·6) | 478 720·6 (450 498·3 to 511 601·6) | 4056·6 (2835·5 to 5535·8) | 5·0% (2·1 to 7·5)* | −0·5% (−2·9 to 1·6) | −13·3% (−15·3 to −11·5)* | −10·6% (−12·7 to −8·9)* | |||
| Meningitis | 10 572·9 (8836·7 to 12 552·2) | 5045·4 (4435·1 to 5877·8) | 933·9 (653·0 to 1255·1) | 10·6% (8·4 to 13·2)* | −3·2% (−5·9 to −0·3)* | −10·3% (−12·2 to −8·1)* | −12·4% (−14·7 to −9·7)* | |||
| Pneumococcal meningitis | 3557·0 (2932·0 to 4337·6) | 444·9 (357·8 to 552·1) | 325·0 (219·2 to 440·0) | 19·9% (16·6 to 23·3)* | −24·8% (−27·4 to −22·1)* | −3·7% (−6·3 to −1·0)* | −32·1% (−34·6 to −29·6)* | |||
| Acute pneumococcal meningitis | 19·9 (15·8 to 25·0) | 444·9 (357·8 to 552·1) | 2·6 (1·6 to 3·9) | 9·7% (3·6 to 15·9)* | −28·4% (−34·2 to −22·4)* | −0·9% (−6·0 to 4·7) | −34·1% (−39·8 to −28·4)* | |||
| Pneumococcal meningitis complications | 3537·1 (2915·9 to 4314·0) | .. | 322·4 (217·6 to 436·2) | 20·0% (16·7 to 23·4)* | −24·7% (−27·4 to −22·1)* | −3·7% (−6·4 to −1·0)* | −32·1% (−34·5 to −29·5)* | |||
| H influenzae type B meningitis | 924·2 (668·2 to 1229·3) | 262·3 (195·1 to 351·1) | 84·3 (57·6 to 115·4) | −2·7% (−5·7 to 0·5) | −48·1% (−50·4 to −45·8)* | −20·3% (−22·8 to −17·6)* | −52·5% (−54·6 to −50·3)* | |||
| Acute H influenzae type B meningitis | 11·3 (8·4 to 15·2) | 262·3 (195·1 to 351·1) | 1·5 (0·9 to 2·4) | −9·6% (−14·9 to −4·3)* | −48·4% (−54·2 to −42·2)* | −16·3% (−21·4 to −11·4)* | −51·7% (−57·2 to −45·6)* | |||
| H influenzae type B meningitis complications | 912·9 (657·9 to 1216·9) | .. | 82·8 (56·6 to 113·3) | −2·6% (−5·6 to 0·7) | −48·1% (−50·4 to −45·8)* | −20·4% (−23·0 to −17·6)* | −52·5% (−54·6 to −50·2)* | |||
| Meningococcal infection | 1076·7 (764·8 to 1424·7) | 402·5 (312·5 to 517·6) | 99·0 (67·5 to 135·4) | 12·4% (9·4 to 15·4)* | −3·2% (−6·4 to −0·1)* | −9·8% (−12·3 to −7·3)* | −12·9% (−15·9 to −10·0)* | |||
| Acute meningococcal meningitis | 18·0 (13·9 to 23·1) | 402·5 (312·5 to 517·6) | 2·4 (1·4 to 3·7) | 5·8% (−1·3 to 13·5) | −4·1% (−12·3 to 4·5) | −3·6% (−9·8 to 3·0) | −12·0% (−19·8 to −3·9)* | |||
| Meningococcal meningitis complications | 1058·6 (749·6 to 1404·6) | .. | 96·6 (65·7 to 132·1) | 12·6% (9·6 to 15·6)* | −3·2% (−6·3 to −0·1)* | −10·0% (−12·5 to −7·4)* | −12·9% (−15·9 to −10·1)* | |||
| Other meningitis | 5015·1 (3735·5 to 6370·4) | 3935·7 (3466·6 to 4569·8) | 425·7 (292·3 to 570·1) | 5·6% (2·9 to 8·6)* | 58·6% (53·4 to 64·1)* | −13·3% (−15·7 to −10·7)* | 43·4% (38·7 to 48·4)* | |||
| Other acute bacterial meningitis | 64·0 (54·6 to 76·8) | 1519·8 (1296·4 to 1836·4) | 8·5 (5·4 to 12·6) | −1·8% (−6·8 to 4·1) | 54·1% (41·2 to 68·0)* | −8·3% (−13·1 to −3·2)* | 42·9% (30·7 to 56·3)* | |||
| Acute viral meningitis | 109·0 (95·5 to 125·5) | 2416·0 (2142·8 to 2745·8) | 14·5 (9·3 to 20·8) | 6·8% (3·0 to 10·6)* | 5·8% (0·5 to 11·4)* | −9·2% (−12·4 to −5·9)* | −3·9% (−9·0 to 1·6) | |||
| Other bacterial meningitis complications | 4842·0 (3574·3 to 6179·3) | .. | 402·7 (275·3 to 539·5) | 5·7% (2·8 to 9·0)* | 61·6% (56·3 to 67·5)* | −13·6% (−16·2 to −10·8)* | 46·1% (41·1 to 51·4)* | |||
| Encephalitis | 6724·9 (3731·2 to 10 760·4) | 2220·5 (2189·1 to 2255·2) | 524·1 (365·5 to 691·3) | 9·0% (6·6 to 11·2)* | 6·7% (4·6 to 8·9)* | −15·8% (−17·5 to −14·1)* | −6·2% (−8·1 to −4·3)* | |||
| Acute encephalitis | 116·9 (115·1 to 118·8) | 2220·5 (2189·1 to 2255·2) | 15·5 (10·4 to 22·2) | 14·1% (13·3 to 14·8)* | 13·9% (13·4 to 14·3)* | −5·2% (−5·8 to −4·7)* | 1·2% (0·8 to 1·6)* | |||
| Encephalitis complications | 6608·0 (3613·0 to 10 644·0) | .. | 508·6 (355·4 to 672·4) | 8·8% (6·4 to 11·1)* | 6·5% (4·3 to 8·8)* | −16·1% (−17·8 to −14·3)* | −6·5% (−8·4 to −4·5)* | |||
| Diphtheria | 1·1 (0·7 to 1·7) | 14·4 (9·7 to 22·4) | 0·1 (0·0 to 0·1) | −76·4% (−81·7 to −69·1)* | −32·3% (−55·3 to 7·2) | −77·6% (−82·6 to −70·7)* | −36·7% (−58·7 to 1·1) | |||
| Whooping cough | 1974·5 (1525·2 to 2490·2) | 14 413·5 (11 134·0 to 18 178·7) | 98·1 (58·2 to 154·8) | −26·1% (−27·9 to −24·0)* | −8·2% (−10·3 to −6·3)* | −26·5% (−28·4 to −24·5)* | −12·9% (−14·8 to −11·0)* | |||
| Tetanus | 59·6 (56·7 to 62·6) | 79·2 (53·4 to 105·3) | 1·7 (1·1 to 2·5) | −59·8% (−66·6 to −51·9)* | −28·6% (−39·7 to −17·5)* | −64·3% (−70·0 to −57·5)* | −36·2% (−46·2 to −26·1)* | |||
| Severe tetanus | 4·4 (3·0 to 5·9) | 79·2 (53·4 to 105·3) | 0·6 (0·3 to 0·9) | −73·0% (−77·3 to −66·9)* | −57·0% (−67·1 to −42·6)* | −75·4% (−79·2 to −70·1)* | −61·3% (−70·2 to −48·0)* | |||
| Neonatal tetanus complications | 55·2 (52·9 to 57·6) | .. | 1·1 (0·6 to 1·8) | 12·2% (9·5 to 14·1)* | 8·6% (6·6 to 10·3)* | −7·3% (−9·0 to −6·1)* | −2·0% (−3·7 to −0·5)* | |||
| Measles | 572·3 (203·7 to 1267·9) | 20 888·3 (7433·5 to 46 276·7) | 51·4 (17·4 to 118·2) | −44·0% (−47·2 to −41·0)* | −46·7% (−51·4 to −41·5)* | −44·6% (−47·8 to −41·6)* | −49·7% (−54·1 to −44·8)* | |||
| Varicella and herpes zoster | 6836·5 (6151·0 to 7510·6) | 95 660·6 (91 657·3 to 99 992·6) | 311·4 (187·5 to 471·2) | 38·1% (34·9 to 41·5)* | 21·7% (19·1 to 24·3)* | 1·8% (0·0 to 3·7)* | 1·0% (−0·6 to 2·5) | |||
| Chickenpox | 1236·7 (1200·1 to 1273·0) | 64 530·2 (62 619·2 to 66 422·9) | 7·1 (2·8 to 15·0) | 1·4% (−1·1 to 3·8) | 5·8% (3·3 to 8·1)* | −0·9% (−3·1 to 1·4) | 0·1% (−2·4 to 2·3) | |||
| Herpes zoster | 5599·7 (4913·3 to 6277·7) | 31 130·4 (27 271·7 to 35 058·2) | 304·3 (183·4 to 461·1) | 39·5% (36·3 to 42·8)* | 22·1% (19·5 to 24·8)* | 1·9% (0·1 to 3·8)* | 1·0% (−0·6 to 2·6) | |||
| Acute hepatitis | 31 960·4 (29 698·0 to 34 406·8) | 340 398·7 (319 758·5 to 362 492·1) | 511·8 (334·5 to 739·0) | 32·1% (21·7 to 42·8)* | 7·5% (−0·8 to 17·2) | 4·9% (−3·5 to 13·5) | −3·8% (−11·0 to 4·7) | |||
| Acute hepatitis A | 13 087·1 (12 396·2 to 13 831·2) | 170 132·3 (161 150·2 to 179 805·9) | 211·2 (134·0 to 308·2) | 24·2% (15·6 to 33·9)* | 6·8% (0·2 to 13·5)* | 5·6% (−1·7 to 13·6) | −0·4% (−6·9 to 6·3) | |||
| Acute hepatitis B | 16 793·7 (14 752·6 to 19 222·1) | 145 731·0 (128 012·1 to 166 802·5) | 263·5 (169·6 to 398·1) | 42·1% (21·9 to 65·7)* | 8·4% (−6·2 to 26·7) | 5·5% (−9·4 to 22·7) | −6·7% (−18·9 to 8·6) | |||
| Acute hepatitis C | 587·4 (532·0 to 649·7) | 5091·1 (4610·8 to 5631·1) | 8·2 (4·0 to 15·8) | 5·7% (0·7 to 10·9)* | 3·1% (−1·3 to 7·5) | −8·6% (−12·4 to −4·9)* | −7·1% (−11·4 to −3·0)* | |||
| Acute hepatitis E | 1492·1 (1330·2 to 1674·3) | 19 444·3 (17 332·9 to 21 836·3) | 28·9 (17·9 to 43·5) | 20·6% (10·1 to 32·1)* | 6·5% (−1·8 to 15·7) | −0·4% (−8·6 to 8·9) | −1·9% (−9·6 to 6·2) | |||
| Other unspecified infectious diseases | 53 643·7 (52 688·5 to 54 671·1) | .. | 1624·1 (1084·1 to 2337·5) | −0·4% (−3·3 to 2·5) | −3·5% (−6·7 to −0·2)* | −16·0% (−18·3 to −13·8)* | −12·1% (−15·1 to −9·0)* | |||
| Guillain-Barré syndrome due to other infectious diseases | 7·4 (5·0 to 10·7) | .. | 2·2 (1·2 to 3·6) | 29·2% (25·3 to 33·5)* | 18·0% (15·5 to 20·6)* | 2·7% (1·1 to 4·3)* | 3·1% (2·0 to 4·2)* | |||
| Other infectious diseases | .. | .. | 187·2 (114·4 to 291·1) | 12·3% (8·1 to 15·9)* | 18·0% (15·7 to 20·2)* | −11·2% (−14·3 to −8·6)* | 6·0% (4·1 to 7·8)* | |||
| Anaemia due to other infectious diseases | 53 636·3 (52 678·9 to 54 662·5) | .. | 1434·7 (967·8 to 2073·7) | −1·6% (−4·7 to 1·4) | −5·7% (−9·1 to −2·2)* | −16·5% (−19·0 to −14·1)* | −13·9% (−17·2 to −10·6)* | |||
| Maternal and neonatal disorders | 158 835·8 (140 427·7 to 179 076·8) | 101 962·6 (94 726·5 to 109 284·9) | 29 894·3 (22 429·9 to 38 381·6) | 49·5% (44·8 to 54·4)* | 22·6% (16·2 to 29·9)* | 24·5% (20·8 to 28·3)* | 11·3% (5·5 to 18·0)* | |||
| Maternal disorders | 8532·0 (7424·5 to 9856·9) | 79 812·2 (72 665·3 to 87 135·8) | 805·6 (570·1 to 1084·3) | 0·7% (−8·3 to 10·5) | −3·3% (−12·0 to 7·1) | −21·9% (−28·6 to −14·6)* | −12·5% (−20·6 to −3·3)* | |||
| Maternal haemorrhage | 1659·9 (1538·9 to 1777·6) | 6988·4 (5611·4 to 8568·4) | 60·9 (40·9 to 87·1) | −16·6% (−28·5 to −3·5)* | −4·5% (−18·5 to 11·5) | −32·4% (−42·0 to −21·7)* | −12·6% (−25·1 to 2·2) | |||
| Maternal haemorrhage complications | 1506·9 (1412·6 to 1601·5) | .. | 35·5 (23·6 to 51·8) | −20·9% (−28·3 to −13·0)* | −6·7% (−14·7 to 1·1) | −35·8% (−41·7 to −29·6)* | −14·6% (−21·7 to −7·5)* | |||
| Maternal haemorrhage episode | 153·0 (100·5 to 227·6) | 6988·4 (5611·4 to 8568·4) | 25·5 (15·0 to 40·0) | −9·3% (−35·3 to 30·5) | −1·2% (−32·3 to 41·8) | −26·6% (−47·7 to 5·4) | −9·5% (−37·8 to 30·0) | |||
| Maternal sepsis and other pregnancy-related infections | 2989·5 (2502·7 to 3623·3) | 12 060·9 (9668·8 to 14 890·9) | 57·0 (29·3 to 101·3) | −1·7% (−39·7 to 68·6) | 5·9% (−34·4 to 65·1) | −21·4% (−51·3 to 33·9) | −3·0% (−40·4 to 51·3) | |||
| Infertility due to puerperal sepsis | 2073·0 (1839·6 to 2335·1) | 113·0 (100·6 to 127·1) | 10·4 (3·9 to 21·8) | 39·6% (36·9 to 42·7)* | 21·8% (19·2 to 24·3)* | −0·3% (−2·2 to 1·7) | 6·6% (4·3 to 8·8)* | |||
| Maternal sepsis and other maternal infection episode | 916·5 (511·3 to 1514·1) | 11 947·9 (9553·3 to 14 781·0) | 46·6 (22·8 to 85·5) | −6·9% (−46·6 to 75·8) | 2·9% (−42·8 to 75·5) | −24·5% (−56·7 to 42·2) | −4·8% (−47·1 to 61·2) | |||
| Maternal hypertensive disorders | 2849·8 (1890·6 to 3972·4) | 15 830·2 (13 530·0 to 18 779·5) | 143·1 (80·7 to 231·8) | −6·3% (−35·5 to 40·3) | −0·9% (−34·3 to 41·0) | −24·7% (−48·6 to 12·5) | −9·1% (−39·6 to 29·3) | |||
| Maternal hypertensive disorder complications | 102·0 (97·7 to 107·0) | 1600·2 (1535·3 to 1675·1) | 6·7 (4·1 to 10·2) | 38·4% (31·0 to 46·7)* | 17·9% (10·7 to 24·7)* | 9·7% (3·8 to 16·4)* | 7·3% (0·7 to 13·4)* | |||
| Maternal hypertensive disorder episode | 2747·7 (1789·8 to 3869·6) | 14 230·0 (11 902·3 to 17 192·4) | 136·4 (75·7 to 220·6) | −7·5% (−37·4 to 40·2) | −1·7% (−36·0 to 41·7) | −25·7% (−49·9 to 12·4) | −9·8% (−41·1 to 30·4) | |||
| Maternal obstructed labour and uterine rupture | 1232·6 (1048·2 to 1449·1) | 7915·2 (6032·2 to 10 169·3) | 397·6 (260·5 to 551·0) | −0·9% (−6·0 to 5·2) | −10·7% (−15·8 to −5·0)* | −24·9% (−28·6 to −20·6)* | −20·0% (−24·5 to −14·9)* | |||
| Obstructed labour, acute event | 105·1 (64·7 to 163·8) | 7694·5 (5811·6 to 9959·4) | 33·0 (16·8 to 55·9) | −9·9% (−42·7 to 51·8) | 0·8% (−40·1 to 61·4) | −26·4% (−53·6 to 23·6) | −7·0% (−44·2 to 48·6) | |||
| Maternal obstructed labour complications | 1127·5 (939·1 to 1338·2) | 220·7 (179·2 to 267·7) | 364·6 (238·5 to 506·1) | −0·1% (−4·2 to 4·3) | −11·6% (−15·7 to −7·2)* | −24·8% (−27·7 to −21·6)* | −21·1% (−24·7 to −17·3)* | |||
| Maternal abortive outcome | 164·2 (109·5 to 234·1) | 20 052·1 (16 262·0 to 25 281·8) | 18·1 (10·2 to 29·7) | 2·5% (−32·1 to 54·5) | 2·4% (−34·5 to 51·8) | −18·0% (−45·6 to 24·0) | −5·6% (−39·4 to 39·1) | |||
| Ectopic pregnancy | 138·7 (90·1 to 199·9) | 16 965·4 (13 647·7 to 20 936·5) | 15·1 (8·3 to 24·0) | 35·5% (−10·4 to 115·0) | 14·6% (−26·3 to 72·1) | 6·5% (−29·1 to 68·3) | 5·1% (−32·4 to 58·5) | |||
| Other maternal disorders | .. | .. | 113·8 (80·5 to 154·3) | 45·4% (32·0 to 60·0)* | 20·1% (8·9 to 33·5)* | 12·9% (3·0 to 23·8)* | 9·0% (−1·0 to 21·2) | |||
| Neonatal disorders | 150 455·9 (131 734·1 to 170 851·4) | 22 150·4 (20 975·1 to 23 700·8) | 29 088·7 (21 771·2 to 37 499·1) | 52·1% (47·2 to 57·4)* | 23·5% (16·8 to 31·2)* | 27·0% (22·9 to 31·3)* | 12·1% (6·2 to 19·2)* | |||
| Neonatal preterm birth | 92 585·6 (81 049·6 to 106 597·3) | 17 416·9 (17 182·7 to 17 646·4) | 13 156·9 (9307·3 to 17 833·1) | 46·0% (39·6 to 52·0)* | 26·1% (10·6 to 41·4)* | 22·2% (17·0 to 27·1)* | 14·8% (0·7 to 28·6)* | |||
| Preterm birth complications | 67 508·3 (56 539·6 to 81 115·5) | .. | 12 537·7 (8824·7 to 17 161·8) | 48·4% (41·1 to 55·5)* | 27·3% (10·6 to 43·7)* | 24·7% (18·7 to 30·8)* | 16·0% (0·8 to 30·8)* | |||
| Retinopathy of prematurity | 11 361·8 (8979·6 to 13 871·7) | .. | 619·2 (415·3 to 861·4) | 14·4% (10·0 to 18·7)* | 6·1% (2·4 to 10·3)* | −8·6% (−12·3 to −5·0)* | −5·9% (−9·5 to −2·0)* | |||
| Uncomplicated preterm birth | 13 715·6 (12 775·0 to 14 383·3) | 17 416·9 (17 182·7 to 17 646·4) | .. | .. | .. | .. | .. | |||
| Neonatal encephalopathy due to birth asphyxia and trauma | 53 823·7 (39 817·7 to 70 951·7) | 2753·4 (1840·4 to 4017·0) | 9703·5 (5872·1 to 15 081·3) | 69·8% (57·8 to 84·9)* | 23·0% (19·3 to 27·6)* | 39·5% (30·0 to 51·5)* | 11·1% (7·7 to 14·9)* | |||
| Neonatal sepsis and other neonatal infections | 14 268·5 (8908·0 to 21 573·1) | 1326·7 (792·7 to 2284·9) | 4171·9 (2230·5 to 7009·0) | 44·7% (39·1 to 50·6)* | 19·5% (15·9 to 22·5)* | 17·5% (13·0 to 22·1)* | 7·5% (4·3 to 10·1)* | |||
| Neonatal sepsis and other neonatal infection complications | 13 944·6 (8561·4 to 21 248·8) | 996·6 (472·4 to 1951·3) | 4171·9 (2230·5 to 7009·0) | 44·7% (39·1 to 50·6)* | 19·5% (15·9 to 22·5)* | 17·5% (13·0 to 22·1)* | 7·5% (4·3 to 10·1)* | |||
| Neonatal sepsis and other neonatal infection episode | 323·9 (254·4 to 405·5) | 330·1 (259·0 to 413·2) | .. | .. | .. | .. | .. | |||
| Haemolytic disease and other neonatal jaundice | 2355·4 (2032·4 to 2684·1) | 653·3 (269·5 to 1211·6) | 877·7 (679·2 to 1090·3) | 37·1% (33·2 to 40·9)* | 20·2% (16·6 to 23·3)* | 14·8% (11·4 to 17·9)* | 9·3% (6·0 to 12·2)* | |||
| Other neonatal disorders | .. | .. | 1178·7 (893·2 to 1519·2) | 35·3% (31·1 to 39·6)* | 16·0% (9·2 to 23·8)* | 35·6% (31·4 to 39·9)* | 9·7% (3·3 to 17·2)* | |||
| Nutritional deficiencies | 1 862 030·8 (1 806 258·9 to 1 921 493·5) | 1 186 745·8 (1 089 728·9 to 1 283 530·0) | 42 376·2 (28 774·0 to 61 009·9) | −8·3% (−10·4 to −6·2)* | −7·8% (−10·6 to −4·9)* | −20·9% (−22·7 to −19·3)* | −16·1% (−18·5 to −13·4)* | |||
| Protein-energy malnutrition | 96 454·6 (93 495·9 to 99 611·1) | 79 726·7 (76 183·7 to 83 392·8) | 1798·0 (1167·7 to 2545·0) | −19·5% (−23·4 to −15·5)* | −3·4% (−6·3 to −0·7)* | −22·0% (−26·0 to −18·1)* | −10·1% (−12·8 to −7·6)* | |||
| Iodine deficiency | 116 021·9 (104 300·5 to 128 878·3) | 3027·9 (2734·2 to 3363·7) | 2057·7 (1247·3 to 3255·6) | −33·6% (−38·2 to −27·8)* | −6·9% (−10·1 to −4·3)* | −46·4% (−50·2 to −41·9)* | −17·4% (−20·1 to −14·9)* | |||
| Visible goitre without symptoms | 113 393·1 (101 868·1 to 126 335·9) | 3027·9 (2734·2 to 3363·7) | 1208·8 (590·5 to 2248·6) | −41·9% (−45·1 to −38·3)* | −6·1% (−8·2 to −4·4)* | −53·3% (−55·6 to −50·6)* | −17·4% (−19·2 to −15·9)* | |||
| Visible goitre with complications | 2628·8 (1500·7 to 3684·3) | .. | 848·9 (445·5 to 1286·3) | −17·0% (−22·5 to −11·1)* | −8·1% (−15·8 to −3·1)* | −32·7% (−37·2 to −27·6)* | −17·3% (−24·2 to −12·8)* | |||
| Vitamin A deficiency | 818 420·2 (748 849·9 to 892 688·1) | 1 103 991·2 (1 007 169·1 to 1 199 987·2) | 8313·0 (5398·6 to 12 150·6) | −19·7% (−22·9 to −16·7)* | −17·3% (−20·8 to −13·6)* | −23·0% (−26·0 to −20·2)* | −22·3% (−25·7 to −18·8)* | |||
| Asymptomatic vitamin A deficiency | 600 048·0 (547 539·5 to 655 650·3) | 1 103 991·2 (1 007 169·1 to 1 199 987·2) | .. | .. | .. | .. | .. | |||
| Vitamin A deficiency complications | 5403·4 (4329·4 to 6754·9) | .. | 304·0 (195·6 to 442·0) | 23·8% (19·4 to 28·3)* | 13·4% (9·9 to 17·1)* | 8·8% (5·3 to 12·1)* | 3·7% (0·6 to 7·1)* | |||
| Vitamin A deficiency with anaemia | 212 971·7 (189 376·4 to 240 436·1) | .. | 8009·0 (5196·4 to 11 716·1) | −20·5% (−23·7 to −17·4)* | −18·1% (−21·8 to −14·3)* | −23·6% (−26·7 to −20·7)* | −23·0% (−26·5 to −19·5)* | |||
| Dietary iron deficiency | 1 136 043·5 (1 117 204·2 to 1 156 043·7) | .. | 30 013·9 (20 323·3 to 43 628·0) | −0·2% (−2·8 to 2·2) | −5·2% (−8·3 to −1·9)* | −17·4% (−19·4 to −15·5)* | −14·3% (−17·2 to −11·4)* | |||
| Other nutritional deficiencies | .. | .. | 193·6 (125·3 to 272·6) | −13·7% (−20·8 to −7·2)* | 2·2% (−2·6 to 6·2) | −25·8% (−32·2 to −19·9)* | −9·6% (−13·9 to −6·2)* | |||
| Non-communicable diseases | 7 011 916·8 (6 965 421·4 to 7 057 358·0) | 10 813 562·6 (10 375 088·4 to 11 286 148·0) | 678 294·4 (510 467·3 to 875 605·3) | 35·0% (34·4 to 35·7)* | 19·3% (18·8 to 19·9)* | −1·3% (−1·7 to −0·9)* | 0·1% (−0·3 to 0·5) | |||
| Neoplasms | 100 482·9 (98 189·8 to 102 850·5) | 24 361·6 (21 911·3 to 27 310·3) | 7775·2 (5747·9 to 10 028·9) | 59·3% (55·6 to 63·3)* | 40·6% (38·3 to 43·2)* | 8·5% (6·0 to 11·2)* | 9·7% (7·6 to 12·0)* | |||
| Lip and oral cavity cancer | 1631·9 (1570·3 to 1691·6) | 389·8 (374·5 to 404·4) | 163·3 (120·3 to 212·3) | 49·6% (44·6 to 54·6)* | 39·8% (34·0 to 45·1)* | 1·1% (−2·3 to 4·4) | 9·2% (4·7 to 13·4)* | |||
| Diagnosis and primary therapy phase of mouth cancer | 95·7 (92·1 to 99·1) | 389·8 (374·5 to 404·4) | 26·6 (18·0 to 36·6) | 50·8% (44·8 to 57·1)* | 40·1% (34·2 to 46·3)* | 2·2% (−1·8 to 6·4) | 9·8% (5·2 to 14·5)* | |||
| Controlled phase of mouth cancer | 1364·1 (1312·8 to 1414·1) | .. | 62·4 (40·8 to 89·4) | 51·8% (46·5 to 56·9)* | 41·0% (35·3 to 46·7)* | 3·6% (0·0 to 6·8)* | 11·2% (6·7 to 15·6)* | |||
| Metastatic phase of mouth cancer | 149·4 (143·4 to 154·9) | .. | 62·1 (42·6 to 81·2) | 47·5% (41·0 to 54·6)* | 38·5% (31·9 to 45·2)* | −1·0% (−5·3 to 3·6) | 7·4% (2·3 to 12·5)* | |||
| Terminal phase of mouth cancer | 22·7 (21·8 to 23·6) | .. | 12·2 (8·5 to 15·7) | 47·4% (42·5 to 51·7)* | 39·5% (33·9 to 44·5)* | −1·4% (−4·4 to 1·4) | 7·8% (3·4 to 11·6)* | |||
| Nasopharynx cancer | 508·7 (480·9 to 539·0) | 109·8 (104·4 to 115·6) | 52·3 (37·8 to 69·6) | 6·6% (−1·2 to 14·3) | 20·3% (13·7 to 28·1)* | −24·7% (−29·8 to −19·7)* | −1·6% (−7·0 to 4·5) | |||
| Diagnosis and primary therapy phase of nasopharynx cancer | 29·1 (27·5 to 30·9) | 109·8 (104·4 to 115·6) | 8·3 (5·6 to 11·7) | 7·7% (−0·9 to 17·5) | 20·3% (12·0 to 29·9)* | −23·4% (−29·4 to −16·9)* | −0·7% (−7·4 to 6·9) | |||
| Controlled phase of nasopharynx cancer | 427·7 (403·8 to 453·3) | .. | 20·3 (13·1 to 29·9) | 6·7% (−1·8 to 15·3) | 19·7% (12·1 to 28·1)* | −23·7% (−29·5 to −18·0)* | −0·7% (−6·9 to 6·0) | |||
| Metastatic phase of nasopharynx cancer | 46·2 (43·9 to 48·7) | .. | 20·6 (14·1 to 27·7) | 6·5% (−1·3 to 14·9) | 20·9% (13·3 to 29·5)* | −25·6% (−30·6 to −19·9)* | −2·6% (−8·6 to 4·2) | |||
| Terminal phase of nasopharynx cancer | 5·7 (5·4 to 5·9) | .. | 3·1 (2·1 to 4·0) | 3·5% (−3·1 to 9·8) | 20·7% (15·4 to 27·1)* | −27·8% (−32·2 to −23·8)* | −3·5% (−7·6 to 1·6) | |||
| Other pharynx cancer | 440·8 (399·7 to 462·4) | 179·3 (160·3 to 188·6) | 59·2 (42·3 to 77·6) | 61·7% (54·3 to 70·4)* | 44·3% (35·0 to 51·2)* | 10·1% (5·1 to 15·8)* | 11·7% (4·4 to 16·9)* | |||
| Diagnosis and primary therapy phase of other pharynx cancer | 24·6 (22·3 to 25·7) | 179·3 (160·3 to 188·6) | 7·0 (4·7 to 9·8) | 69·9% (62·7 to 77·5)* | 46·7% (38·2 to 53·0)* | 15·7% (10·8 to 20·8)* | 13·5% (7·0 to 18·4)* | |||
| Controlled phase of other pharynx cancer | 334·1 (304·3 to 350·1) | .. | 15·5 (10·0 to 22·9) | 72·0% (63·3 to 81·8)* | 46·5% (37·3 to 54·0)* | 17·5% (11·7 to 24·1)* | 13·8% (6·6 to 19·6)* | |||
| Metastatic phase of other pharynx cancer | 69·6 (62·2 to 73·2) | .. | 29·9 (20·4 to 39·7) | 56·4% (48·1 to 66·2)* | 42·7% (32·2 to 51·5)* | 6·4% (0·6 to 12·8)* | 10·3% (2·3 to 16·9)* | |||
| Terminal phase of other pharynx cancer | 12·6 (11·2 to 13·3) | .. | 6·8 (4·7 to 8·7) | 56·7% (49·4 to 64·7)* | 44·2% (34·9 to 51·0)* | 6·6% (1·5 to 11·8)* | 11·3% (4·1 to 16·6)* | |||
| Oesophageal cancer | 806·3 (782·1 to 829·8) | 472·5 (459·5 to 485·3) | 130·3 (94·5 to 166·4) | 34·6% (29·1 to 40·2)* | 19·0% (14·5 to 23·9)* | −9·1% (−12·7 to −5·3)* | −9·1% (−12·6 to −5·4)* | |||
| Diagnosis and primary therapy phase of oesophageal cancer | 67·0 (65·0 to 69·0) | 472·5 (459·5 to 485·3) | 18·4 (12·4 to 25·4) | 45·2% (37·3 to 53·9)* | 23·9% (17·5 to 31·3)* | −1·3% (−6·7 to 4·5) | −5·0% (−9·9 to 0·8) | |||
| Controlled phase of oesophageal cancer | 535·4 (518·8 to 552·0) | .. | 24·6 (16·0 to 35·8) | 52·6% (45·9 to 58·7)* | 26·1% (20·9 to 31·5)* | 4·7% (0·1 to 8·8)* | −2·8% (−6·8 to 1·2) | |||
| Metastatic phase of oesophageal cancer | 167·5 (162·9 to 171·9) | .. | 68·2 (47·0 to 89·1) | 28·6% (22·5 to 35·2)* | 16·1% (10·5 to 21·8)* | −13·3% (−17·4 to −8·9)* | −11·6% (−15·8 to −7·3)* | |||
| Terminal phase of oesophageal cancer | 36·4 (35·4 to 37·4) | .. | 19·0 (13·4 to 24·3) | 29·0% (21·9 to 36·6)* | 16·7% (10·7 to 23·1)* | −13·1% (−17·9 to −8·2)* | −11·2% (−15·7 to −6·3)* | |||
| Stomach cancer | 2823·2 (2740·2 to 2914·9) | 1220·7 (1189·0 to 1254·6) | 348·8 (255·9 to 448·5) | 17·6% (14·4 to 20·9)* | 32·7% (28·1 to 37·7)* | −20·8% (−23·0 to −18·6)* | 1·2% (−2·3 to 5·0) | |||
| Diagnosis and primary therapy phase of stomach cancer | 268·1 (260·2 to 276·6) | 1220·7 (1189·0 to 1254·6) | 70·1 (47·9 to 95·2) | 22·1% (17·7 to 26·4)* | 39·7% (34·3 to 45·6)* | −17·8% (−20·7 to −15·0)* | 6·6% (2·5 to 11·1)* | |||
| Controlled phase of stomach cancer | 2122·2 (2057·1 to 2193·0) | .. | 96·9 (62·7 to 140·7) | 31·4% (28·3 to 34·8)* | 54·0% (48·8 to 59·4)* | −11·0% (−13·1 to −8·8)* | 18·1% (14·2 to 22·2)* | |||
| Metastatic phase of stomach cancer | 344·3 (335·7 to 353·8) | .. | 137·3 (95·8 to 178·7) | 11·2% (7·5 to 15·1)* | 21·4% (16·9 to 26·2)* | −25·3% (−27·7 to −22·7)* | −7·4% (−10·8 to −3·9)* | |||
| Terminal phase of stomach cancer | 88·7 (86·5 to 91·2) | .. | 44·6 (31·3 to 56·9) | 11·8% (7·7 to 15·9)* | 21·1% (16·3 to 26·8)* | −24·8% (−27·6 to −22·0)* | −7·7% (−11·4 to −3·5)* | |||
| Colon and rectum cancer | 9352·3 (9143·0 to 9558·6) | 1833·5 (1791·9 to 1873·5) | 877·6 (650·2 to 1133·2) | 70·2% (65·4 to 74·2)* | 39·8% (35·9 to 43·6)* | 12·3% (9·3 to 15·1)* | 6·0% (3·1 to 9·0)* | |||
| Diagnosis and primary therapy phase of colon and rectum cancers | 401·1 (391·8 to 410·2) | 1833·5 (1791·9 to 1873·5) | 103·1 (70·4 to 139·0) | 78·5% (72·3 to 84·4)* | 43·5% (38·3 to 48·8)* | 18·7% (14·7 to 22·5)* | 9·4% (5·4 to 13·4)* | |||
| Controlled phase of colon and rectum cancers | 7946·7 (7764·5 to 8129·2) | .. | 453·5 (304·5 to 637·7) | 83·2% (79·5 to 86·7)* | 42·8% (38·9 to 47·0)* | 22·9% (20·6 to 25·1)* | 9·2% (6·3 to 12·3)* | |||
| Metastatic phase of colon and rectum cancers | 653·8 (639·1 to 667·7) | .. | 253·1 (176·5 to 327·7) | 54·5% (49·5 to 59·3)* | 35·5% (31·2 to 40·2)* | 0·6% (−2·4 to 3·5) | 1·8% (−1·4 to 5·2) | |||
| Terminal phase of colon and rectum cancers | 92·9 (90·8 to 94·9) | .. | 45·9 (32·6 to 57·9) | 48·8% (42·5 to 54·6)* | 33·5% (28·3 to 38·2)* | −2·9% (−6·8 to 0·7) | 0·2% (−3·7 to 3·8) | |||
| Stoma from colon and rectum cancers, beyond 10 years | 257·8 (249·3 to 266·6) | .. | 22·1 (15·3 to 30·0) | 52·3% (47·4 to 57·0)* | 28·3% (25·1 to 31·6)* | −3·5% (−6·5 to −0·6)* | −5·2% (−7·6 to −2·9)* | |||
| Liver cancer | 803·4 (753·1 to 856·7) | 953·1 (916·5 to 997·0) | 229·5 (163·9 to 301·7) | 52·2% (44·8 to 60·5)* | 39·8% (34·2 to 47·3)* | 4·4% (−0·6 to 9·9) | 8·1% (3·8 to 13·7)* | |||
| Liver cancer due to hepatitis B | 661·2 (617·3 to 713·0) | 404·0 (378·3 to 434·1) | 98·1 (69·9 to 129·6) | 42·1% (34·2 to 52·6)* | 38·1% (30·2 to 48·7)* | −1·5% (−7·0 to 5·6) | 8·6% (2·5 to 17·0)* | |||
| Diagnosis and primary therapy phase of liver cancer due to hepatitis B | 97·9 (91·6 to 105·1) | 404·0 (378·3 to 434·1) | 26·6 (18·0 to 37·2) | 40·5% (29·7 to 53·4)* | 35·2% (24·8 to 48·0)* | −2·5% (−9·9 to 6·5) | 6·4% (−1·6 to 16·5) | |||
| Controlled phase of liver cancer due to hepatitis B | 453·6 (422·8 to 490·7) | .. | 21·3 (13·7 to 31·5) | 61·5% (50·8 to 75·1)* | 70·3% (58·3 to 84·7)* | 12·0% (4·8 to 21·1)* | 35·0% (25·4 to 46·4)* | |||
| Metastatic phase of liver cancer due to hepatitis B | 78·5 (73·5 to 84·4) | .. | 33·5 (22·9 to 44·7) | 37·4% (27·3 to 50·4)* | 29·1% (19·7 to 40·9)* | −4·7% (−11·8 to 4·0) | 1·5% (−6·0 to 10·7) | |||
| Terminal phase of liver cancer due to hepatitis B | 31·3 (29·3 to 33·6) | .. | 16·7 (11·5 to 21·7) | 37·9% (31·2 to 47·0)* | 29·3% (22·3 to 39·6)* | −4·4% (−9·0 to 1·7) | 1·5% (−4·0 to 9·5) | |||
| Liver cancer due to hepatitis C | 366·5 (341·7 to 391·6) | 257·9 (241·3 to 274·5) | 60·6 (43·0 to 79·7) | 62·2% (54·8 to 68·9)* | 38·8% (34·3 to 44·5)* | 9·7% (4·6 to 14·2)* | 4·9% (1·5 to 9·2)* | |||
| Diagnosis and primary therapy phase of liver cancer due to hepatitis C | 60·8 (56·9 to 64·7) | 257·9 (241·3 to 274·5) | 16·8 (11·3 to 23·4) | 61·1% (53·2 to 68·2)* | 37·3% (31·9 to 43·9)* | 8·8% (3·5 to 13·5)* | 3·7% (−0·3 to 8·7) | |||
| Controlled phase of liver cancer due to hepatitis C | 234·4 (217·9 to 250·9) | .. | 10·9 (6·9 to 15·9) | 82·3% (72·8 to 92·3)* | 56·4% (48·6 to 65·8)* | 25·9% (19·4 to 32·6)* | 19·6% (13·6 to 26·7)* | |||
| Metastatic phase of liver cancer due to hepatitis C | 51·0 (47·7 to 54·3) | .. | 22·1 (14·9 to 29·5) | 57·6% (49·8 to 64·5)* | 34·4% (29·1 to 40·1)* | 6·2% (1·0 to 10·8)* | 1·4% (−2·6 to 5·7) | |||
| Terminal phase of liver cancer due to hepatitis C | 20·3 (19·0 to 21·6) | .. | 10·9 (7·6 to 14·1) | 58·4% (51·0 to 64·7)* | 34·7% (30·9 to 39·7)* | 6·7% (1·8 to 10·7)* | 1·5% (−1·4 to 5·2) | |||
| Liver cancer due to alcohol use | 206·3 (180·7 to 239·9) | 143·9 (127·2 to 165·0) | 34·7 (24·8 to 47·1) | 62·6% (52·2 to 70·8)* | 39·4% (33·7 to 46·1)* | 9·6% (2·7 to 15·0)* | 7·2% (2·9 to 12·1)* | |||
| Diagnosis and primary therapy phase of liver cancer due to alcohol use | 34·0 (30·0 to 39·1) | 143·9 (127·2 to 165·0) | 9·7 (6·4 to 13·9) | 61·1% (50·9 to 69·6)* | 38·5% (32·0 to 45·2)* | 8·5% (1·7 to 14·1)* | 6·4% (1·7 to 11·4)* | |||
| Controlled phase of liver cancer due to alcohol use | 132·6 (115·1 to 155·3) | .. | 6·2 (3·8 to 9·2) | 88·0% (74·5 to 101·3)* | 55·3% (45·5 to 65·6)* | 28·8% (19·5 to 37·8)* | 20·5% (13·1 to 28·5)* | |||
| Metastatic phase of liver cancer due to alcohol use | 28·4 (25·2 to 32·6) | .. | 12·7 (8·6 to 17·4) | 57·1% (47·4 to 65·0)* | 35·4% (29·9 to 41·7)* | 5·7% (−0·7 to 10·8) | 3·9% (−0·2 to 8·5) | |||
| Terminal phase of liver cancer due to alcohol use | 11·3 (10·0 to 13·0) | .. | 6·1 (4·2 to 8·1) | 57·4% (47·4 to 65·1)* | 35·3% (30·3 to 41·2)* | 5·9% (−0·8 to 10·8) | 3·8% (0·2 to 8·2)* | |||
| Liver cancer due to NASH | 97·4 (86·8 to 108·0) | 72·2 (64·6 to 79·9) | 17·5 (12·3 to 23·1) | 74·4% (63·9 to 83·0)* | 52·5% (47·5 to 58·9)* | 18·2% (11·2 to 23·6)* | 16·1% (12·4 to 20·9)* | |||
| Diagnosis and primary therapy phase of liver cancer due to NASH | 16·9 (15·1 to 18·6) | 72·2 (64·6 to 79·9) | 4·8 (3·2 to 6·7) | 73·3% (62·6 to 81·8)* | 51·4% (46·5 to 57·5)* | 17·3% (10·3 to 22·7)* | 15·2% (11·6 to 19·8)* | |||
| Controlled phase of liver cancer due to NASH | 60·5 (53·5 to 67·4) | .. | 2·9 (1·8 to 4·4) | 93·7% (82·0 to 103·9)* | 75·6% (66·7 to 85·7)* | 34·2% (26·1 to 40·9)* | 35·6% (28·9 to 43·7)* | |||
| Metastatic phase of liver cancer due to NASH | 14·3 (12·8 to 15·9) | .. | 6·5 (4·4 to 8·7) | 70·7% (60·0 to 79·0)* | 47·3% (42·7 to 53·3)* | 15·3% (8·4 to 20·6)* | 11·9% (8·4 to 16·3)* | |||
| Terminal phase of liver cancer due to NASH | 5·7 (5·1 to 6·3) | .. | 3·2 (2·2 to 4·2) | 70·7% (60·0 to 79·0)* | 47·3% (42·6 to 53·3)* | 15·3% (8·3 to 20·6)* | 11·9% (8·4 to 16·3)* | |||
| Liver cancer due to other causes | 114·8 (102·2 to 128·7) | 75·1 (67·5 to 83·3) | 18·6 (13·2 to 25·1) | 43·9% (36·4 to 52·0)* | 42·3% (36·1 to 50·4)* | −0·3% (−5·4 to 5·0) | 11·0% (6·5 to 17·2)* | |||
| Diagnosis and primary therapy phase of liver cancer due to other causes | 18·0 (16·1 to 20·0) | 75·1 (67·5 to 83·3) | 5·2 (3·5 to 7·3) | 42·7% (35·2 to 50·5)* | 40·6% (34·9 to 47·9)* | −1·1% (−6·0 to 4·0) | 9·7% (5·4 to 15·3)* | |||
| Controlled phase of liver cancer due to other causes | 76·3 (67·5 to 85·8) | .. | 3·7 (2·3 to 5·5) | 61·3% (51·7 to 72·7)* | 68·1% (56·9 to 81·0)* | 12·3% (5·8 to 20·1)* | 32·7% (23·7 to 42·5)* | |||
| Metastatic phase of liver cancer due to other causes | 14·7 (13·2 to 16·3) | .. | 6·6 (4·5 to 9·0) | 40·0% (32·7 to 47·7)* | 35·3% (30·0 to 42·2)* | −3·1% (−7·8 to 2·0) | 5·4% (1·4 to 10·6)* | |||
| Terminal phase of liver cancer due to other causes | 5·8 (5·3 to 6·5) | .. | 3·2 (2·2 to 4·1) | 40·0% (32·7 to 47·7)* | 35·3% (30·0 to 42·2)* | −3·1% (−7·8 to 2·0) | 5·4% (1·4 to 10·6)* | |||
| Gallbladder and biliary tract cancer | 235·9 (209·6 to 252·6) | 210·9 (186·1 to 225·4) | 49·1 (34·4 to 64·3) | 33·4% (23·2 to 38·9)* | 34·6% (28·1 to 41·4)* | −12·1% (−18·8 to −8·5)* | 1·4% (−3·7 to 6·8) | |||
| Diagnosis and primary therapy phase of gallbladder and biliary tract cancer | 33·7 (29·9 to 35·9) | 210·9 (186·1 to 225·4) | 9·3 (6·2 to 12·9) | 34·1% (24·3 to 39·7)* | 35·5% (28·5 to 42·6)* | −11·7% (−18·1 to −7·9)* | 2·1% (−3·3 to 7·8) | |||
| Controlled phase of gallbladder and biliary tract cancer | 126·7 (113·2 to 136·4) | .. | 5·8 (3·7 to 8·5) | 36·9% (28·6 to 44·3)* | 53·1% (42·0 to 64·3)* | −8·1% (−13·8 to −3·1)* | 17·5% (8·9 to 26·4)* | |||
| Metastatic phase of gallbladder and biliary tract cancer | 58·6 (51·7 to 62·7) | .. | 25·0 (16·8 to 33·4) | 32·9% (21·7 to 39·8)* | 31·7% (25·3 to 38·3)* | −12·6% (−20·0 to −8·0)* | −1·0% (−6·1 to 4·3) | |||
| Terminal phase of gallbladder and biliary tract cancer | 16·9 (14·9 to 18·1) | .. | 8·9 (6·2 to 11·6) | 32·3% (21·9 to 37·2)* | 31·4% (25·4 to 37·6)* | −13·3% (−20·0 to −9·8)* | −1·4% (−6·0 to 3·6) | |||
| Pancreatic cancer | 380·6 (372·7 to 388·4) | 447·7 (438·6 to 456·3) | 91·9 (64·7 to 119·3) | 65·8% (62·2 to 69·6)* | 38·5% (34·8 to 42·2)* | 9·8% (7·3 to 12·4)* | 4·7% (1·8 to 7·6)* | |||
| Diagnosis and primary therapy phase of pancreatic cancer | 99·0 (97·0 to 101·0) | 447·7 (438·6 to 456·3) | 26·5 (18·1 to 36·2) | 65·4% (60·1 to 70·8)* | 38·7% (33·2 to 43·5)* | 9·6% (6·0 to 13·2)* | 4·8% (0·6 to 8·4)* | |||
| Controlled phase of pancreatic cancer | 151·7 (148·4 to 155·0) | .. | 7·1 (4·6 to 10·3) | 102·1% (96·0 to 109·5)* | 35·1% (30·2 to 40·4)* | 37·5% (33·3 to 42·6)* | 5·1% (1·4 to 9·2)* | |||
| Metastatic phase of pancreatic cancer | 93·2 (91·3 to 95·0) | .. | 38·9 (26·7 to 51·3) | 62·5% (57·6 to 67·8)* | 39·1% (34·2 to 44·0)* | 7·7% (4·3 to 11·2)* | 4·8% (1·0 to 8·6)* | |||
| Terminal phase of pancreatic cancer | 36·7 (35·9 to 37·4) | .. | 19·4 (13·6 to 24·8) | 62·1% (59·3 to 65·0)* | 38·6% (34·9 to 41·9)* | 6·6% (4·6 to 8·6)* | 4·4% (1·6 to 7·0)* | |||
| Larynx cancer | 1094·9 (1074·7 to 1118·4) | 210·6 (206·4 to 215·5) | 109·4 (79·7 to 142·5) | 25·1% (21·7 to 28·5)* | 34·2% (30·6 to 37·9)* | −14·9% (−17·2 to −12·6)* | 2·8% (0·0 to 5·6)* | |||
| Diagnosis and primary therapy phase of larynx cancer | 65·3 (64·1 to 66·8) | 210·6 (206·4 to 215·5) | 18·1 (12·3 to 24·9) | 27·6% (22·0 to 33·4)* | 38·1% (32·8 to 43·5)* | −13·1% (−17·0 to −9·1)* | 5·8% (1·7 to 9·9)* | |||
| Controlled phase of larynx cancer | 882·3 (864·9 to 902·3) | .. | 48·7 (32·0 to 70·1) | 28·2% (24·5 to 31·8)* | 36·5% (32·5 to 40·5)* | −12·3% (−14·7 to −9·8)* | 4·9% (1·9 to 8·0)* | |||
| Metastatic phase of larynx cancer | 79·7 (78·1 to 81·6) | .. | 33·8 (23·2 to 44·7) | 19·9% (14·9 to 24·9)* | 30·8% (25·3 to 36·1)* | −18·8% (−22·2 to −15·5)* | −0·1% (−4·3 to 4·0) | |||
| Terminal phase of larynx cancer | 11·3 (11·0 to 11·6) | .. | 6·1 (4·2 to 7·8) | 16·3% (13·9 to 19·0)* | 28·2% (25·1 to 31·3)* | −21·3% (−22·9 to −19·6)* | −2·2% (−4·5 to 0·2) | |||
| Laryngectomy from larynx cancer, beyond 10 years | 56·3 (54·4 to 58·2) | .. | 2·7 (1·7 to 4·1) | 48·5% (43·6 to 53·7)* | 25·6% (21·0 to 30·3)* | −0·8% (−4·3 to 2·7) | −4·5% (−8·0 to −0·9)* | |||
| Tracheal, bronchus, and lung cancer | 3343·1 (3267·9 to 3422·5) | 2163·1 (2117·0 to 2212·9) | 537·1 (393·6 to 677·2) | 51·6% (47·5 to 55·5)* | 41·0% (36·8 to 45·4)* | 2·9% (0·1 to 5·5)* | 7·2% (3·9 to 10·4)* | |||
| Diagnosis and primary therapy phase of tracheal, bronchus, and lung cancer | 219·5 (214·6 to 224·8) | 2163·1 (2117·0 to 2212·9) | 57·0 (39·1 to 77·4) | 64·3% (58·4 to 69·9)* | 51·1% (45·1 to 57·5)* | 11·4% (7·3 to 15·2)* | 14·9% (10·3 to 19·7)* | |||
| Controlled phase of tracheal, bronchus, and lung cancer | 2188·1 (2137·3 to 2241·4) | .. | 99·3 (64·4 to 144·3) | 87·5% (83·3 to 91·7)* | 65·8% (61·2 to 70·5)* | 28·0% (25·1 to 30·7)* | 26·4% (22·9 to 30·0)* | |||
| Metastatic phase of tracheal, bronchus, and lung cancer | 765·7 (749·5 to 783·3) | .. | 299·0 (208·3 to 387·8) | 44·3% (40·1 to 48·2)* | 34·5% (30·1 to 38·7)* | −2·0% (−4·8 to 0·5) | 2·2% (−1·1 to 5·3) | |||
| Terminal phase of tracheal, bronchus, and lung cancer | 169·8 (166·2 to 173·7) | .. | 81·8 (58·1 to 103·2) | 44·3% (38·9 to 49·6)* | 34·0% (28·8 to 39·6)* | −2·2% (−5·7 to 1·3) | 1·8% (−2·1 to 6·0) | |||
| Malignant skin melanoma | 2324·4 (1794·8 to 2796·2) | 308·7 (237·6 to 365·9) | 140·9 (90·8 to 201·6) | 104·3% (82·1 to 111·6)* | 32·3% (27·0 to 36·9)* | 41·3% (24·4 to 46·9)* | 4·9% (0·9 to 8·6)* | |||
| Diagnosis and primary therapy phase of malignant skin melanoma | 64·1 (49·0 to 76·8) | 308·7 (237·6 to 365·9) | 17·5 (11·0 to 25·2) | 110·3% (89·4 to 118·3)* | 32·4% (26·1 to 38·8)* | 46·4% (30·5 to 52·6)* | 5·4% (0·5 to 10·6)* | |||
| Controlled phase of malignant skin melanoma | 2208·7 (1709·0 to 2662·4) | .. | 101·2 (59·9 to 154·2) | 113·8% (93·9 to 121·4)* | 32·9% (27·7 to 37·9)* | 50·2% (34·9 to 55·4)* | 6·4% (2·3 to 10·7)* | |||
| Metastatic phase of malignant skin melanoma | 44·3 (32·7 to 49·6) | .. | 18·4 (11·3 to 25·1) | 68·4% (40·0 to 80·0)* | 29·5% (22·6 to 35·5)* | 12·5% (−7·3 to 20·9) | −1·6% (−6·9 to 3·2) | |||
| Terminal phase of malignant skin melanoma | 7·3 (5·4 to 8·2) | .. | 3·9 (2·4 to 5·2) | 64·2% (37·2 to 73·7)* | 28·7% (21·6 to 33·9)* | 9·0% (−9·7 to 15·6) | −2·6% (−7·8 to 1·3) | |||
| Non-melanoma skin cancer | 2537·1 (1666·4 to 3696·8) | 7663·6 (5251·1 to 10 570·3) | 90·2 (49·5 to 149·0) | 211·2% (142·3 to 305·0)* | 32·7% (25·3 to 40·0)* | 96·8% (46·7 to 162·7)* | −2·0% (−7·7 to 3·9) | |||
| Non-melanoma skin cancer (squamous-cell carcinoma) | 2158·9 (1294·8 to 3255·8) | 1778·8 (1068·8 to 2620·9) | 87·7 (46·9 to 146·3) | 221·7% (148·5 to 334·5)* | 32·8% (25·0 to 40·0)* | 102·5% (47·3 to 180·3)* | −2·0% (−7·8 to 4·0) | |||
| Non-melanoma skin cancer (basal-cell carcinoma) | 596·8 (325·9 to 947·0) | 5884·8 (3702·9 to 8742·9) | 2·5 (0·9 to 5·2) | 44·5% (20·3 to 76·5)* | 30·8% (23·1 to 37·0)* | −3·8% (−21·1 to 18·1) | −1·0% (−6·4 to 3·2) | |||
| Breast cancer | 16 697·3 (16 178·9 to 17 171·7) | 1960·7 (1891·4 to 2023·2) | 1307·9 (932·0 to 1769·3) | 67·7% (60·6 to 72·7)* | 33·8% (29·0 to 37·7)* | 11·7% (7·1 to 15·0)* | 4·5% (0·7 to 7·5)* | |||
| Diagnosis and primary therapy phase of breast cancer | 416·5 (401·4 to 430·2) | 1960·7 (1891·4 to 2023·2) | 107·8 (75·1 to 146·7) | 71·1% (61·6 to 79·5)* | 36·1% (29·4 to 42·2)* | 15·1% (9·0 to 20·4)* | 7·3% (2·2 to 11·9)* | |||
| Controlled phase of breast cancer | 13 532·2 (13 027·8 to 13 977·4) | .. | 843·4 (538·9 to 1218·3) | 74·5% (66·8 to 79·7)* | 34·4% (29·3 to 38·7)* | 17·7% (12·9 to 21·0)* | 6·0% (2·1 to 9·3)* | |||
| Metastatic phase of breast cancer | 676·3 (654·5 to 697·0) | .. | 263·8 (183·5 to 341·1) | 57·5% (49·2 to 64·5)* | 33·4% (28·0 to 38·2)* | 2·8% (−2·1 to 7·0) | 2·3% (−1·8 to 5·8) | |||
| Terminal phase of breast cancer | 52·0 (50·4 to 54·0) | .. | 26·9 (18·8 to 34·2) | 49·6% (40·4 to 57·4)* | 31·4% (25·7 to 36·4)* | −2·1% (−7·7 to 2·8) | 0·5% (−3·9 to 4·4) | |||
| Mastectomy from breast cancer, beyond 10 years | 2020·3 (1957·2 to 2080·1) | .. | 66·0 (38·5 to 102·5) | 38·5% (35·8 to 41·3)* | 25·8% (23·9 to 27·7)* | −9·5% (−11·2 to −7·8)* | −6·2% (−7·5 to −4·7)* | |||
| Cervical cancer | 3657·9 (3364·6 to 3803·1) | 601·2 (554·5 to 625·4) | 288·1 (205·6 to 381·5) | 24·2% (12·3 to 32·3)* | 18·9% (12·6 to 23·2)* | −14·2% (−22·3 to −8·7)* | −1·7% (−6·8 to 1·8) | |||
| Diagnosis and primary therapy phase of cervical cancer | 187·6 (172·7 to 195·1) | 601·2 (554·5 to 625·4) | 51·4 (34·5 to 70·5) | 26·3% (13·6 to 35·9)* | 19·2% (12·2 to 25·5)* | −12·2% (−21·1 to −6·0)* | −0·8% (−6·7 to 4·2) | |||
| Controlled phase of cervical cancer | 3275·4 (3011·5 to 3405·2) | .. | 151·8 (96·7 to 222·6) | 25·7% (13·5 to 34·1)* | 19·7% (13·5 to 24·1)* | −12·4% (−20·8 to −6·8)* | 0·1% (−5·2 to 3·7) | |||
| Metastatic phase of cervical cancer | 171·3 (158·6 to 178·3) | .. | 72·2 (48·9 to 95·3) | 20·9% (10·1 to 29·0)* | 17·4% (10·9 to 22·9)* | −17·6% (−24·7 to −12·4)* | −5·1% (−10·3 to −0·6)* | |||
| Terminal phase of cervical cancer | 23·6 (21·9 to 24·6) | .. | 12·8 (8·8 to 16·4) | 17·5% (7·5 to 24·9)* | 17·4% (11·7 to 21·6)* | −20·4% (−27·0 to −15·7)* | −6·4% (−10·9 to −3·0)* | |||
| Uterine cancer | 3084·6 (3005·7 to 3171·3) | 406·8 (396·7 to 418·0) | 210·9 (151·5 to 279·7) | 65·8% (60·6 to 71·6)* | 36·5% (32·7 to 41·1)* | 11·0% (7·5 to 14·9)* | 4·9% (1·9 to 8·2)* | |||
| Diagnosis and primary therapy phase of uterine cancer | 141·8 (138·2 to 145·8) | 406·8 (396·7 to 418·0) | 37·5 (25·9 to 51·1) | 69·1% (60·6 to 78·2)* | 37·4% (30·9 to 44·1)* | 13·5% (7·8 to 19·7)* | 5·9% (1·0 to 10·9)* | |||
| Controlled phase of uterine cancer | 2838·0 (2765·2 to 2918·0) | .. | 129·3 (84·2 to 188·0) | 72·5% (67·5 to 78·1)* | 38·3% (34·6 to 43·0)* | 16·6% (13·3 to 20·2)* | 6·9% (4·1 to 10·5)* | |||
| Metastatic phase of uterine cancer | 94·9 (92·6 to 97·4) | .. | 38·8 (26·7 to 50·7) | 48·4% (40·9 to 56·2)* | 31·1% (25·7 to 37·3)* | −2·3% (−7·2 to 2·9) | −1·0% (−5·2 to 3·8) | |||
| Terminal phase of uterine cancer | 9·9 (9·7 to 10·2) | .. | 5·3 (3·7 to 6·8) | 42·2% (38·7 to 46·5)* | 29·0% (25·9 to 33·0)* | −6·6% (−8·8 to −3·9)* | −3·1% (−5·4 to −0·1)* | |||
| Ovarian cancer | 1353·0 (1313·7 to 1401·1) | 286·1 (278·1 to 295·3) | 176·1 (127·9 to 224·2) | 48·9% (42·2 to 56·6)* | 27·7% (22·9 to 32·9)* | 1·6% (−2·6 to 6·5) | 2·2% (−1·6 to 6·4) | |||
| Diagnosis and primary therapy phase of ovarian cancer | 48·1 (46·7 to 49·8) | 286·1 (278·1 to 295·3) | 13·8 (9·3 to 19·2) | 51·7% (45·6 to 58·8)* | 28·4% (23·9 to 33·0)* | 4·4% (0·5 to 8·9)* | 3·7% (0·1 to 7·4)* | |||
| Controlled phase of ovarian cancer | 1027·2 (997·4 to 1064·3) | .. | 47·3 (30·3 to 69·3) | 52·7% (45·2 to 60·7)* | 28·6% (23·2 to 33·9)* | 5·8% (0·9 to 11·0)* | 4·5% (0·2 to 8·9)* | |||
| Metastatic phase of ovarian cancer | 261·4 (253·9 to 270·1) | .. | 106·2 (72·2 to 139·2) | 47·4% (40·1 to 55·7)* | 27·2% (21·3 to 33·5)* | 0·1% (−4·7 to 5·5) | 1·2% (−3·5 to 6·3) | |||
| Terminal phase of ovarian cancer | 16·3 (15·8 to 16·8) | .. | 8·8 (6·1 to 11·2) | 42·6% (37·6 to 48·5)* | 29·0% (25·2 to 32·9)* | −4·6% (−7·6 to −1·0)* | −0·1% (−2·9 to 3·1) | |||
| Prostate cancer | 9901·9 (8810·8 to 12 762·0) | 1334·3 (1170·9 to 1697·9) | 843·2 (614·4 to 1146·4) | 97·5% (87·3 to 125·6)* | 41·0% (36·3 to 50·9)* | 27·7% (20·5 to 46·5)* | 5·6% (2·1 to 13·2)* | |||
| Diagnosis and primary therapy phase of prostate cancer | 342·9 (303·1 to 446·1) | 1334·3 (1170·9 to 1697·9) | 86·1 (57·9 to 121·6) | 115·8% (103·5 to 149·5)* | 44·0% (37·3 to 56·3)* | 42·5% (34·4 to 65·2)* | 8·6% (3·6 to 17·9)* | |||
| Controlled phase of prostate cancer | 8443·6 (7481·1 to 11 011·9) | .. | 476·0 (309·6 to 698·6) | 123·7% (113·6 to 156·9)* | 43·3% (38·4 to 54·7)* | 49·5% (42·7 to 72·3)* | 8·3% (4·5 to 17·1)* | |||
| Metastatic phase of prostate cancer | 653·8 (568·1 to 817·9) | .. | 244·6 (168·2 to 321·2) | 63·3% (56·2 to 86·0)* | 36·4% (31·6 to 44·7)* | 2·9% (−1·5 to 17·2) | 1·1% (−2·4 to 7·5) | |||
| Terminal phase of prostate cancer | 39·7 (34·2 to 48·1) | .. | 18·5 (13·0 to 23·8) | 57·9% (47·9 to 75·1)* | 35·1% (28·7 to 43·8)* | −0·7% (−6·9 to 10·3) | −0·5% (−5·1 to 6·2) | |||
| Impotence and incontinence after 10-year survival from prostate cancer | 421·9 (411·4 to 432·6) | .. | 18·1 (12·6 to 25·0) | 61·8% (57·7 to 66·2)* | 35·0% (31·2 to 38·9)* | 0·5% (−1·9 to 3·1) | −1·6% (−4·2 to 1·1) | |||
| Testicular cancer | 578·0 (556·4 to 603·6) | 71·3 (68·8 to 74·4) | 36·2 (24·8 to 49·6) | 51·2% (44·3 to 58·7)* | 23·8% (18·3 to 29·5)* | 14·7% (9·4 to 20·4)* | 9·0% (4·1 to 14·1)* | |||
| Diagnosis and primary therapy phase of testicular cancer | 18·9 (18·2 to 19·7) | 71·3 (68·8 to 74·4) | 5·4 (3·6 to 7·5) | 55·1% (48·5 to 62·3)* | 24·9% (19·2 to 30·8)* | 18·2% (13·3 to 23·5)* | 10·4% (5·4 to 15·6)* | |||
| Controlled phase of testicular cancer | 549·1 (528·5 to 573·5) | .. | 26·1 (16·8 to 38·7) | 55·3% (47·5 to 64·2)* | 25·0% (19·0 to 31·4)* | 18·7% (12·7 to 25·4)* | 10·7% (5·2 to 16·2)* | |||
| Metastatic phase of testicular cancer | 9·0 (8·7 to 9·4) | .. | 4·1 (2·8 to 5·4) | 31·0% (26·1 to 35·8)* | 16·9% (13·1 to 21·2)* | −3·8% (−7·2 to −0·3)* | −0·3% (−3·5 to 3·4) | |||
| Terminal phase of testicular cancer | 1·0 (1·0 to 1·1) | .. | 0·6 (0·4 to 0·7) | 22·7% (17·7 to 27·7)* | 9·9% (6·2 to 14·3)* | −8·8% (−12·4 to −5·2)* | −5·7% (−8·8 to −1·8)* | |||
| Kidney cancer | 2184·1 (2081·8 to 2249·0) | 393·0 (371·2 to 404·6) | 141·0 (101·2 to 190·1) | 50·2% (44·0 to 58·6)* | 24·1% (18·8 to 28·9)* | 7·2% (3·5 to 12·3)* | −2·2% (−6·3 to 1·6) | |||
| Diagnosis and primary therapy phase of kidney cancer | .. | 393·0 (371·2 to 404·6) | .. | .. | .. | .. | .. | |||
| Controlled phase of kidney cancer | 2080·7 (1985·3 to 2143·1) | .. | 95·6 (62·2 to 139·5) | 47·6% (39·9 to 57·7)* | 22·6% (16·8 to 27·7)* | 8·2% (3·8 to 14·7)* | −2·0% (−6·7 to 2·0) | |||
| Metastatic phase of kidney cancer | 86·7 (81·4 to 89·3) | .. | 36·4 (24·6 to 48·3) | 55·9% (49·4 to 63·7)* | 27·2% (21·8 to 33·1)* | 5·1% (0·6 to 10·3)* | −2·6% (−6·7 to 1·9) | |||
| Terminal phase of kidney cancer | 16·7 (15·7 to 17·2) | .. | 9·0 (6·3 to 11·6) | 57·3% (52·5 to 62·9)* | 27·0% (23·3 to 31·5)* | 5·8% (2·7 to 9·3)* | −3·0% (−5·8 to 0·4) | |||
| Bladder cancer | 2632·4 (2566·9 to 2717·2) | 473·8 (462·2 to 491·8) | 247·0 (179·4 to 322·8) | 47·3% (43·4 to 53·6)* | 33·0% (29·9 to 36·2)* | −1·9% (−4·6 to 2·2) | 0·9% (−1·4 to 3·3) | |||
| Diagnosis and primary therapy phase of bladder cancer | 141·8 (138·1 to 146·6) | 473·8 (462·2 to 491·8) | 37·4 (25·4 to 50·8) | 47·4% (41·0 to 56·0)* | 34·2% (29·3 to 39·3)* | −1·3% (−5·4 to 4·2) | 2·2% (−1·5 to 6·0) | |||
| Controlled phase of bladder cancer | 2269·1 (2209·3 to 2343·1) | .. | 139·9 (95·0 to 195·4) | 50·9% (46·7 to 58·3)* | 34·1% (30·8 to 37·6)* | 2·0% (−0·8 to 6·6) | 2·7% (0·1 to 5·3)* | |||
| Metastatic phase of bladder cancer | 121·5 (118·5 to 126·6) | .. | 48·2 (33·4 to 63·1) | 37·7% (31·9 to 44·9)* | 29·9% (25·5 to 34·6)* | −10·3% (−14·0 to −5·9)* | −3·1% (−6·4 to 0·3) | |||
| Terminal phase of bladder cancer | 22·6 (22·0 to 23·5) | .. | 11·6 (8·1 to 14·8) | 38·0% (32·5 to 45·2)* | 29·5% (25·2 to 34·1)* | −10·4% (−14·0 to −5·8)* | −3·5% (−6·8 to 0·0) | |||
| Incontinence from bladder cancer, beyond 10 years | 77·5 (74·8 to 80·5) | .. | 10·0 (6·8 to 14·1) | 63·5% (57·7 to 69·4)* | 32·3% (27·9 to 37·3)* | 5·2% (1·6 to 9·2)* | −0·8% (−4·1 to 2·9) | |||
| Brain and nervous system cancer | 1705·7 (1471·0 to 1894·8) | 405·2 (351·0 to 442·6) | 166·9 (117·5 to 223·0) | 56·9% (34·3 to 85·1)* | 49·9% (41·3 to 58·9)* | 19·1% (2·2 to 37·8)* | 24·8% (17·7 to 32·8)* | |||
| Diagnosis and primary therapy phase of brain and nervous system cancers | 100·0 (86·4 to 110·7) | 405·2 (351·0 to 442·6) | 28·6 (19·0 to 40·4) | 76·5% (51·1 to 107·8)* | 61·2% (51·3 to 71·1)* | 34·8% (15·7 to 55·6)* | 35·4% (27·5 to 44·1)* | |||
| Controlled phase of brain and nervous system cancers | 1453·1 (1251·8 to 1625·0) | .. | 68·5 (43·3 to 102·1) | 72·1% (45·5 to 109·1)* | 61·9% (50·1 to 74·9)* | 35·8% (16·1 to 61·4)* | 38·0% (28·0 to 49·2)* | |||
| Metastatic phase of brain and nervous system cancers | 130·1 (112·7 to 139·8) | .. | 57·7 (38·4 to 78·2) | 41·8% (22·1 to 62·1)* | 36·5% (30·0 to 42·0)* | 4·9% (−9·4 to 17·6) | 10·9% (5·6 to 15·2)* | |||
| Terminal phase of brain and nervous system cancers | 22·6 (19·6 to 24·3) | .. | 12·2 (8·4 to 15·9) | 38·7% (18·9 to 59·0)* | 34·3% (27·8 to 39·3)* | 3·0% (−10·8 to 15·6) | 8·8% (3·7 to 12·9)* | |||
| Thyroid cancer | 2144·9 (2059·5 to 2287·8) | 255·5 (245·7 to 272·5) | 132·0 (91·7 to 180·8) | 95·1% (87·1 to 104·5)* | 37·7% (32·4 to 44·0)* | 33·4% (27·9 to 39·2)* | 11·4% (7·1 to 16·5)* | |||
| Diagnosis and primary therapy phase of thyroid cancer | 57·8 (55·5 to 61·6) | 255·5 (245·7 to 272·5) | 16·6 (11·1 to 23·1) | 99·5% (91·6 to 109·7)* | 38·5% (32·3 to 45·3)* | 37·5% (32·6 to 43·9)* | 12·7% (7·6 to 18·1)* | |||
| Controlled phase of thyroid cancer | 2040·7 (1958·4 to 2176·9) | .. | 94·5 (61·6 to 138·2) | 101·9% (93·0 to 113·0)* | 38·1% (32·4 to 45·2)* | 40·1% (34·3 to 46·8)* | 12·9% (8·2 to 18·7)* | |||
| Metastatic phase of thyroid cancer | 42·9 (41·6 to 45·4) | .. | 19·0 (12·9 to 25·3) | 67·5% (60·9 to 73·2)* | 35·7% (31·4 to 40·1)* | 9·9% (5·2 to 13·3)* | 4·3% (1·1 to 7·7)* | |||
| Terminal phase of thyroid cancer | 3·5 (3·4 to 3·8) | .. | 1·9 (1·3 to 2·5) | 63·9% (57·0 to 70·0)* | 34·7% (30·4 to 39·1)* | 8·6% (4·2 to 12·1)* | 3·9% (0·6 to 7·3)* | |||
| Mesothelioma | 78·6 (76·1 to 81·1) | 34·6 (33·5 to 35·7) | 14·9 (10·6 to 19·7) | 33·7% (17·7 to 56·9)* | 23·9% (16·2 to 30·9)* | −10·0% (−20·4 to 5·2) | −4·6% (−10·3 to 0·7) | |||
| Diagnosis and primary therapy phase of mesothelioma | 9·1 (8·8 to 9·4) | 34·6 (33·5 to 35·7) | 2·6 (1·7 to 3·6) | 35·5% (20·0 to 58·2)* | 24·6% (17·0 to 31·2)* | −8·7% (−19·0 to 6·2) | −4·1% (−9·8 to 1·0) | |||
| Controlled phase of mesothelioma | 46·8 (45·3 to 48·3) | .. | 2·2 (1·4 to 3·2) | 34·9% (18·0 to 58·3)* | 23·6% (14·8 to 32·4)* | −8·6% (−19·8 to 7·0) | −4·3% (−11·0 to 2·3) | |||
| Metastatic phase of mesothelioma | 20·0 (19·3 to 20·6) | .. | 8·7 (5·9 to 11·6) | 33·3% (17·0 to 56·9)* | 23·7% (15·3 to 32·1)* | −10·4% (−20·9 to 4·9) | −4·8% (−11·1 to 1·4) | |||
| Terminal phase of mesothelioma | 2·8 (2·7 to 2·9) | .. | 1·5 (1·0 to 1·9) | 31·6% (16·2 to 53·5)* | 24·1% (17·1 to 30·2)* | −11·7% (−21·7 to 2·5) | −4·6% (−9·8 to −0·2)* | |||
| Hodgkin lymphoma | 657·1 (568·9 to 780·8) | 101·1 (88·0 to 118·7) | 50·5 (35·1 to 69·3) | 31·2% (18·9 to 59·3)* | 19·1% (13·8 to 23·7)* | −1·0% (−10·3 to 19·8) | 2·5% (−2·2 to 6·5) | |||
| Diagnosis and primary therapy phase of Hodgkin lymphoma | 21·7 (18·8 to 25·9) | 101·1 (88·0 to 118·7) | 6·2 (4·1 to 9·0) | 44·2% (30·3 to 77·5)* | 22·8% (17·3 to 27·3)* | 10·8% (0·9 to 35·5)* | 6·6% (2·0 to 10·6)* | |||
| Controlled phase of Hodgkin lymphoma | 601·2 (520·5 to 716·2) | .. | 28·6 (17·5 to 43·0) | 43·8% (29·2 to 77·6)* | 22·4% (16·1 to 27·8)* | 11·1% (0·4 to 36·7)* | 6·7% (1·4 to 11·3)* | |||
| Metastatic phase of Hodgkin lymphoma | 31·0 (26·7 to 36·1) | .. | 14·0 (9·1 to 19·0) | 13·5% (4·6 to 33·3)* | 13·3% (8·3 to 17·3)* | −16·9% (−23·0 to −3·0)* | −5·0% (−9·1 to −1·6)* | |||
| Terminal phase of Hodgkin lymphoma | 3·2 (2·7 to 3·7) | .. | 1·7 (1·1 to 2·2) | −2·7% (−10·9 to 13·0) | 4·6% (0·8 to 8·2)* | −28·0% (−33·5 to −17·1)* | −12·1% (−15·3 to −9·1)* | |||
| Non-Hodgkin lymphoma | 2371·9 (2325·0 to 2418·1) | 488·0 (478·9 to 496·9) | 193·1 (140·2 to 254·2) | 77·8% (70·5 to 84·3)* | 41·4% (37·7 to 45·0)* | 26·1% (21·4 to 30·3)* | 11·3% (8·2 to 14·2)* | |||
| Diagnosis and primary therapy phase of non-Hodgkin lymphoma | 87·8 (86·0 to 89·4) | 488·0 (478·9 to 496·9) | 24·2 (16·4 to 33·1) | 90·1% (82·5 to 97·4)* | 45·3% (40·5 to 49·9)* | 35·2% (30·7 to 39·7)* | 14·7% (10·8 to 18·3)* | |||
| Controlled phase of non-Hodgkin lymphoma | 2119·9 (2077·3 to 2161·3) | .. | 97·3 (62·9 to 140·5) | 91·9% (83·9 to 99·1)* | 45·4% (41·4 to 49·4)* | 38·6% (33·9 to 42·8)* | 15·6% (12·3 to 18·9)* | |||
| Metastatic phase of non-Hodgkin lymphoma | 140·1 (137·6 to 142·6) | .. | 58·8 (40·5 to 77·5) | 60·4% (53·7 to 66·4)* | 35·4% (31·3 to 39·6)* | 12·0% (7·9 to 15·8)* | 5·1% (1·9 to 8·4)* | |||
| Terminal phase of non-Hodgkin lymphoma | 24·1 (23·7 to 24·6) | .. | 12·9 (9·0 to 16·5) | 57·3% (51·5 to 62·0)* | 34·0% (30·5 to 37·2)* | 9·4% (6·2 to 11·9)* | 3·8% (1·2 to 6·2)* | |||
| Multiple myeloma | 449·3 (414·6 to 520·9) | 152·7 (140·6 to 172·7) | 90·8 (64·2 to 118·4) | 93·4% (85·2 to 102·7)* | 44·3% (38·6 to 50·3)* | 29·7% (24·3 to 35·4)* | 10·3% (5·9 to 14·7)* | |||
| Diagnosis and primary therapy phase of multiple myeloma | 28·1 (26·0 to 32·7) | 152·7 (140·6 to 172·7) | 8·0 (5·3 to 11·2) | 116·1% (110·1 to 130·1)* | 48·6% (43·2 to 54·8)* | 47·0% (43·2 to 55·9)* | 14·4% (10·2 to 19·0)* | |||
| Controlled phase of multiple myeloma | 252·3 (233·7 to 294·6) | .. | 11·7 (7·5 to 17·3) | 118·2% (107·1 to 135·2)* | 48·9% (42·0 to 56·3)* | 48·8% (41·5 to 60·1)* | 15·0% (9·7 to 20·7)* | |||
| Metastatic phase of multiple myeloma | 157·9 (145·3 to 181·5) | .. | 65·1 (44·2 to 85·7) | 90·5% (80·8 to 100·4)* | 43·8% (37·3 to 50·4)* | 27·7% (21·3 to 34·0)* | 9·8% (4·8 to 14·8)* | |||
| Terminal phase of multiple myeloma | 10·9 (10·1 to 12·3) | .. | 5·9 (4·1 to 7·6) | 63·8% (53·4 to 68·1)* | 35·8% (31·5 to 39·8)* | 8·5% (0·7 to 11·3)* | 2·4% (−0·9 to 5·5) | |||
| Leukaemia | 2432·4 (2190·3 to 2591·6) | 518·5 (472·2 to 548·0) | 263·3 (191·2 to 342·0) | 27·8% (13·5 to 38·0)* | 25·1% (19·7 to 29·5)* | −3·6% (−12·7 to 2·1) | 2·3% (−2·3 to 6·5) | |||
| Acute lymphoid leukaemia | 521·1 (433·1 to 579·5) | 64·2 (56·4 to 70·4) | 43·0 (30·6 to 58·6) | 29·9% (3·6 to 46·7)* | 31·6% (11·9 to 47·7)* | 11·1% (−9·4 to 24·0) | 18·6% (0·3 to 33·7)* | |||
| Diagnosis and primary therapy phase of acute lymphoid leukaemia | 32·0 (28·1 to 35·1) | 64·2 (56·4 to 70·4) | 9·2 (6·1 to 13·0) | 18·6% (−6·0 to 33·6) | 11·8% (−3·0 to 21·9) | 0·6% (−18·0 to 11·8) | −1·0% (−14·5 to 8·0) | |||
| Controlled phase of acute lymphoid leukaemia | 465·2 (383·8 to 521·0) | .. | 22·6 (14·0 to 34·1) | 39·6% (10·2 to 59·8)* | 48·4% (20·2 to 69·2)* | 24·4% (−0·3 to 41·3) | 36·8% (10·2 to 56·6)* | |||
| Metastatic phase of acute lymphoid leukaemia | 20·1 (17·3 to 21·7) | .. | 9·1 (6·0 to 12·4) | 26·3% (3·9 to 42·1)* | 21·6% (10·0 to 31·5)* | 2·4% (−13·6 to 13·8) | 5·8% (−4·5 to 14·3) | |||
| Terminal phase of acute lymphoid leukaemia | 3·7 (3·2 to 4·0) | .. | 2·0 (1·4 to 2·6) | 25·4% (2·9 to 41·5)* | 20·8% (9·0 to 30·9)* | 2·0% (−14·1 to 13·7) | 5·2% (−5·2 to 13·9) | |||
| Chronic lymphoid leukaemia | 567·7 (534·1 to 600·4) | 90·6 (85·6 to 95·6) | 74·6 (54·8 to 96·5) | 72·3% (65·5 to 80·3)* | 42·7% (36·5 to 49·1)* | 12·5% (7·8 to 17·7)* | 7·3% (2·5 to 12·3)* | |||
| Diagnosis and primary therapy phase of chronic lymphoid leukaemia | 30·4 (28·6 to 32·1) | 90·6 (85·6 to 95·6) | 8·6 (5·8 to 11·9) | 78·0% (71·6 to 84·8)* | 45·4% (39·0 to 52·0)* | 18·1% (13·6 to 22·7)* | 10·6% (5·5 to 15·7)* | |||
| Controlled phase of chronic lymphoid leukaemia | 424·3 (399·1 to 449·4) | .. | 19·5 (12·7 to 28·2) | 83·4% (75·4 to 91·3)* | 46·6% (39·4 to 54·0)* | 23·1% (18·0 to 28·5)* | 12·2% (6·9 to 17·9)* | |||
| Metastatic phase of chronic lymphoid leukaemia | 108·9 (103·0 to 114·8) | .. | 44·4 (31·2 to 58·5) | 67·8% (59·1 to 77·9)* | 40·8% (33·9 to 48·3)* | 8·5% (2·8 to 14·8)* | 5·1% (0·0 to 10·7)* | |||
| Terminal phase of chronic lymphoid leukaemia | 4·0 (3·8 to 4·2) | .. | 2·2 (1·5 to 2·8) | 58·4% (52·4 to 64·5)* | 35·9% (30·4 to 41·8)* | 1·6% (−2·4 to 5·5) | 0·5% (−3·6 to 5·0) | |||
| Acute myeloid leukaemia | 150·9 (137·0 to 160·0) | 119·6 (108·4 to 125·9) | 28·8 (20·2 to 37·7) | 52·6% (24·2 to 72·6)* | 22·9% (12·9 to 30·0)* | 13·5% (−4·6 to 25·4) | 1·0% (−7·1 to 6·7) | |||
| Diagnosis and primary therapy phase of acute myeloid leukaemia | .. | 119·6 (108·4 to 125·9) | .. | .. | .. | .. | .. | |||
| Controlled phase of acute myeloid leukaemia | 99·2 (90·5 to 105·8) | .. | 4·8 (3·0 to 7·2) | 63·3% (25·1 to 91·8)* | 18·7% (7·4 to 27·0)* | 26·4% (1·9 to 44·0)* | 0·0% (−9·5 to 7·1) | |||
| Metastatic phase of acute myeloid leukaemia | 42·5 (38·5 to 44·7) | .. | 19·0 (12·5 to 25·5) | 50·4% (23·7 to 69·1)* | 23·8% (14·0 to 30·8)* | 11·1% (−6·0 to 22·1) | 1·1% (−6·4 to 6·8) | |||
| Terminal phase of acute myeloid leukaemia | 9·2 (8·4 to 9·7) | .. | 5·0 (3·4 to 6·5) | 51·0% (24·2 to 69·8)* | 24·0% (14·2 to 30·8)* | 11·6% (−5·6 to 22·6) | 1·2% (−6·2 to 6·8) | |||
| Chronic myeloid leukaemia | 95·8 (88·3 to 103·2) | 34·2 (31·5 to 36·7) | 11·7 (8·4 to 15·4) | 6·5% (1·3 to 11·2)* | 6·6% (3·0 to 10·0)* | −28·1% (−31·5 to −24·8)* | −15·0% (−17·9 to −12·1)* | |||
| Diagnosis and primary therapy phase of chronic myeloid leukaemia | 6·9 (6·4 to 7·4) | 34·2 (31·5 to 36·7) | 2·0 (1·3 to 2·8) | 13·6% (8·5 to 18·5)* | 7·5% (3·9 to 11·0)* | −23·4% (−26·6 to −20·3)* | −13·7% (−16·6 to −10·8)* | |||
| Controlled phase of chronic myeloid leukaemia | 76·1 (70·1 to 82·0) | .. | 3·7 (2·4 to 5·6) | 17·9% (12·1 to 23·7)* | 7·8% (3·9 to 11·5)* | −19·3% (−23·2 to −15·2)* | −12·6% (−15·8 to −9·5)* | |||
| Metastatic phase of chronic myeloid leukaemia | 10·6 (9·7 to 11·3) | .. | 4·8 (3·2 to 6·4) | −1·3% (−6·1 to 2·9) | 5·5% (2·0 to 9·1)* | −33·5% (−36·6 to −30·5)* | −16·7% (−19·7 to −13·8)* | |||
| Terminal phase of chronic myeloid leukaemia | 2·3 (2·1 to 2·5) | .. | 1·2 (0·9 to 1·6) | −1·7% (−6·3 to 2·6) | 5·5% (1·9 to 9·1)* | −33·9% (−36·7 to −31·1)* | −16·8% (−19·6 to −13·9)* | |||
| Other leukaemia | 1096·8 (930·7 to 1204·2) | 209·9 (180·8 to 227·5) | 105·3 (74·7 to 137·1) | 9·1% (−6·7 to 25·2) | 15·4% (8·5 to 22·4)* | −14·8% (−25·1 to −5·3)* | −4·0% (−9·7 to 1·9) | |||
| Diagnosis and primary therapy phase of other leukaemia | .. | 209·9 (180·8 to 227·5) | .. | .. | .. | .. | .. | |||
| Controlled phase of other leukaemia | 957·9 (808·7 to 1058·8) | .. | 45·4 (28·5 to 67·6) | 7·6% (−13·7 to 33·7) | 13·1% (1·7 to 25·4)* | −8·8% (−24·9 to 9·7) | −1·1% (−11·7 to 10·0) | |||
| Metastatic phase of other leukaemia | 130·2 (114·4 to 139·3) | .. | 55·1 (37·6 to 72·8) | 10·8% (−0·2 to 20·4) | 17·4% (13·1 to 23·7)* | −18·7% (−25·8 to −13·5)* | −6·0% (−9·4 to −1·3)* | |||
| Terminal phase of other leukaemia | 8·8 (7·7 to 9·4) | .. | 4·7 (3·3 to 6·1) | 6·4% (−4·0 to 17·1) | 15·2% (11·1 to 20·7)* | −20·7% (−27·2 to −15·4)* | −7·6% (−10·9 to −3·4)* | |||
| Other malignant cancers | 9176·2 (8080·3 to 10 439·8) | 715·5 (656·3 to 740·0) | 678·1 (481·1 to 910·4) | 99·7% (84·8 to 118·8)* | 149·2% (122·1 to 179·0)* | 46·4% (35·6 to 60·0)* | 107·7% (84·2 to 133·3)* | |||
| Diagnosis and primary therapy phase of other malignant neoplasms | 205·1 (181·3 to 231·1) | 715·5 (656·3 to 740·0) | 56·6 (38·0 to 80·5) | 126·8% (107·3 to 150·6)* | 177·7% (146·5 to 210·3)* | 67·9% (55·4 to 83·7)* | 133·3% (107·0 to 161·9)* | |||
| Controlled phase of other malignant neoplasms | 8451·7 (7437·1 to 9683·5) | .. | 397·1 (252·9 to 592·8) | 140·6% (114·5 to 174·5)* | 204·9% (166·8 to 245·8)* | 86·8% (68·6 to 109·9)* | 161·4% (127·6 to 198·8)* | |||
| Metastatic phase of other malignant neoplasms | 460·4 (413·4 to 501·3) | .. | 188·6 (128·3 to 248·2) | 67·0% (58·2 to 80·1)* | 86·3% (71·8 to 101·9)* | 18·3% (12·2 to 27·4)* | 49·1% (37·2 to 61·1)* | |||
| Terminal phase of other malignant neoplasms | 68·0 (61·1 to 73·8) | .. | 35·8 (24·8 to 46·0) | 62·1% (54·1 to 73·7)* | 77·1% (65·3 to 90·1)* | 14·2% (8·8 to 22·0)* | 40·7% (31·0 to 51·3)* | |||
| Other neoplasms | 25 223·0 (24 682·1 to 25 725·3) | 11 159·5 (10 928·2 to 11 416·2) | 55·1 (35·2 to 80·9) | 47·4% (42·6 to 52·3)* | 34·5% (31·6 to 37·3)* | 4·7% (1·8 to 7·7)* | 6·0% (4·0 to 7·9)* | |||
| Myelodysplastic, myeloproliferative, and other haemopoietic neoplasms | 1212·2 (1098·1 to 1332·1) | 134·3 (118·4 to 148·9) | 55·1 (35·2 to 80·9) | 47·4% (42·6 to 52·3)* | 34·5% (31·6 to 37·3)* | 4·7% (1·8 to 7·7)* | 6·0% (4·0 to 7·9)* | |||
| Benign and in-situ intestinal neoplasms | 3966·3 (3840·7 to 4110·3) | 1010·9 (980·1 to 1049·4) | .. | .. | .. | .. | .. | |||
| Benign and in-situ cervical and uterine neoplasms | 1180·0 (1138·1 to 1223·0) | 299·4 (287·6 to 312·8) | .. | .. | .. | .. | .. | |||
| Other benign and in-situ neoplasms | 19 417·1 (18 926·5 to 19 882·6) | 9715·0 (9488·7 to 9966·6) | .. | .. | .. | .. | .. | |||
| Cardiovascular diseases | 485 620·9 (468 031·7 to 504 964·4) | 72 721·2 (70 388·1 to 75 264·1) | 35 697·3 (26 428·2 to 45 510·3) | 39·8% (38·8 to 40·8)* | 34·3% (32·0 to 37·0)* | −5·5% (−6·2 to −4·8)* | 4·5% (2·9 to 6·4)* | |||
| Rheumatic heart disease | 39 345·4 (37 960·8 to 40 828·7) | 1311·3 (1269·4 to 1354·9) | 1901·0 (1232·8 to 2766·0) | 40·9% (40·0 to 41·8)* | 16·0% (15·3 to 16·7)* | 7·3% (6·7 to 7·9)* | 2·4% (1·9 to 3·1)* | |||
| Rheumatic heart disease without heart failure | 38 145·4 (36 705·9 to 39 639·2) | 1311·3 (1269·4 to 1354·9) | 1797·9 (1160·7 to 2619·0) | 40·0% (39·2 to 40·9)* | 15·4% (14·8 to 16·1)* | 7·3% (6·7 to 7·9)* | 2·6% (2·0 to 3·2)* | |||
| Heart failure due to rheumatic heart disease | 1199·9 (1006·1 to 1403·8) | .. | 103·1 (69·7 to 145·1) | 58·9% (54·7 to 62·6)* | 27·2% (24·4 to 30·2)* | 7·9% (5·3 to 10·3)* | −0·1% (−2·2 to 1·9) | |||
| Ischaemic heart disease | 126 451·5 (118 587·5 to 134 706·5) | 10 636·5 (9573·2 to 11 794·5) | 5291·9 (3657·3 to 7238·9) | 35·8% (34·5 to 37·0)* | 23·5% (22·9 to 24·2)* | −10·9% (−11·9 to −10·0)* | −5·2% (−5·7 to −4·7)* | |||
| Asymptomatic ischaemic heart disease following myocardial infarction | 37 908·6 (31 907·4 to 44 225·6) | .. | .. | .. | .. | .. | .. | |||
| Angina due to ischaemic heart disease | 70 969·3 (66 224·1 to 75 830·1) | .. | 3850·4 (2615·6 to 5381·2) | 35·1% (34·3 to 35·9)* | 22·9% (22·2 to 23·5)* | −10·0% (−10·4 to −9·5)* | −4·6% (−5·0 to −4·2)* | |||
| Heart failure due to ischaemic heart disease | 17 007·2 (14 512·0 to 19 849·5) | .. | 1388·9 (951·7 to 1947·2) | 37·2% (33·2 to 41·7)* | 25·9% (24·3 to 27·5)* | −13·5% (−16·2 to −10·7)* | −6·4% (−7·6 to −5·1)* | |||
| Myocardial infarction due to ischaemic heart disease | 566·4 (505·5 to 634·4) | 10 636·5 (9573·2 to 11 794·5) | 52·7 (36·6 to 72·9) | 48·9% (46·1 to 51·7)* | 13·6% (10·5 to 16·6)* | −4·2% (−5·9 to −2·5)* | −14·6% (−17·0 to −12·3)* | |||
| Stroke | 104 178·7 (98 454·0 to 110 125·0) | 11 931·1 (11 118·4 to 12 825·8)‡ | 18 695·4 (13 574·3 to 23 686·9) | 40·0% (38·4 to 41·4)* | 43·6% (39·6 to 47·8)* | −4·7% (−5·8 to −3·7)* | 11·2% (8·1 to 14·3)* | |||
| Ischaemic stroke | 82 417·3 (76 967·8 to 88 516·9) | 7737·5 (6951·1 to 8677·6)‡ | 14 304·4 (10 297·5 to 18 176·0) | 42·8% (40·6 to 44·9)* | 54·3% (49·1 to 59·4)* | −4·1% (−5·5 to −2·7)* | 18·1% (14·1 to 22·0)* | |||
| Acute ischaemic stroke | 587·5 (529·1 to 655·7) | 7737·5 (6951·1 to 8677·6)‡ | 144·3 (100·1 to 188·1) | 40·1% (37·4 to 42·9)* | 43·0% (37·0 to 49·4)* | −6·9% (−8·5 to −5·2)* | 8·8% (4·3 to 13·6)* | |||
| Chronic ischaemic stroke | 81 829·7 (76 384·9 to 87 926·6) | .. | 14 160·1 (10 204·3 to 17 970·9) | 42·8% (40·6 to 45·0)* | 54·4% (49·2 to 59·6)* | −4·1% (−5·4 to −2·7)* | 18·2% (14·1 to 22·2)* | |||
| Intracerebral haemorrhage | 17 914·9 (16 190·6 to 19 666·6) | 3128·6 (2874·6 to 3418·0)‡ | 2946·9 (2121·6 to 3794·1) | 32·1% (29·9 to 34·3)* | 13·9% (8·0 to 20·3)* | −6·8% (−8·2 to −5·4)* | −9·5% (−14·2 to −4·8)* | |||
| Acute intracerebral haemorrhage | 168·7 (154·2 to 184·6) | 3128·6 (2874·6 to 3418·0)‡ | 44·3 (31·0 to 57·8) | 39·4% (36·8 to 42·4)* | −1·9% (−6·8 to 3·2) | −5·5% (−7·3 to −3·7)* | −24·4% (−28·1 to −20·6)* | |||
| Chronic intracerebral haemorrhage | 17 746·2 (16 029·3 to 19 493·5) | .. | 2902·6 (2090·3 to 3738·5) | 32·0% (29·8 to 34·1)* | 14·2% (8·1 to 20·6)* | −6·8% (−8·3 to −5·4)* | −9·3% (−14·0 to −4·4)* | |||
| Subarachnoid haemorrhage | 9321·9 (8523·7 to 10 242·4) | 1064·9 (953·3 to 1182·6)‡ | 1444·2 (1031·6 to 1845·4) | 36·8% (34·7 to 38·9)* | 25·0% (21·3 to 28·6)* | −5·7% (−7·1 to −4·3)* | −1·6% (−4·4 to 1·2) | |||
| Acute subarachnoid haemorrhage | 80·5 (71·7 to 89·5) | 1064·9 (953·3 to 1182·6)‡ | 21·1 (14·5 to 28·0) | 40·2% (31·1 to 43·9)* | 25·2% (19·8 to 27·2)* | −4·6% (−10·2 to −2·5)* | −1·6% (−5·5 to −0·2)* | |||
| Chronic subarachnoid haemorrhage | 9241·4 (8444·1 to 10 171·4) | .. | 1423·1 (1016·6 to 1817·9) | 36·7% (34·6 to 38·8)* | 25·0% (21·2 to 28·6)* | −5·7% (−7·1 to −4·3)* | −1·6% (−4·4 to 1·2) | |||
| Hypertensive heart disease | 17 067·7 (14 426·9 to 19 874·3) | .. | 1408·0 (966·6 to 1982·4) | 63·8% (60·5 to 67·2)* | 34·9% (33·2 to 36·6)* | 6·0% (3·8 to 8·2)* | 1·9% (0·7 to 2·9)* | |||
| Non-rheumatic valvular heart disease | 29 729·1 (28 505·4 to 31 022·5) | 30 691·2 (29 436·4 to 32 002·2) | 360·8 (207·1 to 559·6) | 54·9% (49·0 to 61·0)* | 35·8% (30·9 to 40·7)* | −4·5% (−7·7 to −1·7)* | −1·0% (−4·3 to 2·1) | |||
| Non-rheumatic calcific aortic valve disease | 12 570·2 (11 411·8 to 13 841·1) | 12 570·2 (11 411·8 to 13 841·1) | 168·0 (96·6 to 259·9) | 64·8% (56·5 to 73·5)* | 38·9% (30·9 to 46·2)* | −0·2% (−5·1 to 4·3) | 0·2% (−5·9 to 5·3) | |||
| Heart failure due to calcific aortic valve disease | 1386·0 (896·6 to 2029·9) | .. | 111·0 (63·7 to 173·8) | 42·3% (30·1 to 56·6)* | 30·6% (13·2 to 47·6)* | −14·1% (−21·4 to −6·0)* | −6·0% (−19·0 to 6·2) | |||
| Non-rheumatic calcific aortic valve disease | 11 184·2 (9987·3 to 12 425·7) | 12 570·2 (11 411·8 to 13 841·1) | 56·9 (30·4 to 93·2) | 163·9% (124·2 to 209·0)* | 58·7% (36·3 to 84·3)* | 62·6% (37·1 to 93·2)* | 15·0% (−1·6 to 34·3) | |||
| Non-rheumatic degenerative mitral valve disease | 18 121·0 (17 682·3 to 18 586·4) | 18 121·0 (17 682·3 to 18 586·4) | 190·3 (109·2 to 295·3) | 47·4% (41·5 to 52·7)* | 33·2% (28·1 to 38·0)* | −8·1% (−11·5 to −5·4)* | −2·0% (−5·6 to 1·2) | |||
| Heart failure due to degenerative mitral valve disease | 1723·6 (1111·4 to 2494·0) | .. | 139·9 (81·5 to 217·1) | 33·3% (25·0 to 43·1)* | 26·7% (15·5 to 38·6)* | −17·1% (−22·2 to −11·4)* | −6·8% (−15·0 to 2·0) | |||
| Non-rheumatic degenerative mitral valve disease | 16 397·4 (15 574·9 to 17 179·2) | 18 121·0 (17 682·3 to 18 586·4) | 50·5 (26·7 to 84·0) | 129·8% (95·6 to 171·4)* | 55·2% (33·1 to 78·0)* | 44·9% (22·1 to 72·2)* | 14·0% (−2·5 to 30·9) | |||
| Other non-rheumatic valve diseases | 26·9 (22·1 to 32·2) | .. | 2·5 (1·6 to 3·6) | 63·1% (58·9 to 67·2)* | 37·7% (34·1 to 41·1)* | 7·4% (5·1 to 9·4)* | 6·1% (4·1 to 8·1)* | |||
| Mild heart failure due to other non-rheumatic valve disease | 5·0 (3·5 to 6·8) | .. | 0·2 (0·1 to 0·3) | 63·6% (59·2 to 68·1)* | 38·0% (34·5 to 41·4)* | 7·7% (5·4 to 9·9)* | 6·2% (4·2 to 8·1)* | |||
| Moderate heart failure due to other non-rheumatic valve disease | 3·3 (2·2 to 4·4) | .. | 0·2 (0·1 to 0·4) | 63·6% (59·0 to 68·0)* | 38·0% (34·5 to 41·6)* | 7·7% (5·3 to 10·0)* | 6·2% (4·0 to 8·2)* | |||
| Severe heart failure due to other non-rheumatic valve disease | 8·8 (6·9 to 10·9) | .. | 1·5 (1·0 to 2·3) | 63·0% (58·7 to 67·4)* | 37·7% (33·6 to 41·6)* | 7·3% (4·8 to 9·8)* | 6·1% (3·7 to 8·8)* | |||
| Controlled, medically managed heart failure due to other non-rheumatic valve disease | 9·9 (8·0 to 12·1) | .. | 0·5 (0·3 to 0·7) | 63·2% (58·8 to 67·6)* | 37·6% (33·5 to 41·6)* | 7·4% (5·0 to 10·0)* | 6·1% (3·3 to 8·7)* | |||
| Cardiomyopathy and myocarditis | 5429·9 (4694·4 to 6257·1) | 3071·0 (2745·0 to 3451·2) | 623·8 (424·7 to 859·3) | 27·4% (24·5 to 30·9)* | 21·2% (19·2 to 23·0)* | −12·6% (−14·9 to −10·3)* | −3·9% (−5·0 to −2·9)* | |||
| Myocarditis | 1804·6 (1635·3 to 1983·8) | 3071·0 (2745·0 to 3451·2) | 131·4 (90·1 to 183·0) | 26·6% (23·9 to 29·6)* | 15·9% (13·9 to 18·0)* | −5·4% (−6·8 to −4·1)* | −1·9% (−3·0 to −0·9)* | |||
| Acute myocarditis | 740·8 (656·3 to 830·8) | 3071·0 (2745·0 to 3451·2) | 35·7 (22·5 to 52·6) | 33·3% (30·5 to 36·2)* | 19·1% (16·7 to 21·6)* | −2·4% (−4·0 to −0·6)* | −1·3% (−2·9 to 0·2) | |||
| Heart failure due to myocarditis | 1063·7 (914·1 to 1215·2) | .. | 95·7 (63·9 to 133·5) | 24·4% (21·0 to 28·2)* | 14·8% (12·3 to 17·3)* | −6·5% (−8·1 to −4·9)* | −2·1% (−3·4 to −0·8)* | |||
| Alcoholic cardiomyopathy | 1621·8 (1370·5 to 1902·4) | .. | 139·1 (95·1 to 196·1) | 20·7% (16·8 to 25·1)* | 15·5% (12·9 to 18·1)* | −17·9% (−20·5 to −15·2)* | −9·5% (−11·2 to −7·7)* | |||
| Other cardiomyopathy | 4212·7 (3634·6 to 4869·9) | .. | 353·3 (237·9 to 493·9) | 30·8% (27·2 to 34·9)* | 25·7% (23·4 to 27·9)* | −12·8% (−15·6 to −9·9)* | −2·5% (−3·9 to −1·0)* | |||
| Atrial fibrillation and flutter | 37 574·2 (32 548·8 to 42 588·4) | 3046·0 (2605·8 to 3507·2) | 2921·5 (1992·6 to 4034·2) | 49·0% (46·7 to 51·7)* | 31·4% (30·3 to 32·5)* | −3·7% (−5·1 to −1·9)* | −1·2% (−1·9 to −0·6)* | |||
| Asymptomatic atrial fibrillation and flutter | 22 545·7 (19 530·0 to 25 680·2) | 3046·0 (2605·8 to 3507·2) | .. | .. | .. | .. | .. | |||
| Symptomatic atrial fibrillation and flutter | 15 028·5 (13 016·1 to 17 142·8) | .. | 2921·5 (1992·6 to 4034·2) | 49·0% (46·7 to 51·7)* | 31·4% (30·3 to 32·5)* | −3·7% (−5·1 to −1·9)* | −1·2% (−1·9 to −0·6)* | |||
| Peripheral vascular disease | 118 123·6 (102 706·9 to 134 350·4) | 10 811·7 (9282·1 to 12 503·4) | 515·6 (237·6 to 938·4) | 40·0% (37·6 to 42·8)* | 27·8% (26·6 to 29·3)* | −8·5% (−9·6 to −7·0)* | −4·7% (−5·5 to −3·6)* | |||
| Asymptomatic peripheral arterial disease | 78 631·6 (66 970·1 to 91 233·4) | 10 811·7 (9282·1 to 12 503·4) | .. | .. | .. | .. | .. | |||
| Symptomatic claudication due to peripheral arterial disease | 39 492·0 (31 074·7 to 50 227·2) | .. | 515·6 (237·6 to 938·4) | 40·0% (37·6 to 42·8)* | 27·8% (26·6 to 29·3)* | −8·5% (−9·6 to −7·0)* | −4·7% (−5·5 to −3·6)* | |||
| Endocarditis | 654·1 (567·5 to 743·8) | 1222·5 (1097·6 to 1334·0) | 53·8 (36·6 to 75·3) | 31·1% (27·3 to 35·6)* | 24·6% (22·1 to 27·3)* | −10·7% (−14·3 to −7·2)* | −2·5% (−4·4 to −0·8)* | |||
| Acute endocarditis | 87·9 (78·3 to 96·3) | 1222·5 (1097·6 to 1334·0) | 4·9 (3·2 to 7·3) | 34·3% (31·7 to 36·9)* | 26·2% (23·2 to 29·2)* | 2·1% (1·4 to 2·9)* | 4·3% (2·3 to 6·4)* | |||
| Heart failure due to endocarditis | 566·2 (480·9 to 655·8) | .. | 48·9 (33·3 to 68·7) | 30·8% (26·5 to 35·7)* | 24·5% (21·8 to 27·4)* | −11·7% (−15·5 to −8·1)* | −3·2% (−5·1 to −1·3)* | |||
| Other cardiovascular and circulatory diseases | 75 599·8 (64 068·9 to 88 170·3) | .. | 3925·4 (2650·1 to 5544·1) | 32·5% (30·0 to 35·5)* | 24·4% (22·5 to 26·2)* | −9·1% (−10·9 to −6·9)* | −0·5% (−1·4 to 0·4) | |||
| Heart failure due to other cardiovascular diseases | 1562·0 (1279·4 to 1882·1) | .. | 129·6 (86·6 to 185·3) | 32·6% (28·4 to 37·1)* | 30·0% (27·5 to 32·6)* | −15·0% (−18·0 to −12·0)* | −2·0% (−3·8 to −0·2)* | |||
| Other cardiovascular and circulatory disease episodes | 74 037·8 (62 741·1 to 86 283·3) | .. | 3795·9 (2564·1 to 5373·7) | 32·4% (30·0 to 35·5)* | 24·2% (22·3 to 26·0)* | −8·8% (−10·7 to −6·7)* | −0·4% (−1·3 to 0·5) | |||
| Chronic respiratory diseases | 544 899·2 (506 937·5 to 584 858·4) | 62 161·4 (55 134·8 to 69 320·7) | 44 311·8 (36 751·6 to 51 407·1) | 21·9% (19·7 to 24·3)* | 22·8% (19·0 to 26·5)* | −12·5% (−13·7 to −11·3)* | −0·4% (−3·3 to 2·5) | |||
| Chronic obstructive pulmonary disease | 299 398·2 (269 025·2 to 330 073·8) | 18 475·7 (16 736·0 to 20 255·6) | 30 611·5 (26 034·9 to 34 813·0) | 24·9% (22·7 to 27·2)* | 23·8% (18·6 to 28·6)* | −14·1% (−15·5 to −12·6)* | −2·8% (−6·9 to 0·9) | |||
| Chronic obstructive pulmonary disease with heart failure | 14 890·7 (12 183·6 to 17 715·3) | .. | 5673·6 (4163·8 to 7049·6) | 66·5% (61·8 to 71·3)* | 36·1% (32·1 to 39·1)* | 5·4% (2·6 to 8·1)* | 1·3% (−1·1 to 3·4) | |||
| Chronic obstructive pulmonary disease without heart failure | 284 507·4 (254 368·4 to 315 515·1) | 18 475·7 (16 736·0 to 20 255·6) | 24 937·9 (21 040·1 to 28 738·5) | 18·9% (16·3 to 21·5)* | 21·3% (15·4 to 26·8)* | −17·6% (−19·3 to −15·8)* | −3·7% (−8·4 to 0·6) | |||
| Pneumoconiosis | 527·5 (470·0 to 593·2) | 60·1 (53·1 to 67·0) | 80·5 (54·5 to 111·5) | 41·3% (36·5 to 46·3)* | 27·0% (22·8 to 31·2)* | −3·8% (−6·9 to −0·7)* | −2·0% (−5·2 to 1·1) | |||
| Silicosis | 162·4 (127·5 to 202·6) | 23·7 (19·1 to 29·0) | 24·9 (16·0 to 36·0) | 45·4% (36·4 to 54·7)* | 29·1% (21·3 to 37·1)* | −0·0% (−5·9 to 6·1) | 0·2% (−5·8 to 6·4) | |||
| Heart failure due to silicosis | 11·0 (9·1 to 13·1) | .. | 5·0 (3·4 to 6·9) | 64·3% (58·4 to 70·9)* | 31·0% (26·8 to 35·3)* | 8·7% (5·1 to 13·1)* | −1·6% (−4·8 to 1·9) | |||
| Silicosis without heart failure | 151·4 (117·1 to 190·0) | 23·7 (19·1 to 29·0) | 19·8 (12·2 to 29·4) | 41·3% (30·6 to 52·9)* | 28·6% (19·0 to 38·5)* | −2·1% (−9·3 to 5·9) | 0·6% (−6·9 to 8·3) | |||
| Asbestosis | 92·1 (73·1 to 118·3) | 9·4 (7·7 to 11·6) | 14·4 (9·2 to 21·6) | 42·6% (32·3 to 53·9)* | 35·0% (29·6 to 41·3)* | −2·1% (−9·1 to 5·2) | 4·4% (0·6 to 8·6)* | |||
| Asbestosis without heart failure | 86·6 (67·7 to 112·7) | 9·4 (7·7 to 11·6) | 11·9 (7·4 to 18·2) | 38·3% (27·2 to 50·6)* | 36·6% (30·1 to 44·7)* | −3·9% (−11·9 to 4·7) | 7·1% (2·4 to 12·5)* | |||
| Heart failure due to asbestosis | 5·6 (4·7 to 6·5) | .. | 2·5 (1·7 to 3·5) | 65·2% (54·7 to 77·6)* | 27·6% (23·8 to 31·8)* | 5·5% (−1·3 to 13·3) | −6·0% (−8·9 to −3·0)* | |||
| Coal worker pneumoconiosis | 147·9 (117·5 to 190·1) | 15·1 (12·0 to 19·8) | 21·9 (14·2 to 31·8) | 39·1% (28·8 to 50·1)* | 23·1% (13·8 to 32·3)* | −6·0% (−12·4 to 1·1) | −5·6% (−12·7 to 1·2) | |||
| Coal worker pneumoconiosis without heart failure | 140·9 (110·7 to 182·6) | 15·1 (12·0 to 19·8) | 18·7 (12·0 to 27·8) | 36·5% (24·8 to 48·9)* | 22·4% (11·6 to 33·0)* | −7·3% (−14·7 to 0·9) | −6·0% (−14·1 to 1·7) | |||
| Heart failure due to coal worker pneumoconiosis | 7·0 (5·9 to 8·2) | .. | 3·2 (2·2 to 4·3) | 57·8% (51·8 to 64·5)* | 27·5% (23·0 to 32·1)* | 2·7% (−1·6 to 7·1) | −3·1% (−6·6 to 0·4) | |||
| Other pneumoconiosis | 125·1 (105·0 to 149·3) | 11·9 (9·9 to 14·3) | 19·3 (12·6 to 28·5) | 38·2% (31·9 to 45·3)* | 23·3% (18·5 to 27·9)* | −6·9% (−10·9 to −2·7)* | −5·0% (−8·4 to −1·6)* | |||
| Heart failure due to other pneumoconiosis | 4·1 (3·4 to 4·7) | .. | 1·9 (1·3 to 2·6) | 80·7% (75·2 to 86·3)* | 27·8% (23·5 to 31·9)* | 15·2% (12·3 to 18·2)* | −4·5% (−7·5 to −1·9)* | |||
| Other pneumoconiosis without heart failure | 121·0 (100·9 to 145·2) | 11·9 (9·9 to 14·3) | 17·5 (11·2 to 26·0) | 34·9% (28·3 to 42·1)* | 22·8% (17·7 to 27·8)* | −8·8% (−12·9 to −4·5)* | −5·0% (−8·8 to −1·2)* | |||
| Asthma | 272 677·5 (242 295·9 to 304 699·6) | 43 123·4 (36 191·5 to 50 226·4) | 10 622·9 (7057·0 to 15 056·4) | 8·0% (5·2 to 10·9)* | 19·3% (15·3 to 23·1)* | −13·5% (−14·9 to −11·9)* | 4·9% (1·0 to 8·4)* | |||
| Asymptomatic asthma | 99 070·1 (84 654·0 to 114 607·7) | 15 631·4 (12 827·3 to 18 539·7) | .. | .. | .. | .. | .. | |||
| Symptomatic asthma | 173 607·4 (151 655·5 to 198 619·2) | 27 492·0 (22 746·9 to 32 507·6) | 10 622·9 (7057·0 to 15 056·4) | 8·0% (5·2 to 10·9)* | 19·3% (15·3 to 23·1)* | −13·5% (−14·9 to −11·9)* | 4·9% (1·0 to 8·4)* | |||
| Interstitial lung disease and pulmonary sarcoidosis | 6234·2 (5661·0 to 6848·2) | 502·2 (458·8 to 550·0) | 648·2 (440·3 to 923·2) | 44·3% (41·7 to 47·3)* | 29·1% (26·5 to 31·8)* | −2·3% (−3·9 to −0·5)* | 0·1% (−1·8 to 2·0) | |||
| Heart failure due to interstitial lung disease and pulmonary sarcoidosis | 416·8 (322·3 to 505·6) | .. | 169·8 (114·4 to 236·1) | 60·8% (56·2 to 65·6)* | 31·4% (28·6 to 34·2)* | 5·5% (2·8 to 8·4)* | −1·2% (−3·3 to 0·9) | |||
| Interstitial lung disease and pulmonary sarcoidosis without heart failure | 5817·3 (5242·6 to 6431·9) | 502·2 (458·8 to 550·0) | 478·5 (320·7 to 690·8) | 39·3% (36·3 to 42·8)* | 28·2% (25·3 to 31·5)* | −4·9% (−6·9 to −2·7)* | 0·5% (−1·7 to 2·8) | |||
| Other chronic respiratory diseases | .. | .. | 2348·7 (1930·8 to 2739·6) | 62·5% (58·1 to 67·0)* | 23·8% (19·2 to 28·5)* | 21·4% (17·8 to 25·1)* | 9·2% (5·0 to 13·3)* | |||
| Digestive diseases | 2 049 831·2 (1 983 314·3 to 2 122 941·6) | 465 978·6 (429 600·4 to 500 015·1) | 19 939·7 (13 858·2 to 27 973·1) | 31·1% (29·3 to 32·7)* | 20·5% (19·5 to 21·6)* | −3·4% (−4·1 to −2·7)* | 1·3% (0·6 to 2·0)* | |||
| Cirrhosis and other chronic liver diseases | 1 500 585·1 (1 448 741·6 to 1 556 007·5) | 5154·9 (4935·4 to 5366·5) | 1745·6 (1221·5 to 2387·3) | 50·7% (49·4 to 52·1)* | 34·8% (33·0 to 36·3)* | 8·4% (7·6 to 9·3)* | 10·4% (9·0 to 11·6)* | |||
| Cirrhosis and other chronic liver diseases due to hepatitis B | 431 116·3 (395 729·0 to 468 718·9) | 1531·5 (1419·0 to 1643·9) | 488·4 (337·9 to 665·7) | 53·7% (50·9 to 56·5)* | 33·2% (30·7 to 35·6)* | 8·7% (6·9 to 10·5)* | 9·0% (7·1 to 10·9)* | |||
| Cirrhosis and other chronic liver diseases due to hepatitis B, decompensated | 2974·2 (2810·2 to 3124·4) | 539·5 (509·2 to 570·8) | 488·4 (337·9 to 665·7) | 53·7% (50·9 to 56·5)* | 33·2% (30·7 to 35·6)* | 8·7% (6·9 to 10·5)* | 9·0% (7·1 to 10·9)* | |||
| Chronic hepatitis B without cirrhosis | 391 475·2 (356 323·1 to 429 032·9) | .. | .. | .. | .. | .. | .. | |||
| Cirrhosis and other chronic liver diseases due to hepatitis B, compensated | 36 666·9 (34 057·4 to 39 502·9) | 992·1 (890·6 to 1095·8) | .. | .. | .. | .. | .. | |||
| Cirrhosis and other chronic liver diseases due to hepatitis C | 134 493·9 (118 558·2 to 153 823·8) | 1178·2 (1086·0 to 1272·2) | 431·3 (300·3 to 596·4) | 56·1% (53·5 to 58·4)* | 36·5% (33·9 to 38·9)* | 8·4% (6·7 to 9·9)* | 10·2% (8·2 to 11·9)* | |||
| Cirrhosis and other chronic liver diseases due to hepatitis C, decompensated | 2641·5 (2487·0 to 2806·1) | 467·3 (438·1 to 496·2) | 431·3 (300·3 to 596·4) | 56·1% (53·5 to 58·4)* | 36·5% (33·9 to 38·9)* | 8·4% (6·7 to 9·9)* | 10·2% (8·2 to 11·9)* | |||
| Chronic hepatitis C without cirrhosis | 104 133·4 (88 178·6 to 123 899·7) | .. | .. | .. | .. | .. | .. | |||
| Cirrhosis and other chronic liver diseases due to hepatitis C, compensated | 27 719·0 (25 515·4 to 29 987·7) | 710·9 (628·8 to 800·8) | .. | .. | .. | .. | .. | |||
| Cirrhosis and other chronic liver diseases due to alcohol use | 26 041·9 (24 252·8 to 28 011·2) | 903·7 (839·9 to 973·5) | 400·1 (280·3 to 551·5) | 58·1% (55·4 to 61·0)* | 37·7% (35·1 to 40·5)* | 8·1% (6·3 to 9·9)* | 9·8% (7·8 to 11·9)* | |||
| Cirrhosis and other chronic liver diseases due to alcohol, decompensated | 2457·4 (2313·9 to 2610·3) | 433·1 (407·6 to 458·5) | 400·1 (280·3 to 551·5) | 58·1% (55·4 to 61·0)* | 37·7% (35·1 to 40·5)* | 8·1% (6·3 to 9·9)* | 9·8% (7·8 to 11·9)* | |||
| Cirrhosis and other chronic liver diseases due to alcohol, compensated | 23 584·5 (21 876·0 to 25 478·8) | 470·6 (417·4 to 525·3) | .. | .. | .. | .. | .. | |||
| Cirrhosis due to NASH | 892 322·8 (858 624·9 to 927 954·4) | 367·8 (334·5 to 403·7) | 148·6 (102·8 to 205·0) | 83·2% (78·8 to 87·5)* | 54·6% (51·0 to 58·3)* | 25·6% (22·8 to 28·5)* | 23·5% (20·7 to 26·4)* | |||
| Non-alcoholic fatty liver disease/NASH | 882 058·3 (847 914·0 to 917 435·7) | .. | .. | .. | .. | .. | .. | |||
| Cirrhosis and other chronic liver diseases due to NASH | 10 264·5 (9358·1 to 11 216·7) | 367·8 (334·5 to 403·7) | 148·6 (102·8 to 205·0) | 83·2% (78·8 to 87·5)* | 54·6% (51·0 to 58·3)* | 25·6% (22·8 to 28·5)* | 23·5% (20·7 to 26·4)* | |||
| Cirrhosis and other chronic liver diseases due to other causes | 16 616·0 (15 165·6 to 17 954·6) | 1173·7 (1084·6 to 1260·7) | 277·1 (192·1 to 386·4) | 24·0% (20·6 to 27·3)* | 22·7% (20·0 to 25·7)* | 2·6% (−0·0 to 5·0) | 8·1% (5·8 to 10·6)* | |||
| Cirrhosis and other chronic liver diseases due to other cause, decompensated | 1653·0 (1550·5 to 1755·9) | 248·4 (231·4 to 265·9) | 277·1 (192·1 to 386·4) | 24·0% (20·6 to 27·3)* | 22·7% (20·0 to 25·7)* | 2·6% (−0·0 to 5·0) | 8·1% (5·8 to 10·6)* | |||
| Cirrhosis and other chronic liver diseases due to other cause, compensated | 14 963·1 (13 571·8 to 16 245·0) | 925·4 (840·5 to 1008·8) | .. | .. | .. | .. | .. | |||
| Upper digestive system diseases | 807 369·3 (728 919·0 to 888 668·9) | 384 665·9 (348 550·3 to 419 766·4) | 13 042·1 (8272·3 to 19 986·6) | 32·0% (29·9 to 33·8)* | 19·3% (18·1 to 20·6)* | −3·6% (−4·5 to −2·7)* | 0·6% (−0·2 to 1·4) | |||
| Peptic ulcer disease | 17 161·2 (15 032·4 to 19 357·3) | 6719·1 (6078·7 to 7434·1) | 832·8 (555·4 to 1184·1) | 22·2% (20·1 to 24·6)* | 18·9% (16·5 to 21·1)* | −14·2% (−15·6 to −12·6)* | −1·6% (−3·5 to −0·1)* | |||
| Acute peptic ulcer disease | 7·8 (6·8 to 8·9) | .. | 2·5 (1·7 to 3·6) | 32·0% (25·8 to 39·1)* | 12·6% (10·9 to 14·4)* | −10·3% (−14·4 to −5·4)* | −12·2% (−13·1 to −11·3)* | |||
| Chronic peptic ulcer disease | 17 153·4 (15 023·5 to 19 349·4) | 6719·1 (6078·7 to 7434·1) | 830·2 (553·1 to 1180·9) | 22·2% (20·1 to 24·5)* | 18·9% (16·5 to 21·2)* | −14·2% (−15·6 to −12·6)* | −1·6% (−3·5 to −0·0)* | |||
| Gastritis and duodenitis | 140 449·0 (120 336·3 to 161 832·9) | 96 720·4 (85 853·2 to 108 445·4) | 6196·0 (3976·7 to 8960·7) | 27·7% (25·0 to 30·3)* | 18·2% (16·1 to 20·4)* | −4·5% (−5·8 to −3·3)* | 0·3% (−1·2 to 1·7) | |||
| Acute gastritis and duodenitis | 40·1 (34·5 to 46·3) | .. | 13·1 (8·6 to 18·7) | 27·8% (25·2 to 30·5)* | 15·4% (13·9 to 16·9)* | −10·2% (−11·4 to −8·9)* | −6·1% (−7·0 to −5·3)* | |||
| Chronic gastritis and duodenitis | 140 408·8 (120 292·9 to 161 787·1) | 96 720·4 (85 853·2 to 108 445·4) | 6182·8 (3967·9 to 8944·1) | 27·7% (25·0 to 30·3)* | 18·2% (16·1 to 20·4)* | −4·5% (−5·8 to −3·3)* | 0·3% (−1·2 to 1·7) | |||
| Gastro-oesophageal reflux disease | 709 264·3 (625 708·7 to 794 604·2) | 281 226·3 (246 633·4 to 315 761·3) | 6013·4 (3215·9 to 10 192·9) | 38·5% (36·3 to 40·4)* | 20·7% (19·1 to 22·3)* | −0·7% (−1·5 to −0·0)* | 1·3% (0·6 to 2·0)* | |||
| Appendicitis | 722·7 (673·2 to 775·6) | 19 016·1 (17 716·4 to 20 344·0) | 223·6 (149·1 to 306·5) | 27·7% (23·9 to 31·9)* | 10·3% (6·6 to 14·0)* | 2·3% (−0·7 to 5·5) | 0·2% (−3·1 to 3·7) | |||
| Paralytic ileus and intestinal obstruction | 140·2 (128·1 to 152·3) | 3855·4 (3520·1 to 4187·5) | 44·2 (30·0 to 60·4) | 36·0% (32·4 to 39·3)* | 25·5% (22·8 to 28·4)* | 2·9% (1·2 to 4·5)* | 4·2% (2·1 to 6·4)* | |||
| Inguinal, femoral, and abdominal hernia | 26 490·8 (24 196·8 to 28 760·4) | 41 182·8 (36 372·8 to 46 265·0) | 2567·0 (1713·5 to 3550·5) | 21·2% (17·9 to 24·8)* | 14·5% (12·3 to 17·0)* | −7·1% (−8·9 to −5·3)* | −2·9% (−4·4 to −1·2)* | |||
| Inflammatory bowel disease | 6848·9 (6421·4 to 7304·4) | 4048·8 (3776·1 to 4377·4) | 1019·4 (705·4 to 1381·8) | 48·5% (44·4 to 52·7)* | 21·7% (18·0 to 25·1)* | 4·7% (1·9 to 7·6)* | −0·2% (−3·1 to 2·3) | |||
| Ulcerative colitis | 4701·0 (4318·4 to 5113·6) | 2690·9 (2440·5 to 2994·3) | 684·0 (468·6 to 935·0) | 54·8% (50·4 to 59·5)* | 29·5% (24·9 to 33·9)* | 7·7% (4·8 to 10·9)* | 4·6% (1·2 to 7·8)* | |||
| Crohn's disease | 2147·9 (2007·7 to 2301·8) | 1357·8 (1240·2 to 1484·4) | 335·4 (227·1 to 460·4) | 38·8% (34·0 to 43·8)* | 8·6% (5·0 to 11·8)* | −0·1% (−3·5 to 3·4) | −8·7% (−11·5 to −6·2)* | |||
| Vascular intestinal disorders | 89·8 (80·0 to 100·8) | 619·8 (555·7 to 686·7) | 27·1 (18·5 to 36·7) | 56·5% (50·4 to 63·2)* | 25·2% (20·2 to 30·8)* | 12·4% (8·9 to 16·2)* | −1·3% (−5·1 to 2·8) | |||
| Gallbladder and biliary diseases | 30 575·9 (27 503·2 to 34 125·0) | 5790·7 (5195·0 to 6386·5) | 26·4 (18·0 to 37·5) | 29·3% (26·7 to 32·1)* | 27·5% (24·1 to 31·3)* | −9·6% (−11·0 to −8·1)* | 3·9% (1·7 to 6·3)* | |||
| Pancreatitis | 6115·8 (5533·9 to 6704·1) | 1644·2 (1525·6 to 1769·5) | 364·4 (186·3 to 612·8) | 52·0% (48·7 to 54·8)* | 26·6% (23·3 to 29·7)* | 6·5% (4·1 to 8·3)* | 2·5% (0·0 to 4·9)* | |||
| Acute pancreatitis | 118·6 (107·5 to 130·0) | 1300·9 (1181·4 to 1426·0) | 47·7 (34·2 to 63·9) | 33·9% (30·5 to 37·3)* | 17·5% (15·7 to 19·4)* | −6·6% (−8·6 to −4·2)* | −4·4% (−5·6 to −3·2)* | |||
| Chronic pancreatitis | 5997·3 (5412·4 to 6583·8) | 343·3 (311·5 to 375·0) | 316·7 (145·2 to 556·1) | 55·5% (52·7 to 58·8)* | 28·1% (24·5 to 31·8)* | 9·0% (7·2 to 11·1)* | 3·7% (0·9 to 6·5)* | |||
| Other digestive diseases | .. | .. | 879·9 (605·6 to 1191·4) | 0·9% (−2·8 to 5·0) | 30·6% (28·9 to 32·1)* | −19·4% (−21·5 to −17·3)* | 9·5% (8·2 to 10·6)* | |||
| Neurological disorders | 3 121 435·3 (2 951 124·5 to 3 316 268·0) | 1 006 294·5 (907 590·7 to 1 098 468·9) | 73 161·8 (50 721·9 to 100 409·9) | 35·1% (31·9 to 38·1)* | 17·8% (15·8 to 20·2)* | 0·5% (−1·6 to 2·4) | 1·4% (−0·3 to 3·4) | |||
| Alzheimer's disease and other dementias | 44 988·8 (39 716·2 to 50 377·8) | 7300·6 (6515·7 to 8133·4) | 6570·4 (4678·1 to 8588·5) | 62·7% (60·6 to 64·9)* | 36·9% (35·2 to 38·8)* | −2·3% (−3·3 to −1·2)* | −1·7% (−2·3 to −1·1)* | |||
| Parkinson's disease | 8525·4 (7037·3 to 10 185·6) | 1025·9 (854·1 to 1229·9) | 1219·0 (823·7 to 1662·2) | 69·2% (66·5 to 72·6)* | 34·3% (32·5 to 36·2)* | 8·9% (7·1 to 11·0)* | 1·0% (−0·1 to 2·1) | |||
| Epilepsy | 27 288·3 (21 576·0 to 33 443·8) | 2470·8 (1905·5 to 3062·9) | 8561·9 (5380·6 to 12 551·5) | 24·1% (8·0 to 42·9)* | 15·9% (3·5 to 31·2)* | 0·1% (−12·3 to 14·9) | 3·4% (−7·8 to 16·8) | |||
| Multiple sclerosis | 1761·1 (1598·2 to 1947·9) | 54·9 (50·1 to 60·8) | 456·6 (327·7 to 595·0) | 41·6% (38·2 to 45·2)* | 18·3% (16·1 to 20·5)* | −0·9% (−3·2 to 1·4) | −2·4% (−4·2 to −0·4)* | |||
| Motor neuron disease | 237·1 (211·2 to 264·1) | 67·3 (60·7 to 74·3) | 50·4 (35·7 to 67·5) | 39·6% (36·3 to 43·2)* | 25·9% (23·1 to 28·9)* | 4·6% (3·5 to 5·9)* | 4·5% (3·0 to 6·1)* | |||
| Headache disorders | 3 072 812·1 (2 904 886·2 to 3 266 065·0) | 995 374·9 (896 864·3 to 1 087 335·4) | 54 341·8 (35 570·5 to 76 780·4) | 34·0% (33·0 to 35·1)* | 15·4% (14·6 to 16·2)* | 0·4% (−0·2 to 1·0) | 1·0% (0·5 to 1·5)* | |||
| Migraine | 1 331 364·6 (1 237 219·6 to 1 433 357·2) | 112 933·5 (102 829·9 to 122 899·8) | 47 245·4 (29 986·7 to 68 669·3) | 34·2% (33·1 to 35·4)* | 15·3% (14·5 to 16·2)* | 0·6% (−0·0 to 1·2) | 1·1% (0·6 to 1·7)* | |||
| Medication overuse headache due to migraine | 83 755·8 (70 723·8 to 97 287·8) | .. | 9166·1 (5759·6 to 13 329·2) | 35·5% (33·6 to 37·3)* | 17·5% (16·2 to 18·7)* | −1·4% (−2·5 to −0·5)* | 0·1% (−0·3 to 0·6) | |||
| Migraine | 1 247 608·8 (1 154 817·3 to 1 347 980·9) | 112 933·5 (102 829·9 to 122 899·8) | 38 079·3 (23 576·3 to 57 421·4) | 33·9% (32·6 to 35·3)* | 14·8% (13·8 to 15·8)* | 1·1% (0·4 to 1·9)* | 1·3% (0·7 to 2·0)* | |||
| Tension-type headache | 2 331 334·7 (2 110 373·3 to 2 575 461·4) | 882 441·4 (783 241·2 to 975 064·3) | 7096·4 (4044·6 to 11 213·5) | 32·7% (31·0 to 34·6)* | 15·6% (14·5 to 16·9)* | −0·9% (−1·7 to −0·3)* | 0·3% (−0·1 to 0·6) | |||
| Medication overuse headache due to tension-type headache | 31 134·3 (21 220·1 to 41 990·3) | .. | 3382·8 (1753·7 to 5875·5) | 35·5% (33·5 to 37·5)* | 17·5% (16·0 to 18·8)* | −1·4% (−2·5 to −0·4)* | 0·1% (−0·6 to 0·8) | |||
| Tension-type headache | 2 300 200·4 (2 079 425·9 to 2 547 509·0) | 882 441·4 (783 241·2 to 975 064·3) | 3713·6 (1525·8 to 6887·1) | 30·3% (28·5 to 32·4)* | 14·0% (12·9 to 15·3)* | −0·5% (−1·4 to 0·4) | 0·4% (0·0 to 0·7)* | |||
| Other neurological disorders | 38·9 (25·6 to 53·2) | .. | 1961·8 (1276·3 to 2823·8) | 35·7% (19·8 to 54·5)* | 31·9% (18·8 to 47·1)* | 11·8% (−0·5 to 26·1) | 19·5% (7·2 to 33·4)* | |||
| Other neurological disorders | .. | .. | 1950·3 (1267·2 to 2813·5) | 35·8% (19·7 to 54·7)* | 32·0% (18·8 to 47·3)* | 11·9% (−0·5 to 26·4) | 19·6% (7·2 to 33·6)* | |||
| Guillain-Barré syndrome due to other neurological disorders | 38·9 (25·6 to 53·2) | .. | 11·5 (6·4 to 18·1) | 29·7% (25·8 to 34·1)* | 18·2% (15·8 to 20·8)* | 2·7% (1·0 to 4·3)* | 3·1% (2·0 to 4·3)* | |||
| Mental disorders | 970 812·4 (923 455·4 to 1 020 930·6) | 336 996·3 (315 596·6 to 362 049·6) | 122 746·3 (91 620·8 to 157 883·6) | 31·6% (30·5 to 32·7)* | 13·5% (12·9 to 14·1)* | −0·6% (−1·2 to −0·0)* | −1·1% (−1·5 to −0·7)* | |||
| Schizophrenia | 19 776·9 (17 578·3 to 22 210·7) | 1130·5 (1004·6 to 1281·9) | 12 657·9 (9481·9 to 15 563·7) | 38·6% (37·1 to 40·2)* | 17·2% (16·1 to 18·3)* | −0·0% (−0·8 to 0·7) | −0·3% (−1·1 to 0·4) | |||
| Depressive disorders | 264 455·6 (246 380·1 to 286 312·0) | 258 164·5 (238 280·7 to 281 665·5) | 43 099·9 (30 536·4 to 58 895·6) | 33·4% (31·0 to 35·8)* | 14·3% (13·1 to 15·6)* | −1·9% (−3·2 to −0·4)* | −2·6% (−3·5 to −1·8)* | |||
| Major depressive disorder | 163 044·1 (149 530·9 to 178 929·1) | 241 893·3 (222 032·7 to 265 574·7) | 32 846·7 (23 081·1 to 44 291·2) | 32·1% (29·2 to 35·0)* | 12·6% (11·3 to 14·0)* | −2·4% (−4·0 to −0·6)* | −3·6% (−4·6 to −2·7)* | |||
| Dysthymia | 106 904·4 (93 445·9 to 122 812·3) | 16 271·1 (14 236·4 to 18 420·1) | 10 253·2 (6878·0 to 14 982·1) | 38·3% (35·5 to 41·0)* | 20·4% (18·2 to 22·6)* | −0·3% (−1·8 to 1·3) | 0·8% (−0·8 to 2·3) | |||
| Bipolar disorder | 45 549·4 (39 864·5 to 52 852·8) | 4525·2 (3944·7 to 5237·5) | 9293·8 (5868·2 to 13 748·5) | 34·0% (32·6 to 35·4)* | 15·2% (14·0 to 16·6)* | 0·4% (−0·3 to 1·1) | 1·2% (0·6 to 1·8)* | |||
| Anxiety disorders | 284 360·1 (265 607·5 to 304 531·7) | 42 340·0 (39 597·5 to 45 199·5) | 27 121·4 (19 248·3 to 36 106·3) | 32·3% (30·6 to 34·0)* | 12·8% (11·7 to 14·0)* | 0·4% (−0·5 to 1·3) | −1·2% (−2·0 to −0·4)* | |||
| Eating disorders | 15 801·7 (12 596·2 to 19 488·6) | 9589·7 (6950·1 to 13 126·9) | 3351·9 (2149·3 to 4871·6) | 37·7% (35·4 to 40·0)* | 18·9% (17·3 to 20·5)* | 7·9% (6·8 to 8·9)* | 9·4% (8·2 to 10·5)* | |||
| Anorexia nervosa | 3360·3 (2533·8 to 4321·5) | 1027·8 (777·5 to 1329·1) | 715·8 (440·9 to 1066·2) | 30·9% (28·0 to 33·9)* | 13·5% (11·0 to 15·7)* | 5·4% (3·3 to 7·2)* | 6·2% (4·1 to 8·1)* | |||
| Bulimia nervosa | 12 509·7 (9480·4 to 15 976·5) | 8561·9 (5957·9 to 12 142·7) | 2636·2 (1660·3 to 3937·1) | 39·7% (36·9 to 42·7)* | 20·5% (18·6 to 22·2)* | 8·6% (7·5 to 9·8)* | 10·3% (9·0 to 11·6)* | |||
| Autism spectrum disorders | 31 179·7 (28 000·9 to 34 413·8) | 670·7 (602·2 to 739·1) | 4731·3 (3238·8 to 6518·6) | 22·8% (22·1 to 23·5)* | 11·4% (10·8 to 12·1)* | −0·7% (−1·2 to −0·2)* | −0·3% (−0·8 to 0·3) | |||
| Attention-deficit/hyperactivity disorder | 73 317·5 (62 267·0 to 85 889·6) | 3302·7 (2683·9 to 4031·4) | 888·8 (543·2 to 1411·8) | 20·1% (17·5 to 22·6)* | 6·9% (5·2 to 8·5)* | −0·2% (−2·1 to 1·7) | −0·6% (−2·1 to 0·8) | |||
| Conduct disorder | 53 228·4 (41 976·6 to 65 750·3) | 17 273·1 (13 809·1 to 20 989·8) | 6445·2 (3869·6 to 10 299·8) | 16·1% (14·4 to 17·8)* | 4·8% (3·1 to 6·5)* | 1·5% (0·1 to 2·9)* | 2·4% (0·9 to 3·8)* | |||
| Idiopathic developmental intellectual disability | 100 572·2 (58 404·5 to 143 878·6) | .. | 4046·4 (1940·2 to 6859·5) | 13·0% (9·1 to 15·9)* | 0·0% (−2·8 to 1·5) | −5·8% (−9·0 to −3·1)* | −8·7% (−11·1 to −7·5)* | |||
| Other mental disorders | 149 478·6 (130 882·3 to 170 462·4) | .. | 11 109·6 (7355·5 to 15 324·6) | 37·7% (36·9 to 38·6)* | 17·6% (17·0 to 18·3)* | 0·0% (−0·5 to 0·4) | 0·0% (−0·4 to 0·5) | |||
| Substance use disorders | 175 588·8 (161 747·6 to 189 304·3) | 60 099·6 (53 685·6 to 67 048·7) | 31 052·9 (22 217·1 to 40 499·7) | 34·3% (32·2 to 36·2)* | 16·7% (14·4 to 19·2)* | 2·2% (1·1 to 3·4)* | 2·9% (0·8 to 5·1)* | |||
| Alcohol use disorders | 107 420·2 (95 908·0 to 119 660·2) | 52 406·2 (45 976·6 to 59 250·1) | 10 712·5 (7368·0 to 14 760·1) | 35·9% (33·8 to 38·3)* | 10·1% (8·5 to 11·7)* | 0·9% (−0·1 to 1·9) | −4·3% (−5·4 to −3·1)* | |||
| Alcohol dependence | 107 118·2 (95 586·5 to 119 383·0) | 52 397·0 (45 967·6 to 59 241·9) | 10 701·5 (7361·4 to 14 747·1) | 36·0% (33·8 to 38·4)* | 10·1% (8·5 to 11·7)* | 0·9% (−0·1 to 2·0) | −4·3% (−5·4 to −3·1)* | |||
| Fetal alcohol syndrome | 302·0 (240·9 to 370·5) | 9·1 (7·5 to 11·1) | 11·1 (6·6 to 17·0) | 2·5% (−3·2 to 7·2) | −4·7% (−10·1 to −0·2)* | −17·6% (−22·1 to −13·9)* | −14·7% (−19·4 to −10·6)* | |||
| Drug use disorders | 71 244·4 (63 963·8 to 79 771·6) | 7693·4 (6880·2 to 8628·5) | 20 340·3 (14 276·7 to 26 665·5) | 33·3% (30·3 to 36·3)* | 20·4% (17·4 to 23·6)* | 3·1% (1·3 to 4·8)* | 7·1% (4·3 to 9·9)* | |||
| Opioid use disorders | 40 484·6 (34 271·4 to 47 941·6) | 4085·2 (3463·6 to 4794·2) | 16 844·7 (11 549·8 to 22 534·5) | 38·4% (35·4 to 41·9)* | 23·7% (20·2 to 27·2)* | 6·2% (4·5 to 8·2)* | 9·3% (6·0 to 12·5)* | |||
| Cocaine use disorders | 5017·2 (4521·0 to 5610·4) | 260·3 (227·9 to 301·6) | 680·0 (446·1 to 974·8) | 24·7% (21·2 to 28·6)* | 12·6% (11·0 to 14·4)* | −4·7% (−6·9 to −2·1)* | 0·3% (−1·2 to 2·0) | |||
| Amphetamine use disorders | 7382·6 (5376·5 to 9821·8) | 887·2 (666·2 to 1170·2) | 977·5 (560·1 to 1537·4) | 5·8% (1·9 to 10·9)* | 2·7% (−0·4 to 5·7) | −13·8% (−16·6 to −10·4)* | −4·0% (−6·8 to −1·5)* | |||
| Cannabis use disorders | 17 857·3 (14 597·9 to 21 953·6) | 2460·7 (2061·0 to 3022·0) | 517·7 (329·1 to 765·6) | 23·8% (19·7 to 28·5)* | 4·4% (2·2 to 6·6)* | −2·2% (−4·7 to 0·6) | −3·7% (−5·7 to −1·7)* | |||
| Other drug use disorders | 2237·7 (1984·3 to 2509·6) | .. | 1320·5 (888·2 to 1854·3) | 16·8% (12·0 to 22·4)* | 8·2% (5·2 to 11·2)* | −8·3% (−11·3 to −4·9)* | −1·9% (−4·3 to 0·6) | |||
| Diabetes and kidney diseases | 1 011 116·6 (962 767·9 to 1 065 061·5) | 43 444·6 (40 700·3 to 46 375·6) | 45 884·4 (32 018·9 to 62 235·3) | 68·4% (66·5 to 70·4)* | 29·1% (24·8 to 34·0)* | 15·4% (14·2 to 16·7)* | 3·2% (−0·4 to 6·9) | |||
| Diabetes mellitus | 475 995·8 (436 590·5 to 522 782·8) | 22 935·6 (21 082·9 to 25 040·9) | 38 575·4 (26 083·6 to 53 398·2) | 75·9% (73·5 to 78·3)* | 30·1% (25·0 to 35·8)* | 20·3% (18·8 to 21·9)* | 3·9% (−0·1 to 8·3) | |||
| Type 1 diabetes mellitus | 13 019·0 (11 698·8 to 14 614·6) | 400·3 (362·3 to 441·7) | 964·3 (659·9 to 1356·0) | 40·6% (38·2 to 43·1)* | 15·1% (13·8 to 16·7)* | 3·5% (2·0 to 4·9)* | −1·2% (−2·3 to −0·1)* | |||
| Uncomplicated type 1 diabetes mellitus | 8762·6 (7743·9 to 9877·9) | 400·3 (362·3 to 441·7) | 412·4 (256·1 to 601·4) | 34·7% (32·1 to 37·3)* | 11·9% (10·1 to 13·6)* | 3·5% (1·8 to 5·1)* | −1·2% (−2·7 to 0·1) | |||
| Vision loss due to type 1 diabetes mellitus retinopathy | 82·5 (65·3 to 102·7) | .. | 6·9 (4·5 to 10·1) | 61·4% (56·5 to 66·9)* | 4·0% (−0·9 to 9·0) | 10·4% (7·4 to 14·1)* | −15·1% (−19·2 to −11·1)* | |||
| Diabetic neuropathy due to type 1 diabetes mellitus | 4173·9 (3612·2 to 4837·5) | .. | 545·0 (365·7 to 762·7) | 45·4% (42·2 to 48·6)* | 17·9% (15·2 to 20·7)* | 3·3% (1·4 to 5·3)* | −1·0% (−3·3 to 1·2) | |||
| Type 2 diabetes mellitus | 462 976·9 (423 591·9 to 509 485·3) | 22 535·3 (20 693·8 to 24 626·7) | 37 611·1 (25 451·4 to 52 049·5) | 77·2% (74·7 to 79·8)* | 30·5% (25·3 to 36·4)* | 20·9% (19·3 to 22·5)* | 4·0% (−0·1 to 8·6) | |||
| Uncomplicated type 2 diabetes mellitus | 263 762·9 (232 967·8 to 297 029·0) | 22 535·3 (20 693·8 to 24 626·7) | 12 152·7 (7658·0 to 17 914·1) | 74·0% (70·9 to 77·3)* | 28·5% (22·8 to 34·5)* | 20·6% (18·5 to 22·8)* | 4·0% (−0·7 to 8·9) | |||
| Vision loss due to type 2 diabetes mellitus retinopathy | 4509·0 (3835·7 to 5282·0) | .. | 362·5 (252·6 to 500·2) | 97·1% (90·5 to 104·5)* | 21·1% (18·2 to 23·6)* | 31·3% (27·0 to 36·3)* | −5·7% (−7·7 to −3·8)* | |||
| Diabetic neuropathy due to type 2 diabetes mellitus | 194 704·9 (169 971·1 to 224 314·8) | .. | 25 095·9 (16 801·1 to 34 866·6) | 78·5% (75·0 to 82·2)* | 31·6% (25·7 to 38·1)* | 20·9% (18·6 to 23·3)* | 4·2% (−0·4 to 9·2) | |||
| Chronic kidney disease | 697 509·5 (649 209·4 to 752 050·7) | 19 735·6 (17 726·6 to 21 982·7) | 7306·3 (5434·9 to 9214·6) | 38·8% (35·2 to 42·7)* | 24·4% (19·7 to 29·5)* | −4·1% (−6·9 to −1·3)* | −0·2% (−3·8 to 3·8) | |||
| Chronic kidney disease due to type 1 diabetes mellitus | 3246·5 (2916·0 to 3615·5) | 118·3 (100·5 to 141·5) | 264·7 (187·5 to 353·0) | 58·2% (52·8 to 63·9)* | 21·7% (17·4 to 26·3)* | 10·3% (6·8 to 14·0)* | 0·3% (−3·0 to 3·7) | |||
| Albuminuria with preserved GFR due to type 1 diabetes mellitus | 1406·8 (1223·8 to 1605·5) | .. | .. | .. | .. | .. | .. | |||
| End-stage chronic kidney disease due to type 1 diabetes mellitus | 412·3 (326·6 to 512·2) | .. | 168·0 (110·5 to 233·7) | 67·5% (60·5 to 75·9)* | 22·1% (16·5 to 27·4)* | 13·8% (8·8 to 19·2)* | −0·2% (−4·4 to 3·9) | |||
| Stage III chronic kidney disease due to type 1 diabetes mellitus | 1186·3 (1002·9 to 1413·2) | 118·3 (100·5 to 141·5) | 22·8 (15·1 to 33·1) | 12·2% (5·2 to 23·4)* | 14·8% (5·8 to 24·0)* | −13·6% (−18·6 to −5·9)* | 0·4% (−7·6 to 8·5) | |||
| Stage IV chronic kidney disease due to type 1 diabetes mellitus | 149·4 (118·7 to 187·7) | .. | 20·5 (12·8 to 29·7) | 54·8% (47·9 to 62·3)* | 25·6% (16·0 to 34·9)* | 7·4% (2·8 to 12·3)* | 1·6% (−6·2 to 9·2) | |||
| Stage V chronic kidney disease due to type 1 diabetes mellitus | 91·7 (74·9 to 111·7) | .. | 53·5 (36·6 to 73·1) | 61·3% (54·0 to 69·3)* | 22·1% (15·2 to 29·4)* | 14·7% (10·1 to 19·9)* | 1·5% (−4·2 to 7·5) | |||
| Chronic kidney disease due to type 2 diabetes mellitus | 125 811·6 (116 308·7 to 135 941·1) | 2352·5 (2063·9 to 2680·9) | 1450·3 (1080·6 to 1875·1) | 49·9% (41·4 to 55·6)* | 29·6% (23·0 to 35·6)* | 0·7% (−3·5 to 4·3) | −0·5% (−5·2 to 4·0) | |||
| Albuminuria with preserved GFR due to type 2 diabetes mellitus | 85 416·5 (76 825·4 to 94 433·7) | .. | .. | .. | .. | .. | .. | |||
| End-stage chronic kidney disease due to type 2 diabetes mellitus | 1046·2 (889·3 to 1236·3) | .. | 432·3 (296·9 to 564·4) | 94·0% (85·7 to 104·3)* | 32·2% (27·7 to 36·7)* | 31·7% (26·2 to 38·3)* | 0·8% (−2·5 to 4·0) | |||
| Stage III chronic kidney disease due to type 2 diabetes mellitus | 35 357·3 (31 403·1 to 39 849·1) | 2352·5 (2063·9 to 2680·9) | 156·1 (102·1 to 234·4) | 10·9% (5·6 to 17·2)* | 19·0% (10·9 to 27·0)* | −26·2% (−29·6 to −22·1)* | −8·1% (−14·2 to −1·9)* | |||
| Stage IV chronic kidney disease due to type 2 diabetes mellitus | 2906·1 (2314·3 to 3621·8) | .. | 308·5 (198·6 to 443·0) | 37·1% (31·0 to 41·1)* | 30·5% (21·2 to 40·3)* | −9·4% (−11·7 to −7·4)* | −0·8% (−7·6 to 6·7) | |||
| Stage V chronic kidney disease due to type 2 diabetes mellitus | 1085·5 (915·0 to 1281·7) | .. | 553·5 (383·2 to 745·7) | 47·7% (30·4 to 55·4)* | 30·4% (19·5 to 39·2)* | 0·2% (−7·0 to 4·8) | 1·2% (−6·6 to 7·8) | |||
| Chronic kidney disease due to hypertension | 23 605·4 (21 734·7 to 25 994·1) | 911·2 (810·0 to 1033·5) | 1390·7 (1036·0 to 1772·1) | 47·7% (44·0 to 52·1)* | 28·0% (23·0 to 33·1)* | 0·8% (−1·7 to 3·7) | 1·4% (−2·4 to 5·4) | |||
| Albuminuria with preserved GFR due to hypertension | 4310·3 (3891·2 to 4793·2) | .. | .. | .. | .. | .. | .. | |||
| End-stage chronic kidney disease due to hypertension | 825·3 (700·2 to 968·4) | .. | 341·2 (232·8 to 450·8) | 78·0% (70·5 to 86·4)* | 33·5% (28·9 to 37·6)* | 20·2% (15·4 to 25·5)* | 2·6% (−0·7 to 5·4) | |||
| Stage III chronic kidney disease due to hypertension | 14 545·5 (13 086·5 to 16 401·2) | 911·2 (810·0 to 1033·5) | 123·0 (81·8 to 181·1) | 16·0% (10·7 to 22·4)* | 16·6% (9·1 to 23·6)* | −22·9% (−26·2 to −18·7)* | −9·3% (−14·9 to −3·8)* | |||
| Stage IV chronic kidney disease due to hypertension | 2743·0 (2268·8 to 3328·2) | .. | 299·7 (200·7 to 418·4) | 39·4% (36·2 to 42·9)* | 29·0% (20·5 to 37·3)* | −7·1% (−8·7 to −5·1)* | 0·4% (−5·9 to 6·7) | |||
| Stage V chronic kidney disease due to hypertension | 1181·3 (1017·6 to 1370·2) | .. | 626·7 (432·1 to 829·9) | 47·3% (43·9 to 52·4)* | 27·2% (20·9 to 33·9)* | 3·3% (1·3 to 6·5)* | 3·6% (−1·2 to 9·0) | |||
| Chronic kidney disease due to glomerulonephritis | 28 809·4 (26 470·2 to 31 575·8) | 1509·5 (1345·4 to 1699·8) | 1047·9 (753·5 to 1372·2) | 38·1% (34·5 to 43·1)* | 20·4% (15·5 to 25·6)* | 0·8% (−1·4 to 3·8) | 2·2% (−1·8 to 6·8) | |||
| Albuminuria with preserved GFR due to glomerulonephritis | 5008·3 (4410·3 to 5616·9) | .. | .. | .. | .. | .. | .. | |||
| End-stage chronic kidney disease due to glomerulonephritis | 691·9 (594·2 to 812·8) | .. | 270·4 (188·0 to 360·3) | 57·3% (52·0 to 63·4)* | 22·7% (18·4 to 27·2)* | 10·2% (6·6 to 14·3)* | −0·4% (−3·6 to 2·8) | |||
| Stage III chronic kidney disease due to glomerulonephritis | 20 751·9 (18 673·1 to 23 071·0) | 1509·5 (1345·4 to 1699·8) | 85·8 (55·6 to 125·3) | 7·4% (1·1 to 17·8)* | 8·3% (0·1 to 16·9)* | −17·2% (−21·6 to −10·0)* | −4·7% (−12·1 to 2·5) | |||
| Stage IV chronic kidney disease due to glomerulonephritis | 1435·8 (1169·9 to 1762·1) | .. | 172·4 (110·5 to 246·3) | 30·8% (27·3 to 35·6)* | 21·3% (13·0 to 29·7)* | −6·1% (−8·3 to −3·2)* | 2·2% (−5·4 to 9·3) | |||
| Stage V chronic kidney disease due to glomerulonephritis | 921·6 (765·1 to 1104·5) | .. | 519·3 (351·4 to 713·8) | 39·4% (35·4 to 44·9)* | 21·2% (14·8 to 28·3)* | 2·8% (0·7 to 6·2)* | 4·9% (−0·7 to 10·7) | |||
| Chronic kidney disease due to other and unspecified causes | 516 036·7 (480 273·8 to 555 659·4) | 14 844·1 (13 340·7 to 16 532·6) | 3152·6 (2327·5 to 4005·4) | 30·2% (27·0 to 34·6)* | 22·2% (17·2 to 27·6)* | −10·3% (−13·0 to −7·3)* | −1·5% (−5·5 to 2·8) | |||
| Albuminuria with preserved GFR due to other and unspecified causes | 285 109·9 (256 788·7 to 314 368·4) | .. | .. | .. | .. | .. | .. | |||
| End-stage chronic kidney disease due to other and unspecified causes | 955·4 (822·5 to 1111·7) | .. | 380·7 (257·9 to 504·2) | 59·9% (54·4 to 66·0)* | 23·9% (19·3 to 28·3)* | 13·4% (9·5 to 17·3)* | 0·2% (−3·1 to 3·2) | |||
| Stage III chronic kidney disease due to other and unspecified causes | 222 956·2 (200 778·0 to 247 902·5) | 14 844·1 (13 340·7 to 16 532·6) | 1105·1 (727·3 to 1640·7) | 11·4% (7·2 to 15·7)* | 15·6% (9·4 to 22·0)* | −24·8% (−27·6 to −22·1)* | −8·4% (−13·4 to −3·2)* | |||
| Stage IV chronic kidney disease due to other and unspecified causes | 4825·1 (4024·2 to 5754·4) | .. | 520·5 (346·0 to 725·0) | 37·3% (34·0 to 40·9)* | 27·9% (20·0 to 36·0)* | −7·8% (−9·3 to −5·9)* | 0·3% (−5·5 to 6·5) | |||
| Stage V chronic kidney disease due to other and unspecified causes | 2190·0 (1894·3 to 2551·5) | .. | 1146·3 (788·6 to 1517·9) | 43·4% (39·4 to 49·2)* | 25·9% (19·9 to 32·2)* | 2·9% (0·8 to 6·3)* | 4·5% (−0·4 to 9·7) | |||
| Acute glomerulonephritis | 52·4 (45·5 to 60·7) | 773·4 (672·8 to 877·3) | 2·6 (1·6 to 4·0) | −1·3% (−13·9 to 2·3) | 1·0% (−2·1 to 3·5) | −24·3% (−34·2 to −21·4)* | −12·6% (−15·3 to −10·1)* | |||
| Skin and subcutaneous diseases | 1 974 238·4 (1 916 671·8 to 2 034 645·7) | 4 185 971·3 (3 971 760·5 to 4 391 218·2) | 41 621·9 (27 371·7 to 61 859·5) | 24·0% (22·9 to 25·3)* | 13·0% (12·5 to 13·6)* | 0·9% (0·4 to 1·4)* | 0·6% (0·1 to 1·1)* | |||
| Dermatitis | 291 689·4 (276 520·7 to 308 059·0) | 274 034·1 (246 120·0 to 302 497·5) | 11 128·1 (6484·1 to 17 733·4) | 19·3% (18·2 to 20·7)* | 12·1% (11·3 to 12·8)* | −0·1% (−0·7 to 0·5) | 1·1% (0·4 to 1·8)* | |||
| Atopic dermatitis | 205 517·2 (193 701·2 to 218 582·4) | 27 134·4 (25 282·9 to 29 055·0) | 9003·4 (4887·0 to 14 981·0) | 17·0% (16·1 to 17·9)* | 11·6% (10·8 to 12·5)* | 0·4% (−0·4 to 1·1) | 1·7% (0·9 to 2·6)* | |||
| Contact dermatitis | 79 666·7 (70 425·7 to 89 554·9) | 221 252·8 (193 775·3 to 249 726·6) | 1989·2 (1304·4 to 2950·5) | 31·0% (28·8 to 33·2)* | 14·4% (12·6 to 16·2)* | −1·6% (−2·3 to −1·0)* | −1·1% (−1·7 to −0·5)* | |||
| Seborrhoeic dermatitis | 10 035·9 (9450·2 to 10 668·4) | 25 646·9 (23 981·6 to 27 315·9) | 135·6 (78·1 to 215·0) | 20·8% (18·5 to 23·3)* | 8·4% (6·6 to 10·3)* | −7·7% (−9·0 to −6·4)* | −7·1% (−8·3 to −5·8)* | |||
| Psoriasis | 64 609·6 (62 454·3 to 66 767·5) | 7846·6 (7564·9 to 8162·8) | 5569·5 (3956·1 to 7354·3) | 43·1% (42·0 to 44·2)* | 21·1% (20·3 to 21·9)* | 5·1% (4·3 to 5·8)* | 2·3% (1·6 to 2·9)* | |||
| Bacterial skin diseases | 11 397·9 (11 061·4 to 11 741·7) | 266 779·7 (260 229·3 to 273 665·3) | 177·9 (112·3 to 274·1) | 29·2% (27·2 to 31·0)* | 15·5% (14·0 to 17·1)* | 2·0% (−0·5 to 4·4) | 0·8% (−1·1 to 2·9) | |||
| Cellulitis | 2071·5 (1952·2 to 2186·2) | 42 958·6 (40 535·7 to 45 172·9) | 118·2 (78·7 to 167·8) | 26·7% (24·9 to 28·6)* | 12·9% (11·7 to 14·2)* | −2·6% (−3·8 to −1·3)* | −2·9% (−3·8 to −2·0)* | |||
| Pyoderma | 10 557·2 (10 245·5 to 10 853·2) | 223 821·2 (217 649·0 to 230 259·5) | 59·6 (23·9 to 123·5) | 35·0% (33·7 to 36·4)* | 20·9% (19·8 to 22·2)* | 13·0% (11·9 to 14·2)* | 8·8% (7·8 to 9·9)* | |||
| Impetigo | 4620·7 (4358·2 to 4870·5) | 84 007·5 (79 485·3 to 88 529·9) | 26·4 (10·4 to 55·8) | 35·7% (33·6 to 37·8)* | 20·7% (18·7 to 22·7)* | 24·1% (22·2 to 26·0)* | 13·4% (11·5 to 15·2)* | |||
| Abscess and other bacterial skin diseases | 5936·4 (5770·4 to 6098·7) | 139 813·6 (135 314·1 to 143 965·8) | 33·2 (13·4 to 69·5) | 34·5% (32·8 to 36·3)* | 21·1% (19·7 to 22·6)* | 5·5% (4·2 to 6·8)* | 5·1% (3·8 to 6·4)* | |||
| Scabies | 175 406·7 (154 517·9 to 198 404·1) | 527 476·5 (462 050·9 to 598 087·9) | 4528·7 (2506·4 to 7414·6) | 16·1% (13·8 to 18·5)* | 6·6% (5·3 to 8·0)* | −4·3% (−5·0 to −3·6)* | −3·1% (−3·6 to −2·6)* | |||
| Fungal skin diseases | 743 458·4 (681 568·4 to 808 149·7) | 2 126 927·9 (1 917 361·6 to 2 317 274·7) | 4154·5 (1651·4 to 8633·2) | 21·5% (19·0 to 24·0)* | 10·9% (9·2 to 12·5)* | −3·1% (−3·8 to −2·4)* | −4·4% (−5·4 to −3·4)* | |||
| Tinea capitis | 160 239·3 (133 390·6 to 194 439·3) | 303 016·6 (245 340·4 to 369 760·2) | 916·5 (357·3 to 1965·4) | −5·8% (−7·3 to −4·3)* | −13·0% (−14·5 to −11·3)* | −13·8% (−15·0 to −12·7)* | −19·0% (−20·4 to −17·3)* | |||
| Other fungal skin diseases | 583 219·1 (526 500·8 to 645 363·9) | 1 823 911·3 (1 638 297·9 to 2 009 788·9) | 3238·0 (1305·4 to 6694·4) | 37·1% (35·2 to 39·3)* | 20·2% (19·0 to 21·6)* | 1·8% (1·5 to 2·1)* | 1·3% (1·1 to 1·5)* | |||
| Viral skin diseases | 130 639·2 (125 604·0 to 136 047·9) | 116 329·8 (111 012·4 to 121 710·1) | 4033·0 (2595·4 to 5995·6) | 10·4% (9·8 to 11·1)* | 6·4% (6·0 to 6·9)* | −2·8% (−3·2 to −2·3)* | −1·8% (−2·2 to −1·4)* | |||
| Viral warts | 54 309·6 (52 104·2 to 56 403·2) | 30 140·5 (29 078·5 to 31 211·0) | 1662·2 (1066·0 to 2439·8) | 13·7% (12·8 to 14·6)* | 5·6% (4·8 to 6·3)* | −6·8% (−7·3 to −6·3)* | −4·8% (−5·4 to −4·3)* | |||
| Molluscum contagiosum | 76 329·6 (71 596·6 to 81 134·1) | 86 189·3 (80 984·6 to 91 427·2) | 2370·7 (1511·7 to 3525·9) | 8·2% (7·5 to 8·9)* | 7·1% (6·5 to 7·6)* | 0·2% (−0·3 to 0·8) | 0·3% (−0·3 to 0·8) | |||
| Acne vulgaris | 119 082·3 (107 127·9 to 133 651·4) | 60 118·8 (53 260·2 to 68 180·7) | 2547·6 (1518·8 to 4056·6) | 46·1% (44·6 to 47·6)* | 16·2% (15·2 to 17·2)* | 19·8% (18·6 to 20·9)* | 11·4% (10·3 to 12·5)* | |||
| Alopecia areata | 15 981·0 (15 477·3 to 16 515·9) | 28 185·2 (27 302·2 to 29 126·3) | 523·1 (334·9 to 774·8) | 28·8% (27·6 to 30·1)* | 12·7% (11·8 to 13·8)* | −2·3% (−3·1 to −1·4)* | −1·5% (−2·3 to −0·6)* | |||
| Pruritus | 71 224·3 (63 948·2 to 80 034·2) | 55 643·1 (49 208·3 to 62 689·4) | 755·6 (356·1 to 1433·2) | 36·4% (34·1 to 38·8)* | 18·9% (17·5 to 20·4)* | 2·9% (2·5 to 3·4)* | 1·6% (1·2 to 2·0)* | |||
| Urticaria | 83 610·0 (73 335·4 to 95 162·9) | 147 198·5 (129 941·2 to 166 345·6) | 5014·8 (3321·0 to 7046·4) | 19·3% (17·4 to 21·5)* | 10·8% (9·8 to 11·9)* | 0·7% (0·2 to 1·2)* | 0·3% (−0·2 to 0·8) | |||
| Decubitus ulcer | 1143·7 (1022·6 to 1288·5) | 4199·3 (3752·4 to 4741·3) | 181·2 (125·8 to 244·3) | 45·2% (42·7 to 47·7)* | 28·9% (26·3 to 31·9)* | −3·3% (−4·9 to −1·8)* | −0·4% (−2·2 to 1·5) | |||
| Other skin and subcutaneous diseases | 550 810·3 (538 490·7 to 563 961·3) | 571 231·9 (558 726·3 to 584 649·5) | 3008·1 (1446·7 to 5557·4) | 45·1% (44·6 to 45·6)* | 25·6% (25·2 to 26·0)* | 6·6% (6·4 to 6·8)* | 4·3% (4·1 to 4·5)* | |||
| Sense organ diseases | 2 035 737·0 (1 994 115·8 to 2 079 908·6) | .. | 66 576·1 (44 700·8 to 95 675·1) | 42·0% (41·1 to 42·8)* | 24·1% (23·4 to 24·8)* | −1·0% (−1·6 to −0·5)* | −0·9% (−1·5 to −0·3)* | |||
| Blindness and vision impairment | 1 193 642·8 (1 154 777·0 to 1 237 118·0) | .. | 29 895·2 (20 277·7 to 44 036·0) | 39·3% (37·8 to 40·5)* | 23·1% (22·0 to 24·0)* | −2·7% (−3·5 to −1·9)* | −1·8% (−2·7 to −0·9)* | |||
| Glaucoma | 5993·5 (5157·5 to 6984·8) | .. | 686·1 (462·9 to 948·8) | 41·5% (39·1 to 44·2)* | 27·9% (26·4 to 29·4)* | −6·0% (−7·4 to −4·2)* | −4·7% (−5·8 to −3·6)* | |||
| Cataract | 107 987·7 (95 775·3 to 122 319·3) | .. | 8005·8 (5579·2 to 10 820·9) | 49·4% (46·9 to 52·0)* | 29·6% (27·4 to 31·7)* | −2·8% (−4·2 to −1·2)* | −2·0% (−3·6 to −0·5)* | |||
| Age-related macular degeneration | 6758·8 (5612·6 to 8183·0) | .. | 530·7 (363·6 to 728·6) | 59·3% (54·5 to 63·9)* | 30·7% (28·6 to 32·9)* | 2·8% (−0·7 to 6·1) | −3·7% (−5·3 to −2·1)* | |||
| Refraction disorders | 185 392·8 (165 673·9 to 208 575·2) | .. | 7984·3 (5353·0 to 11 487·0) | 24·6% (21·7 to 27·7)* | 15·3% (13·6 to 17·0)* | −6·1% (−7·8 to −4·3)* | −3·1% (−4·2 to −1·9)* | |||
| Near vision loss | 969 669·5 (932 613·8 to 1 009 067·7) | .. | 9802·9 (4669·6 to 17 922·5) | 46·4% (45·6 to 47·1)* | 24·6% (24·0 to 25·2)* | 1·2% (0·8 to 1·7)* | 0·5% (0·1 to 0·9)* | |||
| Other vision loss | 34 607·5 (30 956·5 to 38 397·4) | .. | 2885·3 (2013·7 to 3884·0) | 36·7% (34·6 to 38·8)* | 21·0% (19·4 to 22·6)* | −4·6% (−5·8 to −3·3)* | −3·7% (−4·8 to −2·6)* | |||
| Age-related and other hearing loss | 1 317 431·7 (1 276 962·6 to 1 356 229·1) | .. | 34 229·6 (23 176·8 to 48 684·1) | 44·4% (43·0 to 45·7)* | 24·9% (23·9 to 26·0)* | 0·4% (−0·4 to 1·1) | −0·2% (−1·0 to 0·5) | |||
| Other sense organ diseases | 103 750·5 (100 613·2 to 107 050·4) | .. | 2451·3 (1519·6 to 3573·5) | 42·1% (41·1 to 43·1)* | 25·0% (24·2 to 25·8)* | 1·8% (1·3 to 2·3)* | 0·9% (0·4 to 1·4)* | |||
| Chronic other sense organ diseases | 87 788·5 (84 748·6 to 91 039·5) | .. | 2232·4 (1381·5 to 3246·2) | 44·3% (43·4 to 45·3)* | 26·1% (25·4 to 26·9)* | 1·8% (1·3 to 2·3)* | 0·9% (0·4 to 1·4)* | |||
| Acute other sense organ diseases | 15 962·1 (15 501·3 to 16 458·6) | .. | 218·9 (133·2 to 332·7) | 24·3% (22·6 to 25·9)* | 14·6% (13·2 to 16·2)* | 1·7% (0·5 to 2·9)* | 1·0% (−0·3 to 2·4) | |||
| Musculoskeletal disorders | 1 312 131·3 (1 248 058·7 to 1 383 422·6) | 334 744·9 (309 934·0 to 363 175·8) | 135 881·3 (99 022·6 to 179 645·0) | 38·4% (36·4 to 40·2)* | 19·9% (18·8 to 21·2)* | −2·3% (−3·3 to −1·2)* | −1·1% (−1·7 to −0·5)* | |||
| Rheumatoid arthritis | 19 965·1 (17 990·5 to 21 955·7) | 1204·6 (1071·1 to 1331·7) | 2626·0 (1783·4 to 3529·9) | 45·8% (44·1 to 47·5)* | 33·5% (30·6 to 36·4)* | 0·9% (−0·1 to 1·9) | 6·7% (4·7 to 8·8)* | |||
| Osteoarthritis | 303 096·5 (273 279·8 to 338 632·0) | 14 933·5 (13 386·3 to 16 739·6) | 9604·0 (4808·6 to 19 139·0) | 63·1% (61·5 to 64·9)* | 31·4% (30·7 to 32·1)* | 8·5% (7·5 to 9·6)* | 1·0% (0·5 to 1·6)* | |||
| Osteoarthritis of the hip | 40 010·0 (37 473·8 to 42 725·7) | 2045·1 (1913·7 to 2195·9) | 1265·4 (648·2 to 2609·3) | 59·1% (57·9 to 60·4)* | 35·3% (34·5 to 36·2)* | 5·7% (4·9 to 6·4)* | 3·8% (3·2 to 4·4)* | |||
| Osteoarthritis of the knee | 263 086·5 (232 661·9 to 298 640·0) | 12 888·4 (11 375·0 to 14 656·0) | 8338·6 (4152·3 to 16 431·9) | 63·7% (61·8 to 65·8)* | 30·8% (30·1 to 31·6)* | 9·0% (7·7 to 10·3)* | 0·6% (0·1 to 1·2)* | |||
| Low back pain | 576 980·9 (518 940·4 to 637 177·9) | 245 858·9 (221 816·5 to 272 419·6) | 64 946·7 (46 512·3 to 87 417·1) | 30·0% (27·9 to 31·9)* | 17·5% (16·2 to 19·0)* | −7·2% (−8·4 to −6·0)* | −2·1% (−2·6 to −1·6)* | |||
| Low back pain with leg pain | 187 103·9 (167 946·8 to 209 695·8) | 78 640·7 (69 782·0 to 87 714·4) | 26 843·2 (19 173·1 to 36 078·7) | 31·2% (29·0 to 33·4)* | 19·0% (17·6 to 20·6)* | −7·8% (−8·9 to −6·5)* | −2·2% (−2·7 to −1·6)* | |||
| Low back pain without leg pain | 389 877·0 (350 624·1 to 429 901·0) | 167 218·2 (150 726·4 to 185 159·5) | 38 103·5 (27 216·0 to 51 524·8) | 29·1% (27·1 to 31·1)* | 16·5% (15·1 to 18·0)* | −6·9% (−8·1 to −5·7)* | −2·0% (−2·5 to −1·6)* | |||
| Neck pain | 288 718·6 (254 715·3 to 323 483·0) | 65 310·3 (57 678·2 to 73 917·2) | 28 631·1 (19 951·8 to 40 202·3) | 44·4% (41·9 to 47·0)* | 21·4% (19·5 to 23·6)* | −0·0% (−1·2 to 1·2) | −0·7% (−1·6 to 0·5) | |||
| Gout | 41 217·7 (36 699·8 to 46 101·3) | 7437·7 (6573·8 to 8457·4) | 1285·0 (867·4 to 1768·9) | 54·7% (52·5 to 56·9)* | 30·9% (29·2 to 32·6)* | 4·4% (3·1 to 5·8)* | 2·7% (1·6 to 3·7)* | |||
| Other musculoskeletal disorders | 336 467·8 (285 415·0 to 383 783·9) | .. | 28 788·6 (19 498·0 to 39 995·7) | 46·1% (43·6 to 48·6)* | 19·0% (15·5 to 22·4)* | 4·3% (3·3 to 5·4)* | −0·8% (−3·3 to 1·4) | |||
| Other non-communicable diseases | 4 916 184·8 (4 793 498·0 to 5 046 526·7) | 4 209 631·0 (3 838 652·6 to 4 611 876·0) | 53 645·9 (36 899·7 to 74 479·3) | 25·7% (24·2 to 27·5)* | 12·9% (11·8 to 14·2)* | −5·3% (−6·0 to −4·6)* | −3·2% (−3·9 to −2·4)* | |||
| Congenital anomalies | 100 366·3 (95 153·7 to 106 524·9) | 5445·3 (5088·8 to 5844·4) | 12 056·9 (8552·1 to 16 062·8) | 23·1% (22·0 to 24·2)* | 12·7% (11·7 to 13·7)* | −0·1% (−0·9 to 0·8) | 0·8% (−0·2 to 1·6) | |||
| Neural tube defects | 2874·4 (2566·3 to 3205·2) | 163·9 (145·4 to 185·1) | 854·7 (600·1 to 1133·9) | 25·1% (22·7 to 27·5)* | 17·0% (13·8 to 20·3)* | 2·1% (0·2 to 4·1)* | 5·1% (2·2 to 8·0)* | |||
| Severe motor and cognitive impairment due to anencephaly | 0·1 (0·1 to 0·1) | 12·8 (10·2 to 16·3) | 0·0 (0·0 to 0·1) | −5·3% (−7·2 to −3·3)* | −6·5% (−8·6 to −4·5)* | −4·5% (−6·4 to −2·4)* | −8·9% (−11·0 to −7·0)* | |||
| Encephalocoele due to neural tube defects | 300·6 (246·9 to 354·9) | 28·8 (22·3 to 37·4) | 51·8 (34·6 to 72·3) | 17·0% (14·3 to 20·0)* | 12·8% (9·8 to 15·6)* | −6·3% (−8·1 to −4·4)* | −0·7% (−3·4 to 1·9) | |||
| Spina bifida due to neural tube defects | 2573·8 (2296·6 to 2874·9) | 122·3 (106·0 to 141·4) | 802·9 (557·1 to 1069·3) | 25·7% (23·1 to 28·3)* | 17·3% (14·1 to 20·6)* | 2·8% (0·7 to 4·8)* | 5·5% (2·6 to 8·5)* | |||
| Congenital heart anomalies | 11 998·3 (10 958·7 to 13 123·9) | 2481·7 (2203·2 to 2775·4) | 589·5 (287·2 to 973·4) | 12·2% (9·7 to 13·9)* | 7·6% (5·7 to 9·1)* | 1·9% (0·4 to 3·2)* | 0·2% (−1·5 to 1·5) | |||
| Critical malformations of great vessels, congenital valvular heart disease, and patent ductus arteriosus | 2075·2 (1788·4 to 2407·9) | 519·5 (406·2 to 650·6) | 124·7 (62·7 to 201·6) | 10·0% (7·1 to 12·6)* | 6·9% (4·3 to 9·1)* | 0·9% (−1·5 to 2·9) | −0·1% (−2·3 to 2·1) | |||
| Other congenital heart anomalies | 2540·8 (2333·1 to 2769·7) | 398·3 (353·7 to 445·6) | 142·9 (62·3 to 243·7) | 14·2% (11·1 to 16·6)* | 8·9% (6·5 to 11·1)* | 1·5% (−0·6 to 3·5) | 0·4% (−1·8 to 2·4) | |||
| Severe congenital heart anomalies excluding single ventricle heart defects | 2899·7 (2567·0 to 3266·8) | 565·8 (453·1 to 699·6) | 170·9 (86·1 to 282·1) | 20·6% (17·0 to 23·4)* | 9·2% (6·5 to 11·6)* | 6·5% (4·1 to 8·7)* | 0·7% (−1·7 to 3·0) | |||
| Single ventricle and single ventricle pathway congenital heart anomalies | 344·0 (285·0 to 413·7) | 263·5 (186·1 to 356·8) | 21·1 (11·3 to 33·7) | 13·0% (9·0 to 17·2)* | 7·2% (3·2 to 11·1)* | 5·5% (1·8 to 9·4)* | 0·8% (−3·1 to 4·6) | |||
| Ventricular septal defect and atrial septal defect | 4138·6 (3401·3 to 4864·5) | 734·5 (588·6 to 908·7) | 129·8 (62·0 to 225·5) | 2·9% (−0·0 to 5·7) | 5·1% (2·5 to 7·5)* | −2·4% (−4·7 to −0·0)* | −0·7% (−3·3 to 1·6) | |||
| Orofacial clefts | 10 816·4 (9945·7 to 11 654·1) | 195·5 (152·0 to 249·3) | 320·8 (211·9 to 468·2) | 8·7% (3·4 to 14·7)* | 13·5% (7·5 to 20·0)* | −11·2% (−15·5 to −6·4)* | 1·5% (−4·0 to 7·3) | |||
| Down syndrome | 3535·7 (3092·1 to 4015·5) | 110·5 (95·2 to 130·6) | 326·4 (222·7 to 452·6) | 22·5% (21·3 to 23·8)* | 11·8% (9·1 to 14·7)* | −1·5% (−2·6 to −0·5)* | −0·2% (−2·6 to 2·4) | |||
| Turner syndrome | 572·3 (502·0 to 652·8) | 19·6 (17·0 to 22·9) | 10·1 (5·0 to 16·5) | 21·6% (19·5 to 24·1)* | 9·1% (7·3 to 10·9)* | 1·1% (−0·6 to 2·7) | 0·9% (−0·7 to 2·5) | |||
| Klinefelter syndrome | 866·8 (747·4 to 994·2) | 28·3 (24·2 to 32·8) | 5·2 (2·4 to 9·7) | 28·6% (24·5 to 33·0)* | 7·4% (4·3 to 10·7)* | 4·4% (1·4 to 7·6)* | −1·7% (−4·5 to 1·1) | |||
| Other chromosomal abnormalities | 6379·1 (5052·5 to 7827·4) | 301·3 (236·2 to 371·0) | 593·1 (389·9 to 833·1) | 24·2% (22·1 to 26·3)* | 19·6% (16·9 to 22·4)* | 2·3% (0·7 to 4·1)* | 7·1% (4·7 to 9·5)* | |||
| Congenital musculoskeletal and limb anomalies | 31 506·6 (28 137·2 to 36 022·4) | 1537·0 (1327·4 to 1777·0) | 4622·5 (3030·7 to 6345·8) | 24·8% (23·9 to 25·8)* | 13·4% (12·5 to 14·2)* | −0·6% (−1·4 to 0·1) | 0·4% (−0·4 to 1·1) | |||
| Polydactyly and syndactyly | 432·6 (342·4 to 538·9) | 218·7 (158·9 to 295·2) | 4·7 (2·1 to 9·1) | 0·3% (−3·9 to 5·2) | 7·1% (3·1 to 10·9)* | −4·4% (−8·1 to −0·2)* | 0·9% (−3·2 to 4·7) | |||
| Congenital limb deficiency | 14 811·3 (13 154·2 to 17 016·1) | 389·3 (343·2 to 449·2) | 2217·3 (1452·1 to 3057·6) | 22·4% (21·2 to 23·6)* | 11·8% (10·8 to 12·9)* | −0·1% (−1·1 to 0·8) | 0·5% (−0·4 to 1·5) | |||
| Other congenital musculoskeletal anomalies | 16 262·8 (14 519·3 to 18 611·7) | 929·0 (801·7 to 1074·0) | 2400·4 (1574·9 to 3296·1) | 27·3% (26·1 to 28·5)* | 14·8% (13·8 to 15·8)* | −1·1% (−2·1 to −0·2)* | 0·2% (−0·7 to 1·0) | |||
| Urogenital congenital anomalies | 5725·5 (4984·9 to 6504·8) | 249·7 (216·9 to 285·3) | 141·0 (82·3 to 233·3) | 13·0% (11·5 to 14·6)* | 4·2% (2·2 to 6·3)* | −4·7% (−5·8 to −3·6)* | −4·1% (−6·0 to −2·3)* | |||
| Digestive congenital anomalies | 17 662·5 (15 899·6 to 19 748·8) | 357·9 (323·3 to 398·8) | 794·3 (528·2 to 1134·1) | 16·3% (15·0 to 17·5)* | 8·7% (4·3 to 13·2)* | −8·5% (−9·5 to −7·5)* | −4·3% (−8·3 to −0·4)* | |||
| Congenital diaphragmatic hernia | 315·6 (276·8 to 357·7) | 15·5 (12·9 to 17·9) | 6·2 (3·6 to 10·1) | 13·9% (12·9 to 14·9)* | 6·5% (5·6 to 7·3)* | −1·3% (−2·0 to −0·5)* | −1·8% (−2·6 to −1·0)* | |||
| Congenital atresia or stenosis of the digestive tract | 111·9 (83·4 to 142·7) | 137·3 (96·5 to 174·1) | 8·9 (5·4 to 13·7) | −5·9% (−8·5 to −3·4)* | 6·1% (3·2 to 9·1)* | −7·8% (−10·3 to −5·4)* | 0·7% (−2·1 to 3·6) | |||
| Congenital malformations of the abdominal wall after treatment | 1258·9 (1109·6 to 1431·5) | 84·7 (71·3 to 99·3) | 54·0 (34·5 to 79·4) | 15·2% (14·3 to 16·2)* | 7·4% (6·6 to 8·2)* | 0·1% (−0·6 to 0·8) | −0·8% (−1·6 to −0·1)* | |||
| Other congenital malformations of the digestive tract | 15 976·1 (14 219·3 to 18 092·5) | 120·3 (88·9 to 169·7) | 725·2 (480·5 to 1035·6) | 16·7% (15·2 to 18·2)* | 8·8% (4·0 to 13·7)* | −9·2% (−10·3 to −8·1)* | −4·7% (−9·0 to −0·4)* | |||
| Other congenital anomalies | 25 911·9 (22 431·7 to 30 006·9) | .. | 3799·4 (2595·5 to 5226·3) | 25·9% (23·0 to 28·7)* | 12·1% (9·6 to 14·5)* | 2·9% (0·5 to 5·3)* | 0·8% (−1·4 to 3·0) | |||
| Other congenital birth defects | .. | .. | 446·4 (309·1 to 601·8) | 34·8% (32·6 to 37·3)* | 19·3% (17·3 to 22·0)* | 19·0% (17·6 to 20·5)* | 9·8% (8·0 to 11·9)* | |||
| Hearing loss due to other congenital anomalies | 25 911·9 (22 431·7 to 30 006·9) | .. | 3353·0 (2227·2 to 4697·0) | 24·8% (21·6 to 28·0)* | 11·2% (8·4 to 13·9)* | 1·1% (−1·4 to 3·6) | −0·4% (−2·8 to 2·1) | |||
| Urinary diseases and male infertility | 110 267·4 (99 363·2 to 120 483·9) | 366 721·5 (337 838·9 to 396 838·4) | 3135·6 (2053·6 to 4529·0) | 33·7% (31·9 to 35·6)* | 26·9% (25·5 to 28·4)* | −7·6% (−9·0 to −6·2)* | −0·8% (−1·7 to 0·1) | |||
| Urinary tract infections | 5250·9 (4741·8 to 5801·2) | 274 626·5 (247 558·6 to 303 427·3) | 173·0 (106·4 to 256·5) | 29·8% (27·1 to 32·4)* | 16·6% (14·0 to 19·3)* | 0·3% (−1·2 to 1·9) | 1·9% (0·1 to 3·7)* | |||
| Urolithiasis | 3147·5 (2808·1 to 3483·6) | 83 173·6 (74 603·1 to 91 918·7) | 230·9 (159·6 to 317·0) | 31·2% (28·7 to 34·1)* | 18·6% (16·2 to 20·9)* | −7·5% (−9·3 to −5·7)* | −2·0% (−3·5 to −0·3)* | |||
| Benign prostatic hyperplasia | 74 541·9 (65 358·9 to 84 081·8) | 8921·5 (7859·8 to 10 046·2) | 2427·3 (1562·8 to 3460·0) | 36·7% (34·1 to 39·5)* | 32·0% (30·7 to 33·3)* | −8·0% (−9·5 to −6·2)* | −0·2% (−1·1 to 0·8) | |||
| Male infertility | 30 432·7 (24 686·0 to 36 812·7) | .. | 180·9 (74·8 to 373·9) | 33·1% (29·7 to 36·8)* | 17·0% (13·7 to 20·1)* | 1·3% (−0·5 to 3·3) | 6·9% (4·1 to 9·7)* | |||
| Other urinary diseases | .. | .. | 123·5 (84·7 to 170·6) | 8·4% (6·5 to 10·3)* | −7·1% (−8·6 to −5·7)* | −18·0% (−19·3 to −16·7)* | −20·3% (−21·5 to −19·2)* | |||
| Gynaecological diseases | 815 073·8 (787 646·5 to 843 595·7) | 195 631·4 (189 141·1 to 202 275·1) | 11 619·6 (7966·6 to 16 279·1) | 33·9% (31·3 to 36·5)* | 10·2% (9·0 to 11·6)* | −1·9% (−3·4 to −0·5)* | −2·4% (−3·3 to −1·4)* | |||
| Uterine fibroids | 159 444·4 (139 576·9 to 182 588·5) | 8445·5 (7062·0 to 10 077·7) | 1473·4 (866·6 to 2386·3) | 44·3% (39·5 to 48·4)* | 8·1% (3·9 to 11·7)* | −2·5% (−5·7 to 0·4) | −8·0% (−11·5 to −5·1)* | |||
| Polycystic ovarian syndrome | 52 159·9 (41 652·7 to 66 540·8) | 2129·0 (1727·3 to 2716·3) | 459·4 (203·7 to 886·2) | 33·2% (31·8 to 34·6)* | 13·1% (12·1 to 14·1)* | 0·6% (−0·3 to 1·4) | 1·8% (1·0 to 2·7)* | |||
| Female infertility | 61 238·4 (43 321·2 to 82 668·2) | .. | 342·6 (129·5 to 723·4) | 32·1% (26·8 to 37·5)* | 27·5% (22·2 to 32·7)* | −0·0% (−2·6 to 2·7) | 16·5% (12·0 to 20·8)* | |||
| Endometriosis | 44 656·0 (37 289·1 to 52 852·4) | 6291·6 (5083·7 to 7555·2) | 4121·5 (2752·3 to 5940·5) | 31·2% (26·0 to 37·5)* | 9·2% (7·9 to 10·5)* | −3·1% (−6·3 to 0·5) | −3·0% (−3·9 to −2·0)* | |||
| Genital prolapse | 108 559·4 (96 272·0 to 121 882·8) | 12 319·0 (10 947·3 to 13 860·3) | 337·3 (161·9 to 634·2) | 26·0% (25·0 to 27·2)* | 19·9% (18·5 to 21·3)* | −13·7% (−14·4 to −12·9)* | −3·6% (−4·4 to −2·8)* | |||
| Premenstrual syndrome | 472 189·7 (451 411·0 to 493 266·2) | 127 157·4 (121 707·4 to 132 919·3) | 3930·0 (2533·7 to 5900·3) | 32·3% (30·9 to 33·7)* | 8·8% (7·2 to 10·1)* | −0·6% (−1·4 to 0·3) | −2·2% (−3·6 to −1·0)* | |||
| Other gynaecological diseases | 50 421·8 (48 042·0 to 52 824·5) | 39 288·9 (37 076·3 to 41 538·6) | 955·4 (643·6 to 1384·7) | 42·2% (36·5 to 47·7)* | 14·5% (11·6 to 17·4)* | 3·0% (−0·6 to 6·7) | 1·3% (−1·5 to 3·9) | |||
| Other gynaecological diseases | 45 859·4 (43 492·6 to 48 226·9) | 39 288·9 (37 076·3 to 41 538·6) | 855·8 (576·7 to 1238·9) | 41·5% (35·6 to 47·2)* | 15·5% (12·2 to 18·6)* | 2·5% (−1·2 to 6·4) | 1·9% (−1·1 to 5·0) | |||
| Other gynaecological diseases with anaemia | 4562·4 (4423·1 to 4703·7) | .. | 99·6 (66·3 to 146·8) | 47·3% (39·9 to 55·6)* | 6·6% (1·1 to 11·8)* | 6·4% (0·9 to 12·5)* | −4·2% (−8·9 to 0·6) | |||
| Haemoglobinopathies and haemolytic anaemias | 1 922 603·3 (1 878 676·9 to 1 967 411·4) | 42 237·7 (40 961·6 to 43 660·7) | 5313·7 (3608·1 to 7683·0) | 1·1% (−2·0 to 4·1) | −5·3% (−8·4 to −2·3)* | −17·8% (−20·2 to −15·5)* | −15·2% (−17·9 to −12·5)* | |||
| Thalassaemias | 411·4 (384·1 to 441·7) | 106·3 (99·7 to 113·5) | 17·2 (11·4 to 25·3) | −38·9% (−42·9 to −34·6)* | −20·0% (−25·4 to −15·4)* | −41·0% (−44·8 to −36·6)* | −24·4% (−29·6 to −20·0)* | |||
| Thalassaemias trait | 298 566·6 (287 549·2 to 309 863·6) | 4868·2 (4697·5 to 5051·2) | 1908·8 (1282·8 to 2781·8) | −8·2% (−12·8 to −3·6)* | −12·1% (−16·1 to −7·7)* | −25·7% (−29·1 to −22·1)* | −21·6% (−25·1 to −18·0)* | |||
| Sickle cell disorders | 3131·7 (2845·5 to 3434·9) | 613·1 (514·6 to 732·0) | 252·7 (173·0 to 354·4) | 42·0% (34·4 to 50·4)* | 15·1% (8·0 to 21·2)* | 28·0% (21·0 to 35·3)* | 8·4% (1·8 to 14·2)* | |||
| Sickle cell trait | 460 730·8 (416 642·3 to 511 272·8) | 10 822·4 (9887·9 to 11 861·3) | 1203·4 (812·3 to 1731·4) | 20·5% (16·4 to 24·3)* | −1·3% (−5·1 to 2·9) | 1·2% (−1·9 to 4·2) | −10·3% (−13·9 to −6·4)* | |||
| G6PD deficiency | 359 180·8 (344 591·4 to 374 393·5) | 7844·9 (7507·8 to 8199·3) | 24·7 (17·1 to 34·4) | 13·8% (8·1 to 21·1)* | 2·3% (−4·6 to 8·7) | −6·9% (−11·5 to −1·1)* | −8·8% (−15·2 to −3·1)* | |||
| G6PD trait | 940 308·4 (924 830·5 to 955 818·2) | 17 982·7 (17 673·9 to 18 299·5) | 0·4 (0·3 to 0·6) | 28·3% (22·4 to 34·0)* | 3·0% (−1·7 to 7·8) | 1·3% (−3·2 to 5·7) | −8·1% (−12·2 to −3·9)* | |||
| Other haemoglobinopathies and haemolytic anaemias | 79 442·9 (77 864·8 to 81 099·0) | .. | 1906·4 (1289·0 to 2768·5) | −0·4% (−3·3 to 2·5) | −2·5% (−5·8 to 1·0) | −20·8% (−23·0 to −18·7)* | −13·8% (−16·8 to −10·6)* | |||
| Endocrine, metabolic, blood, and immune disorders | 109 922·2 (106 937·4 to 113 100·4) | .. | 3215·7 (2232·5 to 4501·4) | 6·1% (4·1 to 8·2)* | 3·2% (1·0 to 5·4)* | −16·0% (−17·4 to −14·5)* | −9·5% (−11·4 to −7·4)* | |||
| Anaemia due to endocrine, metabolic, blood, and immune disorders | 81 387·3 (80 146·9 to 82 729·4) | .. | 2177·1 (1481·4 to 3130·1) | 0·0% (−2·5 to 2·6) | −4·9% (−8·1 to −1·5)* | −19·4% (−21·4 to −17·4)* | −14·3% (−17·2 to −11·3)* | |||
| Endocrine, metabolic, blood, and immune disorders | 28 144·8 (25 572·5 to 30 946·4) | .. | 1005·7 (684·2 to 1398·9) | 27·2% (24·6 to 30·0)* | 25·4% (22·2 to 28·7)* | −5·4% (−6·6 to −4·0)* | 3·3% (1·0 to 5·5)* | |||
| Heart failure due to endocrine, metabolic, blood, and immune disorders | 390·1 (322·2 to 465·9) | .. | 32·9 (21·8 to 46·4) | 34·0% (27·5 to 40·8)* | 28·1% (24·7 to 31·5)* | −13·9% (−18·2 to −9·7)* | −4·6% (−6·9 to −2·1)* | |||
| Oral disorders | 3 466 894·0 (3 271 733·1 to 3 676 485·6) | 3 599 595·0 (3 233 032·9 to 3 992 824·0) | 18 304·4 (10 992·8 to 28 338·1) | 38·4% (36·9 to 39·8)* | 21·4% (20·5 to 22·3)* | −2·7% (−3·8 to −1·8)* | −1·3% (−2·0 to −0·6)* | |||
| Caries of deciduous teeth | 531 801·7 (443 844·0 to 622 463·7) | 1 057 534·3 (756 100·5 to 1 400 908·8) | 138·9 (59·4 to 278·1) | −4·5% (−6·2 to −2·9)* | 4·9% (3·1 to 6·3)* | −7·0% (−8·6 to −5·6)* | −2·1% (−3·7 to −0·8)* | |||
| Caries of permanent teeth | 2 301 999·2 (2 104 931·2 to 2 525 509·0) | 2 452 124·9 (2 233 639·1 to 2 665 441·2) | 1618·9 (697·9 to 3087·7) | 20·6% (18·9 to 22·5)* | 9·4% (8·6 to 10·3)* | −8·2% (−9·3 to −7·0)* | −4·0% (−4·8 to −3·3)* | |||
| Periodontal disease | 796 122·9 (670 981·0 to 930 283·0) | 71 483·7 (61 593·0 to 81 227·2) | 5185·6 (2039·3 to 10 653·7) | 50·2% (48·8 to 51·6)* | 26·6% (25·1 to 27·9)* | 3·2% (2·6 to 3·7)* | 2·8% (2·3 to 3·2)* | |||
| Edentulism and severe tooth loss | 267 457·5 (235 214·4 to 300 011·3) | 18 452·1 (16 192·9 to 20 997·1) | 7345·9 (4894·2 to 10 408·2) | 40·8% (39·4 to 42·1)* | 24·6% (23·7 to 25·5)* | −6·3% (−7·1 to −5·5)* | −4·1% (−4·7 to −3·4)* | |||
| Other oral disorders | 139 086·3 (133 117·0 to 145 643·0) | .. | 4015·1 (2507·7 to 5900·3) | 32·7% (31·9 to 33·6)* | 15·7% (15·0 to 16·3)* | 0·0% (−0·3 to 0·4) | 0·2% (−0·1 to 0·5) | |||
| Injuries | 1 507 481·4 (1 439 758·0 to 1 587 209·4) | 520 710·3 (493 430·2 to 547 988·6) | 57 174·5 (42 073·9 to 75 427·0) | 23·7% (22·1 to 25·3)* | 23·4% (22·0 to 24·8)* | −10·4% (−11·2 to −9·5)* | 2·9% (2·1 to 3·7)* | |||
| Transport injuries | 226 305·6 (209 529·5 to 244 291·1) | 63 920·6 (56 848·5 to 71 592·2) | 13 394·4 (9586·9 to 17 861·0) | 32·9% (30·5 to 35·3)* | 21·6% (20·4 to 22·9)* | −4·0% (−5·4 to −2·7)* | 1·2% (0·4 to 2·0)* | |||
| Road injuries | 174 209·6 (162 042·0 to 187 472·1) | 54 192·3 (47 381·6 to 61 645·9) | 10 159·7 (7272·0 to 13 618·8) | 42·8% (41·0 to 44·8)* | 21·7% (20·5 to 22·9)* | 1·7% (0·6 to 2·8)* | 0·5% (−0·3 to 1·3) | |||
| Pedestrian road injuries | 46 000·9 (39 776·2 to 54 538·8) | 11 038·9 (9097·7 to 13 168·8) | 2710·1 (1912·5 to 3722·5) | 35·6% (32·3 to 38·5)* | 18·1% (16·2 to 19·8)* | −3·1% (−4·8 to −1·5)* | −2·4% (−3·6 to −1·3)* | |||
| Cyclist road injuries | 30 602·6 (25 887·6 to 35 843·6) | 11 912·9 (9669·7 to 14 669·8) | 1701·1 (1203·1 to 2311·2) | 49·1% (45·4 to 52·5)* | 27·8% (25·6 to 29·8)* | 6·6% (4·5 to 8·4)* | 5·1% (3·9 to 6·4)* | |||
| Motorcyclist road injuries | 43 911·6 (37 802·2 to 50 950·2) | 10 099·8 (8264·3 to 12 257·1) | 2563·7 (1759·1 to 3510·3) | 61·6% (58·6 to 64·8)* | 22·5% (20·7 to 24·4)* | 15·6% (14·0 to 17·3)* | 2·0% (0·6 to 3·4)* | |||
| Motor vehicle road injuries | 42 004·6 (36 541·9 to 49 398·3) | 16 209·2 (13 485·6 to 19 383·3) | 2568·1 (1842·3 to 3439·8) | 30·8% (29·3 to 32·4)* | 16·3% (14·8 to 17·7)* | −7·7% (−8·5 to −6·9)* | −4·5% (−5·6 to −3·5)* | |||
| Other road injuries | 11 689·9 (9728·7 to 14 348·1) | 4931·4 (3777·3 to 6241·2) | 616·6 (438·2 to 853·2) | 52·6% (49·6 to 55·3)* | 45·4% (42·4 to 47·9)* | 9·0% (7·4 to 10·5)* | 20·3% (18·6 to 21·8)* | |||
| Other transport injuries | 52 096·1 (43 127·5 to 61 355·1) | 9728·3 (8120·6 to 11 627·0) | 3234·7 (2315·7 to 4345·0) | 9·0% (6·9 to 11·4)* | 21·4% (19·8 to 23·3)* | −18·5% (−19·8 to −17·2)* | 3·5% (2·0 to 5·0)* | |||
| Unintentional injuries | 935 298·2 (876 022·5 to 1 008 077·1) | 415 410·3 (390 092·6 to 441 943·0) | 36 509·7 (26 384·7 to 49 052·5) | 19·8% (18·0 to 21·6)* | 26·5% (25·2 to 27·7)* | −13·8% (−14·7 to −12·8)* | 4·5% (3·7 to 5·3)* | |||
| Falls | 411 712·0 (366 391·0 to 465 355·0) | 171 691·2 (152 472·7 to 194 061·9) | 19 252·7 (13 725·4 to 26 140·4) | 23·1% (21·3 to 24·9)* | 27·7% (26·5 to 29·0)* | −12·7% (−13·6 to −11·8)* | 3·9% (3·0 to 4·6)* | |||
| Drowning | 2207·3 (1940·6 to 2531·3) | 357·5 (311·4 to 411·9) | 131·6 (94·3 to 175·8) | −11·2% (−14·0 to −8·2)* | 14·2% (10·4 to 17·9)* | −33·1% (−34·9 to −31·2)* | −3·8% (−6·6 to −1·3)* | |||
| Fire, heat, and hot substances | 99 746·8 (85 298·5 to 115 988·1) | 8991·5 (7481·2 to 10 740·9) | 3177·0 (2210·4 to 4396·7) | 0·8% (−4·4 to 6·2) | 17·8% (13·9 to 21·7)* | −25·3% (−28·5 to −22·0)* | 1·1% (−1·6 to 3·7) | |||
| Poisonings | 4556·0 (3808·4 to 5352·3) | 4079·6 (3287·6 to 4973·7) | 467·4 (308·0 to 663·8) | 8·6% (7·2 to 10·0)* | 29·9% (28·3 to 31·8)* | −18·1% (−19·0 to −17·1)* | 12·2% (10·8 to 13·9)* | |||
| Poisoning by carbon monoxide | 854·2 (717·2 to 1034·9) | 1043·5 (770·9 to 1392·2) | 75·5 (50·4 to 109·9) | 16·0% (14·1 to 18·0)* | 33·4% (30·2 to 36·5)* | −13·1% (−14·4 to −11·9)* | 14·7% (12·0 to 17·5)* | |||
| Poisoning by other means | 3701·8 (2951·6 to 4490·9) | 3036·0 (2379·5 to 3782·1) | 391·9 (252·7 to 576·0) | 7·3% (5·8 to 8·8)* | 29·3% (27·2 to 31·4)* | −19·0% (−19·9 to −18·0)* | 11·8% (9·9 to 13·7)* | |||
| Exposure to mechanical forces | 194 479·9 (169 045·7 to 225 589·9) | 72 503·4 (62 042·8 to 84 320·6) | 4959·6 (3445·4 to 6978·5) | 16·5% (14·3 to 18·6)* | 29·0% (27·6 to 30·5)* | −16·0% (−17·2 to −14·9)* | 7·4% (6·5 to 8·4)* | |||
| Unintentional firearm injuries | 8469·2 (6941·4 to 9838·8) | 1911·8 (1390·6 to 2544·6) | 320·1 (224·6 to 436·7) | 13·7% (12·2 to 15·2)* | 28·0% (26·5 to 29·5)* | −16·5% (−17·4 to −15·7)* | 8·6% (7·7 to 9·6)* | |||
| Other exposure to mechanical forces | 186 010·7 (159 749·5 to 216 401·4) | 70 591·6 (60 734·7 to 82 371·3) | 4639·5 (3204·1 to 6560·6) | 16·7% (14·4 to 18·9)* | 29·1% (27·7 to 30·6)* | −16·0% (−17·2 to −14·8)* | 7·3% (6·3 to 8·4)* | |||
| Adverse effects of medical treatment | 2673·1 (2059·9 to 3308·5) | 34 975·0 (29 997·9 to 40 308·2) | 356·5 (223·9 to 533·8) | 60·5% (55·4 to 65·6)* | 48·0% (41·2 to 54·5)* | 18·5% (16·0 to 21·0)* | 19·6% (15·3 to 24·0)* | |||
| Animal contact | 38 403·6 (34 169·0 to 43 179·8) | 43 844·6 (37 631·9 to 51 149·2) | 1075·6 (732·1 to 1484·0) | 11·3% (9·7 to 12·9)* | 17·9% (16·1 to 19·6)* | −17·0% (−17·9 to −16·2)* | 1·1% (−0·2 to 2·3) | |||
| Venomous animal contact | 15 812·1 (13 211·3 to 18 557·7) | 21 097·9 (17 255·4 to 25 592·6) | 717·2 (487·1 to 1004·2) | 14·7% (12·7 to 17·1)* | 18·2% (16·2 to 20·3)* | −13·6% (−14·8 to −12·2)* | 2·7% (1·1 to 4·3)* | |||
| Non-venomous animal contact | 22 591·5 (19 045·6 to 26 729·8) | 22 746·6 (18 607·8 to 27 654·5) | 358·4 (224·3 to 555·6) | 5·0% (2·4 to 7·6)* | 17·2% (14·8 to 19·1)* | −22·9% (−24·3 to −21·8)* | −1·8% (−3·5 to −0·5)* | |||
| Foreign body | 19 350·9 (16 787·2 to 22 108·8) | 23 101·7 (19 925·9 to 26 454·1) | 949·3 (683·3 to 1285·0) | 16·3% (13·6 to 19·1)* | 21·5% (20·3 to 22·9)* | −13·0% (−15·0 to −11·0)* | 3·4% (2·4 to 4·5)* | |||
| Pulmonary aspiration and foreign body in airway | 3008·1 (2442·0 to 3662·4) | 1346·3 (1115·6 to 1607·1) | 150·4 (103·1 to 204·4) | 12·2% (6·2 to 19·3)* | 23·8% (20·7 to 26·9)* | −14·1% (−17·9 to −9·5)* | 5·8% (3·6 to 8·2)* | |||
| Foreign body in eyes | 3190·4 (1644·6 to 4857·3) | 17 672·8 (14 633·0 to 20 947·8) | 201·6 (104·6 to 334·5) | 20·3% (17·7 to 23·1)* | 20·3% (18·8 to 22·1)* | −9·4% (−12·1 to −7·4)* | 2·7% (1·3 to 3·6)* | |||
| Foreign body in other body part | 13 152·5 (10 991·9 to 15 298·2) | 4082·5 (3342·2 to 5009·6) | 597·3 (427·3 to 783·4) | 16·0% (13·3 to 19·2)* | 21·4% (20·0 to 22·9)* | −13·9% (−15·6 to −11·9)* | 3·1% (1·8 to 4·3)* | |||
| Environmental heat and cold exposure | 34 896·7 (29 946·9 to 40 886·4) | 8769·0 (7357·0 to 10 370·5) | 1509·5 (1072·5 to 2023·8) | 13·6% (11·0 to 16·4)* | 24·5% (22·3 to 26·6)* | −16·7% (−18·2 to −15·1)* | 4·9% (3·4 to 6·4)* | |||
| Exposure to forces of nature | 15 757·0 (11 656·5 to 20 853·3) | 689·2 (587·4 to 817·5) | 725·5 (524·9 to 975·9) | 220·3% (200·7 to 238·8)* | 22·6% (19·0 to 26·1)* | 156·4% (140·2 to 171·7)* | 7·8% (5·0 to 10·4)* | |||
| Other unintentional injuries | 115 519·2 (98 844·3 to 134 764·7) | 46 407·6 (39 513·5 to 53 786·8) | 3904·9 (2715·6 to 5485·4) | 20·4% (18·4 to 22·2)* | 28·4% (27·0 to 29·7)* | −13·9% (−14·9 to −13·0)* | 5·7% (4·9 to 6·6)* | |||
| Self-harm and interpersonal violence | 351 859·6 (316 749·7 to 390 321·7) | 41 379·4 (37 344·5 to 45 834·4) | 7270·4 (5637·2 to 9008·3) | 27·2% (24·7 to 30·0)* | 13·0% (10·8 to 15·0)* | −3·5% (−5·4 to −1·3)* | −2·0% (−3·7 to −0·5)* | |||
| Self-harm | 8502·0 (7072·4 to 10 011·6) | 3939·8 (3338·1 to 4603·3) | 435·3 (306·0 to 574·8) | 18·5% (15·2 to 21·9)* | 6·3% (4·8 to 7·9)* | −16·0% (−18·2 to −13·9)* | −12·1% (−13·1 to −11·1)* | |||
| Self-harm by firearm | 114·4 (100·5 to 130·9) | 41·6 (26·1 to 63·2) | 4·8 (3·4 to 6·5) | 13·5% (11·6 to 15·7)* | 7·6% (5·3 to 9·9)* | −21·3% (−22·7 to −19·9)* | −12·9% (−14·7 to −11·1)* | |||
| Self-harm by other specified means | 8387·6 (6963·0 to 9894·9) | 3898·2 (3299·6 to 4570·6) | 430·5 (301·7 to 568·8) | 18·6% (15·2 to 22·0)* | 6·3% (4·8 to 7·9)* | −16·0% (−18·1 to −13·9)* | −12·1% (−13·1 to −11·1)* | |||
| Interpersonal violence | 297 781·5 (268 378·9 to 330 722·3) | 22 919·4 (19 569·3 to 26 696·3) | 4561·8 (3522·0 to 5756·8) | 24·0% (21·7 to 26·3)* | 14·6% (13·1 to 15·9)* | −7·4% (−8·7 to −5·9)* | −0·8% (−1·6 to −0·0)* | |||
| Assault by firearm | 2599·6 (2158·5 to 3151·0) | 551·9 (421·7 to 725·6) | 116·9 (83·8 to 159·3) | 41·0% (38·7 to 43·5)* | 20·2% (18·3 to 22·0)* | 1·1% (−0·3 to 2·4) | 0·5% (−0·9 to 1·9) | |||
| Assault by sharp object | 14 754·5 (12 033·6 to 20 359·8) | 4233·0 (3265·4 to 5366·7) | 475·1 (333·8 to 659·8) | 21·0% (18·2 to 23·7)* | 13·8% (12·1 to 15·7)* | −12·0% (−13·5 to −10·5)* | −3·4% (−4·9 to −1·9)* | |||
| Sexual violence | 238 200·3 (209 368·6 to 270 335·5) | .. | 2142·0 (1447·1 to 3106·7) | 26·1% (22·5 to 30·1)* | 12·4% (10·2 to 14·3)* | −1·9% (−3·5 to −0·1)* | 0·6% (−0·6 to 1·6) | |||
| Assault by other means | 42 227·1 (35 479·3 to 50 750·5) | 18 134·5 (15 426·3 to 21 180·0) | 1827·8 (1295·0 to 2446·7) | 21·3% (18·4 to 24·5)* | 17·1% (15·7 to 18·6)* | −12·4% (−14·1 to −10·6)* | −1·9% (−3·0 to −0·7)* | |||
| Conflict and terrorism | 41 912·3 (28 964·3 to 59 365·8) | 12 492·6 (10 797·4 to 15 087·4) | 2134·0 (1438·2 to 3191·0) | 35·1% (30·0 to 40·8)* | 10·1% (4·9 to 15·5)* | 8·2% (4·0 to 12·7)* | −3·2% (−7·6 to 1·4) | |||
| Executions and police conflict | 3680·5 (2459·9 to 5304·1) | 2027·6 (1683·1 to 2486·1) | 139·3 (99·1 to 197·0) | 59·4% (45·9 to 74·0)* | 32·9% (27·9 to 51·1)* | 22·3% (11·9 to 33·5)* | 14·6% (9·9 to 31·1)* | |||
| Nature of injury aggregates | ||||||||||
| Amputations | 371 422·5 (343 523·2 to 407 748·4) | 9847·8 (8414·6 to 11 519·6) | 6409·0 (4283·7 to 9318·6) | 17·4% (12·9 to 21·9)* | 19·6% (15·7 to 23·2)* | −15·5% (−18·6 to −12·2)* | −0·4% (−3·5 to 2·4) | |||
| Burns | 208 679·9 (192 327·8 to 227 204·0) | 14 307·6 (12 437·8 to 16 359·2) | 6720·1 (4841·1 to 9083·9) | 5·8% (0·9 to 11·2)* | 14·3% (10·1 to 18·6)* | −21·0% (−24·2 to −17·8)* | −1·5% (−4·3 to 1·2) | |||
| Fractures | 360 136·5 (338 070·9 to 385 693·0) | 139 646·3 (128 305·0 to 152 504·8) | 19 793·8 (13 702·1 to 27 655·9) | 30·3% (29·1 to 31·5)* | 27·3% (26·1 to 28·3)* | −8·6% (−9·3 to −7·8)* | 3·0% (2·1 to 3·7)* | |||
| Head injuries | 46 873·2 (44 984·0 to 48 892·5) | 21 652·5 (19 206·0 to 24 416·0) | 6898·0 (4883·9 to 9277·6) | 35·6% (34·5 to 36·8)* | 27·9% (27·1 to 28·7)* | −2·5% (−3·2 to −1·8)* | 6·2% (5·6 to 6·9)* | |||
| Spinal injuries | 22 489·5 (20 671·6 to 25 115·6) | 775·8 (643·3 to 957·7) | 6633·4 (4708·0 to 8639·5) | 26·1% (23·4 to 28·9)* | 25·0% (22·9 to 26·6)* | −6·6% (−8·7 to −4·1)* | 6·3% (5·0 to 7·3)* | |||
| Minor injuries | 198 921·3 (187 143·0 to 213 281·5) | 181 177·5 (167 026·3 to 195 833·2) | 1752·5 (831·1 to 3319·5) | 25·5% (24·1 to 27·1)* | 27·5% (26·8 to 28·4)* | −10·2% (−11·1 to −9·2)* | 5·1% (4·6 to 5·8)* | |||
| Other injuries | 71 339·1 (67 479·1 to 75 358·0) | 153 302·9 (143 603·2 to 162 955·6) | 6825·7 (4830·6 to 9168·5) | 20·4% (18·7 to 22·4)* | 23·1% (21·0 to 24·8)* | −10·7% (−11·8 to −9·4)* | 4·1% (2·6 to 5·4)* | |||
| Impairments | ||||||||||
| Anaemia | 1 950 345·6 (1 909 153·0 to 1 990 086·8) | .. | 58 197·1 (39 535·4 to 83 046·0) | −0·9% (−3·3 to 1·5) | −6·7% (−9·5 to −3·8)* | −17·1% (−18·9 to −15·2)* | −16·2% (−18·8 to −13·5)* | |||
| Epilepsy | 63 783·6 (55 496·5 to 73 199·5) | .. | 25 957·3 (20 369·4 to 32 900·4) | 34·1% (25·9 to 42·1)* | 16·3% (10·6 to 22·1)* | 8·8% (1·9 to 15·2)* | 4·5% (−0·7 to 9·8) | |||
| Guillain-Barré syndrome | 103·7 (82·7 to 127·2) | .. | 30·7 (19·3 to 44·4) | 29·4% (25·5 to 33·8)* | 18·3% (15·9 to 21·0)* | 2·7% (1·0 to 4·3)* | 3·4% (2·2 to 4·5)* | |||
| Hearing loss | 1 428 450·1 (1 388 276·9 to 1 465 389·9) | .. | 39 454·3 (27 100·6 to 55 310·2) | 40·0% (38·7 to 41·0)* | 22·4% (21·4 to 23·3)* | 0·0% (−0·7 to 0·6) | −0·5% (−1·2 to 0·1) | |||
| Heart failure | 64 343·9 (57 187·0 to 71 648·3) | .. | 9906·9 (7261·9 to 12 443·6) | 55·4% (51·7 to 59·1)* | 32·6% (30·3 to 34·6)* | −0·4% (−2·6 to 1·9) | −0·5% (−2·0 to 0·7) | |||
| Infertility | 123 084·9 (99 543·3 to 150 556·1) | .. | 956·9 (487·4 to 1791·9) | 31·7% (28·0 to 34·8)* | 17·3% (13·6 to 20·5)* | −0·7% (−3·0 to 1·0) | 6·8% (3·5 to 9·8)* | |||
| Developmental intellectual disability | 188 585·1 (145 641·8 to 230 402·8) | .. | 25 301·2 (19 706·5 to 31 400·2) | 30·2% (25·9 to 35·0)* | 12·9% (10·0 to 16·1)* | 7·1% (3·7 to 11·0)* | 2·1% (−0·5 to 5·1) | |||
| Pelvic inflammatory disease | 1064·1 (906·7 to 1249·0) | .. | 141·0 (94·8 to 197·2) | 42·3% (39·0 to 45·9)* | 16·0% (13·6 to 18·7)* | 4·5% (2·5 to 6·7)* | 2·5% (0·4 to 4·7)* | |||
| Vision loss | 1 339 970·3 (1 291 077·0 to 1 393 811·0) | .. | 34 125·4 (23 206·6 to 48 924·6) | 38·3% (36·9 to 39·6)* | 22·2% (21·2 to 23·3)* | −2·4% (−3·2 to −1·6)* | −1·5% (−2·3 to −0·7)* | |||
Data in parentheses are 95% uncertainty intervals. We did not calculate incidence for the nine impairments and certain neglected tropical diseases. Blank cells mean that no estimate is available or that the estimate has a magnitude less than 50. G6PD=glucose-6-phosphate dehydrogenase. GFR=glomerular filtration rate. H influenzae=Haemophilus influenzae. NASH=non-alcoholic steatohepatitis. YLDs=years lived with disability.
*
Percentage changes that are statistically significant.
†
Incidence of HIV/AIDS represents new infections of HIV only and does not include new infections of tuberculosis in HIV positive cases.
‡
Incidence estimates for stroke represent first-ever stroke only.